A major milestone for cancer care in South Florida.
Baptist Health Herbert Wertheim Cancer Institute is now Florida’s only Care Partner of @MSKCancerCenter, expanding access to specialized expertise and innovative care close to home.
Learn more: baptisthealth.net/newsroom/press-release/herbert-wertheim…
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK or MSKCC) is a cancer treatment and research institution in Manhattan in New York City. MSKCC is one of 72 National Cancer Institute–designated Comprehensive Cancer Centers. Its main campus is located at 1275 York Avenue between 67th and 68th Streets in Manhattan. More on Wikipedia
-
Memorial Sloan Kettering Cancer Center reposted
Baptist Health
@BaptistHealthSF
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🎉 Congratulations to the 33 researchers whose work at MSK earned them a place on @Clarivate's 2026 Highly Cited Researchers list.
About 1 in 1,000 scientists worldwide earn this distinction, according to Clarivate. To qualify, researchers must have published papers over the past decade that rank in the top 1% by citations in their field. Those citations show how other scientists are building on their work.
Explore the full list of MSK researchers recognized for their influence on science: www.mskcc.org/news/mskcc-applauds-highly-cited-researcher… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨 A new cancer vaccine appears to significantly improve survival in people in remission from acute myeloid leukemia (AML), according to new results from a phase 3 clinical trial.
The vaccine, galinpepimut-S (GPS), is an “off-the-shelf” vaccine invented by MSK leukemia specialist and physician-scientist Dr. David A. Scheinberg (@DASLab_MSKCC). In the trial of 126 patients, it reduced the risk of death by 41%. Median overall survival was 24.0 months with the vaccine compared with 14.7 months for patients on standard treatments.
“These data bring us closer to having the first off-the-shelf vaccine for AML patients." Learn more: www.mskcc.org/news/vaccine-improves-survival-in-people-wi… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
“Our findings point toward a new era where we don’t just go after tumors, but also the broken neighborhood that supports cancer,” says MSK cancer biologist Dr. Scott Lowe of @LoweLabMSKCC.
Learn more about how MSK researchers are revealing cancer cells as active architects of their environment: www.mskcc.org/news/what-are-cancer-ecosystems-how-cancer-… -
Memorial Sloan Kettering Cancer Center reposted
David H Aggen, MD PhD
@Dr_Aggen
Trials are critical for defining what comes after EV + pembrolizumab (EV/P) in advanced bladder cancer?
🧵 1/9
At @MSKCancerCenter with @MSK_DeptOfMed @UrologyMSK we're exploring all these approaches through several clinical trials to overcome EV resistance
New Patients Contact for appointments: 866-432-3416
www.mskcc.org/experience/become-patient/appointment
- NEW cancer targets (TROP2, EGFR/HER3)
- NEW ADC payloads (Topo-I)
- T-cell engagers
- Radioligand therapies
@MSK_DeptOfMed #blcsm -
Memorial Sloan Kettering Cancer Center reposted
Gʀᴇɢᴏʀʏ Rɪᴇʟʏ
@RielyMD
Adam Schoenfeld @AdamJSchoenfeld imagining how we might be combining pd-l1\vegf antibodies in the future for NSCLC, hoping we can be rational. @MSKCancerCenter @MSK_DeptOfMed at NY Lung @gotoPER
-
Memorial Sloan Kettering Cancer Center reposted
DAVA Oncology
@DAVAOnc
Can biomarkers inform RT de-escalation in HPV+ oropharyngeal cancer? At #davaheadandneck, Dr. Eric Sherman (@MSKCancerCenter) reviewed selected cohorts: 5-year PFS 90% with 30 Gy vs 89% with 70 Gy (median follow-up 4.1 years).
-
Memorial Sloan Kettering Cancer Center reposted
Gʀᴇɢᴏʀʏ Rɪᴇʟʏ
@RielyMD
Mark Awad @DrMarkAwad talk at NY Lung Cancers Symposium, discusses value of neo-adjuvant chemoIO and open questions @gotoPER @MSK_DeptOfMed
-
Memorial Sloan Kettering Cancer Center reposted
Gʀᴇɢᴏʀʏ Rɪᴇʟʏ
@RielyMD
My colleague Jamie Chaft @MSK_DeptOfMed on treating brain metastases in small cell presenting at NY Lung Cancers Symposium, questions role of RT @gotoPER
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Our Summer at Memorial Sloan Kettering Cancer Center (MSK) research programs are now open to current sophomores and juniors interested in biomedicine, chemistry, computational biology, and engineering.
These in-person programs in NYC offer students the opportunity to gain research experience, build new skills, expand their scientific knowledge, and explore STEM career paths.
Learn more at: www.mskcc.org/education-training/summer-scientific-underg… -
Memorial Sloan Kettering Cancer Center reposted
Isabel Preeshagul
@ipreeshagul
The lungs have been successfully installed! #lcam
Proud to be part of this incredible team @MSKCancerCenter raising awareness about #lungcancer , highlighting our @TheWRP4LC ribbon as well. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Researchers at MSK have developed a new computational approach to better understand why #tcells, the immune system’s primary cancer-fighting cells, respond differently to immunotherapies.
Led by computational oncologists @bengrbm and @SohrabShah, the team created a statistical model called TCRi that links a T cell’s unique receptor sequence to its biological behavior, helping reveal how these cells recognize and react to cancer.
By analyzing more than 167,000 T cells from patients treated with checkpoint inhibitor immunotherapies, the researchers aimed to uncover how a T cell’s genetic identity influences its activity and how those behaviors change during treatment, potentially improving the ability to predict which patients will benefit from immunotherapy.
“This approach produces a standardized measurement that lets us compare results across different studies and clinical trials,” Dr. Greenbaum says. “We have a way to learn from this data what a meaningful T cell response to an immunotherapy looks like — or doesn’t.”
Learn more about this research: www.mskcc.org/news/new-tool-to-predict-cell-behavior-and-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
In a phase 1/2 trial led by MSK thoracic medical oncologist Dr. Kathryn Arbour, more than 30% of patients with previously treated metastatic lung cancer responded to daraxonrasib, meaning their tumors shrank.
Learn how daraxonrasib targets multiple KRAS mutations and what the early findings could mean for people with lung cancer: www.mskcc.org/news/potential-new-treatment-for-lung-cance… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's most recent awards and appointments, including @_Choi_Junhong on receiving a 2026 @NIH Director’s New Innovator Award; Dr. Gregory Goldgof and @juanosoriomd for being named Damon Runyon Clinical Investigators; Dr. Michael Postow on receiving a 2026 @CureMelanoma Breakthrough Consortium Pilot Translational Award; and more: www.mskcc.org/news-releases/msk-awards-and-appointments-o…
-
Memorial Sloan Kettering Cancer Center reposted
Caleb Lareau
@CalebLareau
Our bodies are colonized by trillions of viruses that we live with in homeostasis. The most diverse and abundant of these viral families are anelloviruses. A new paper from us at @MSKCancerCenter explores what happens after we *all* have been infected
www.biorxiv.org/content/10.64898/2026.11.05.764726v1 1/n -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK will be hosting a Virtual Residency Information Session for our PGY2 Oncology Pharmacy Residency Programs (Adult and Pediatrics) on Tuesday, November 24 at 5pm ET.
During these sessions we will provide an overview of our programs and answer any questions you may have. This is also an excellent opportunity to meet our program directors.
Register here: events.teams.microsoft.com/event/c7b84987-abd5-4a2a-a02b-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
“The promise of AI to transform biology is real, and it’s important — but it needs to be done right.
MSK computational biologist Dr. Christina Leslie discusses how AI could help design better therapies and decode why tumors resist treatment. Learn more: www.mskcc.org/news/decoding-cell-conversation-with-dr-chr… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Shrinking a tumor before surgery helped protect a young patient’s voice.
MSK experts took an unconventional approach, using larotrectinib to make a less extensive operation possible. Read about her treatment: www.mskcc.org/news/thyroid-cancer-expertise-saves-young-v… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Catch up on the cancer research MSK presented at #esmo26. 🔬
Our roundup covers a pancreatic cancer vaccine, targeted therapy for advanced GIST, and new treatment approaches for ovarian cancer, lung cancer, and sarcoma.
Learn more: www.mskcc.org/clinical-updates/esmo-2026-research-roundup… -
Memorial Sloan Kettering Cancer Center reposted
Melanoma Research Foundation
@CureMelanoma
Congratulations to the recipients of this year's MRF Breakthrough Consortium (MRFBC) Pilot Translational Awards: Shankar Suman, PhD of the @MayoClinic in Rochester and Michael Postow, MD of @MSKCancerCenter!
The MRFBC is a national network of 34 centers of excellence in melanoma that collaborate to accelerate research and the development of the most promising therapies in melanoma treatment.
Learn more about this year's MRFBC Pilot Translational Awardees: melanoma.org/research-science/research-grants-rfps/funded… -
Memorial Sloan Kettering Cancer Center reposted
Memorial Sloan Kettering Radiation Oncology
@MSK_RadOnc
This October, Breast Cancer Awareness Month, we spotlight Breast Radiation Oncologist Dr. J. Isabelle Choi.
"It is a privilege to walk alongside my patients through treatment and help them get back to the things that matter most to them."
#breastcancerawarenessmonth #radonc -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
As members of the @CAIAorg, MSK is helping accelerate development and deployment of AI models to improve cancer care
"Rather than developing separate tools for every clinical question, we are training foundational models across institutions," says Dr. @SohrabShah, Chief of Computational Oncology in the Department of Epidemiology and Biostatistics at MSK.
"Our goal is to develop models that learn from patients full clinical trajectories with multimodal data and at national scales. This will ultimately inform clinical recommendations for new patients, leading to improved personalized treatment and care."
Learn more ⬇️
Cancer AI Alliance
@CAIAorg
Two years ago, the Cancer AI Alliance set out to transform cancer research. Today, we're celebrating how far CAIA has come.
In just two years, CAIA has united insights from the data of over 1 million patients, proving what’s possible when cancer centers collaborate at scale. -
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
Join us next week, November 5–6, for the 10th Advances in Colorectal Oncology Symposium @MSKCancerCenter, a milestone event bringing together international experts to explore the latest advances, emerging strategies, and real-world challenges in multidisciplinary colorectal cancer care.
Hear from @DrPaulRomesser as he shares what makes this year’s program especially exciting and why you won’t want to miss it.
We hope you’ll join us! Learn more and register: mskcc.cloud-cme.com/course/courseoverview?P=5&EID=62467
@jgarciaaguilarThis media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
There's a lot of buzz around mRNA #cancervaccines, but how do they actually work?
These vaccines help train your body’s immune system to recognize the unique genetic signature of cancer cells. Once activated, the immune system can:
🔹 Target and attack cancer cells while helping spare healthy cells
🔹 Work alongside other cancer treatments
🔹 Create a lasting immune response that may help prevent cancer from returning or spreading
📽️ Hear more from Dr. Vinod Balachandran (@TheVinodLab), Director of the Olayan Center for Cancer Vaccines at MSK, about what patients should know about experimental mRNA cancer vaccines.This media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK Employee Spotlight | @dana_peer, Chair of the Computational and Systems Biology Program the Sloan Kettering institute (SKI) at Memorial Sloan Kettering Cancer Center (MSK), was recently elected to the National Academy of Medicine (NAM), one of the most respected distinctions in science and medicine.
Dr. Pe’er is a preeminent computational biologist whose work has transformed how scientists use large-scale genomic data to understand complex biological systems. Her lab has pioneered widely used machine-learning and AI approaches to reveal how cells take on certain states, communicate with one another, and organize into tissues. She applies these approaches to fundamental questions in organismal development and in cancer, with a focus on cellular plasticity, metastasis, and how cancer cells shape — and are shaped by — their tissue ecosystems during progression and therapy.
Currently, Dr. Pe’er is the Chair of Computational and Systems Biology and Scientific Director of SKI’s Single-cell Analytics Innovation Lab, as well as a Howard Hughes Medical Institute Investigator. She holds the Alan and Sandra Gerry Endowed Chair.
Join us in congratulating Dr. Pe'er in the comments below! -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK Employee Spotlight | Dr. Ross Levine, Chief Scientific Officer (CSO) at MSK, was recently elected to the @theNAMedicine (NAM), one of the most respected distinctions in science and medicine.
Dr. Levine’s research focuses on the genetic changes that drive myeloid malignancies, including myeloproliferative neoplasms and acute myeloid leukemia, and translating these discoveries into more effective treatments. As MSK’s CSO, he leads basic and translational research strategy, overseeing programs, centers, technology cores, and the financial and operational resources that support MSK’s research enterprise.
Previously, Dr. Levine served as HOPP's first chief of the Molecular Cancer Medicine Service, inaugural Director of the Center for Hematologic Malignancies, and Senior Vice President for Translational Research at Memorial Hospital. He holds the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes.
Join us in congratulating Dr. Levine in the comments below! -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨 MSK’s @AndreaCercek presented full interim results from the AZUR-1 trial at #esmo26 in Madrid. The trial tested Jemperli (dostarlimab) in people with stage 2 and 3 rectal cancer whose tumors are mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H).
Among patients for whom the approach worked, no cancer has returned during follow-up.
The approach, developed at MSK by Dr. Cercek and Dr. Luis Diaz Jr. (@ldiaz1971), allows some patients to avoid treatments that can have life-altering consequences, including infertility and bowel and bladder dysfunction. The @FDA approved the approach in October 2026, calling it "groundbreaking.
“It’s incredibly rewarding,” says Dr. Cercek, “to get these happy tears and happy emails from the patients who finish treatment and realize, ‘Oh my God, I get to keep all my normal body functions that I feared I might lose to radiation or surgery.’”
Learn more: www.mskcc.org/news/rectal-cancer-disappears-after-experim… -
Memorial Sloan Kettering Cancer Center reposted
Herbert Loong, MBBS, FASCO
@herbloong
#pingchi from @MSKCancerCenter presented on the #final results of FIH #nb003 trial, a potent and selective KIT inhibitor in GISTs. Broad spectrum of activity seen in different mutations. Phase 3 trial compared with #regorafenib planned.
@ctosociety @Liferaftgroup @myESMO #esmo26 #esmoambassadors -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Tomorrow at #esmo26: MSK hepatopancreatobiliary surgeon Dr. Vinod Balachandran (@TheVinodLab) will discuss immunotherapy in pancreatic cancer and overcoming barriers to success.
🗓️ Monday, October 26 | 11:15 a.m. CET -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Tomorrow at #esmo26: MSK sarcoma medical oncologist Dr. Lauren Banks will present research on lifileucel in undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma.
🗓️ Monday, October 26 | 9:34 a.m. CET -
Memorial Sloan Kettering Cancer Center reposted
Marc Hilmi
@MarcHilmi
Grateful to present 3 posters at #esmo2026 in Madrid! 🇪🇸
1. Pathogenic germline ATM alterations define a distinct pancreatic cancer subtype with improved survival, less liver metastases and reduced KRAS signaling. @CentralParkWMD @EileenMOReilly @ciacobu @CpcrMsk
2. POSTN+ fibroblasts identify an aggressive tumor microenvironment and poorer survival in pancreatic cancer (#prodige24). @RemyNicolle @cros_jerome
3. Early CT-derived body composition changes predict survival in biliary tract cancer patients receiving immunotherapy, independently of radiological progression, CA19-9, ECOG PS, and weight loss (#prodige57). @DelayeMatthieu
Grateful to all collaborators at @MSKCancerCenter, @institut_curie, and GERCOR/PRODIGE!
#pancreaticcancer #gioncology -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today at #esmo26: Research co-authored by MSK gastrointestinal medical oncologist Dr. Yelena Janjigian will be presented from CLARITY-Gastric 01, a phase 3 study of sonesitatug vedotin in second- or later-line advanced or metastatic Claudin 18.2-positive gastroesophageal carcinoma.
🗓️ Sunday, October 25 | 5:18 p.m. CET -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
AZUR-1 presented by @AndreaCercek @MSKCancerCenter: dostarlimab x 6 months in locally advanced dMMR/MSI-H #rectalcancer (recently FDA approved): 71% clinical complete response (cCR) rate, 100% durable (2 cCR patients had surgery with path complete response (pCR)), overall 76% had cCR at 12 months or pCR #esmo26 @myESMO #crcsm
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Coming up at #esmo26: MSK thoracic surgeon Dr. Daniela Molena will discuss perioperative therapy for locally advanced gastric and gastroesophageal cancer.
🗓️ Sunday, October 25 | 4:30 p.m. CET -
Memorial Sloan Kettering Cancer Center reposted
Targeted Onc
@TargetedOnc
At #esmo26, @DrDarrenFeldman (@MSKCancerCenter) discusses phase 1 data showing ixotatug vedotin drives notable responses in heavily pretreated #germcelltumors, with manageable ADC safety and potential phase 2 plans.
🎥 WATCH: www.targetedonc.com/view/ixotatug-vedotin-claudin-6-adc-g…
#oncology #cancertreatment -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Tomorrow at #esmo26: MSK gastrointestinal medical oncologist @AndreaCercek will present the first results from the global AZUR1 trial of dostarlimab monotherapy in patients with dMMR/MSI-H locally advanced rectal cancer.
🗓️ Sunday, October 25 | 11:00 a.m. CET -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Today at #esmo26: Mrinal Gounder will present updated safety and efficacy data from a phase 1/2 trial of zolucatetide in patients with desmoid tumors. @MSKCancerCenter
🗓️ October 24 | 2:55 p.m. CEST -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
🧬 In phase 1 CATALINA-1, ixotatug vedotin achieved a 45.5% response rate in 11 patients with heavily pretreated germ cell tumors. Half of those previously treated with HDCT/ASCT responded.
Read more about the findings presented at @myESMO
#esmo26 @DrDarrenFeldman @MSKCancerCenter: www.onclive.com/view/ixotatug-vedotin-elicits-responses-i… -
Memorial Sloan Kettering Cancer Center reposted
UroToday.com
@urotoday
TORL-1-23: Safety and Efficacy of Ixotatug Vedotin, a Claudin 6-Targeted ADC, as Monotherapy in Germ Cell Tumors. Presented by @DrDarrenFeldman @MSKCancerCenter. #esmo26 written coverage by @zklaassen_md > www.urotoday.com/conference-highlights/esmo-2026/esmo-202… #testicularcancer #germcelltumors #clinicaltrials @myESMO
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Coming up at #esmo26: MSK cancer biologist @nikolausschultz will present on AI-augmented integration of real-world data to improve cancer outcome prediction.
🗓️ Saturday, October 24 | 12:20 p.m. CEST -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Tomorrow at #esmo26: MSK melanoma medical oncologist Dr. Michael Postow will present a poster on real-world outcomes among patients with resectable stage III melanoma treated with neoadjuvant nivolumab plus relatlimab or nivolumab plus ipilimumab.
🗓️ Saturday, October 24 | 12:00 p.m. CEST -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Good news for #melanoma cancer patients: New results from a personalized #cancervaccine designed to prevent melanoma from returning after surgery showed positive results, according to research presented at this year’s #esmo26 meeting in Madrid.
The study found that adding a specially tailored cancer vaccine to standard treatment with immunotherapy successfully reduced the risk of melanoma coming back by 42% compared with standard immunotherapy alone.
“The idea of this treatment is that by specifically boosting a patient’s immune system to recognize their own tumor cells, we can reduce the risk that the cancer comes back,” says Dr. Michael Postow, Chief of the Melanoma Service at MSK. “Even when we can’t see any cancer on a CT or PET scan, we know that often it’s still there — because such a high proportion of patients eventually have a cancer recurrence. That’s why there is tremendous need for this type of treatment.”
Read more about one of the three MSK patients treated in the trial: www.mskcc.org/news/promising-results-for-melanoma-mrna-va… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A new vaccine continues to show potential as a ready-made treatment for pancreatic cancer, according to a study co-led by MSK researchers.
MSK's @EileenMOReilly presented phase 2 results from AMPLIFY-7P at #esmo26. The vaccine targets KRAS mutations, which are found in more than 90% of pancreatic cancers.
99% of patients receiving the vaccine developed cancer-fighting immune T cells. Patients with the strongest immune responses had the lowest recurrence rates.
“Having a vaccine that’s ‘off-the-shelf’ would make it easier, faster, and less expensive to treat a larger number of patients,” says Dr. O’Reilly. “This gives hope for people with pancreatic cancer who have been out of effective treatments when their disease returns.” Learn more: www.mskcc.org/news/vaccine-targeting-kras-in-pancreatic-a… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Don't miss posters today at #esmo26: Salomon Tendler will present data showing that DLL3 PET identifies neuroendocrine differentiation and tumor heterogeneity in advanced prostate cancer. @Tendler_S @MSKCancerCenter
📅 October 23 | 3:15 p.m. CEST -
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
🧬 One of my FAVORITE pancreatic cancer meetings ever!
The 3rd Botton-Champalimaud International Pancreatic Cancer Conference in beautiful Lisbon 🇵🇹
www.bcipcc.org/programme/faculty
An extraordinary gathering of 💡brilliant minds from around the world, united by one mission: transforming #pancreaticcancer care.
Deep 🧪science, bold ideas and exciting discussions on #kras #ras biology, therapeutic resistance, 🦀tumor evolution 🐒 and the next generation of treatments.
The pace of progress in this field is extraordinary! 🚀
So much learned. So many new ideas. And even more reasons to be optimistic about the future! 💜
#pdac #translationalresearch @MSKCancerCenter @CpcrMsk @MSK_DeptOfMed -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Coming up at #esmo26: MSK gastrointestinal medical oncologist @EileenMOReilly will present the AMPLIFY-7P randomized phase 2 study comparing an mKRAS-specific immunotherapy with observation in patients with resected pancreatic ductal adenocarcinoma.
🗓️ Friday, October 23 | 2:32 p.m. CEST -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Through a recent collaboration, Memorial Sloan Kettering Cancer Center (MSK) and @OpenEvidence are making precision oncology expertise more accessible within clinicians’ everyday workflows.
The collaboration brings OpenEvidence and MSK's OncoKB™ knowledge base together to help deliver trusted, evidence-based guidance when and where it’s needed most.
Watch to learn more ⬇️This media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
When the immune system is weakened by cancer treatment — especially by a stem cell or bone marrow transplant (BMT) for blood cancer — common viruses like herpes simplex virus (HSV) can become a serious problem.
For someone who is immunocompromised, an HSV infection can mean dealing with large, painful sores that resist the usual therapies and ultimately lead to more critical medical conditions.
The good news: The @FDA recently approved #pritelivir (Hovilpri) for HSV infection in immunocompromised patients, including those who are undergoing cancer treatment.
The study that resulted in the drug’s approval was co-led by Dr. @GenPapaMD, Clinical Director for Infectious Diseases at MSK, and Dr. June Lee, an infectious disease specialist at MSK, among others.
Learn more: www.mskcc.org/news/fda-approves-pritelivir-to-treat-herpe… -
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
Congratulations 🎉🍾🎊 So so proud to be working with the legends in this team with @AndreaCercek and @ldiaz1971 @MSKCancerCenter
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨: The @FDA has granted accelerated approval to the immunotherapy Jemperli (dostarlimab) for adults with stage 2 or 3 rectal cancer whose tumors have specific genetic characteristics known as mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H).
The approach, developed at MSK by gastrointestinal medical oncologists Dr. Andrea Cercek (@AndreaCercek) and Dr. Luis Diaz Jr. (@ldiaz1971), uses immunotherapy alone to harness the body’s own immune system to fight cancer.
This allows some patients to skip standard treatment for rectal cancer, which includes surgery, radiation, and chemotherapy, and can have life-altering consequences for bowel and urinary function, as well as fertility.
Learn more: www.mskcc.org/news/rectal-cancer-disappears-after-experim… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK uncovers an unknown role for immune cells in fueling triple-negative breast cancer; identifies a new strategy for fighting leptomeningeal metastases; finds trastuzumab deruxtecan shows enhanced benefit for patients with ERBB2 mutations in breast cancer; and more: www.mskcc.org/news/msk-research-highlights-october-9-2026
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨: The @FDA has granted accelerated approval to the immunotherapy Jemperli (dostarlimab) for adults with stage 2 or 3 rectal cancer whose tumors have specific genetic characteristics known as mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H).
The approach, developed at MSK by gastrointestinal medical oncologists Dr. Andrea Cercek (@AndreaCercek) and Dr. Luis Diaz Jr. (@ldiaz1971), uses immunotherapy alone to harness the body’s own immune system to fight cancer.
This allows some patients to skip standard treatment for rectal cancer, which includes surgery, radiation, and chemotherapy, and can have life-altering consequences for bowel and urinary function, as well as fertility.
Learn more: www.mskcc.org/news/rectal-cancer-disappears-after-experim… -
Memorial Sloan Kettering Cancer Center reposted
Waxman Institute
@WaxmanCancer
How does aging influence cancer development & the lung’s ability to regenerate? @TuomasTammela from @MSKCancerCenter, a 2026 Aging & Cancer Awardee, is presenting how aging alters cellular behavior and tumorigenesis #2026agingcancermeeting @TheMarkFdn @AmericanCancer
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Specialists at MSK know how to modify tests and treatment protocols to navigate the special needs of people who have cancer during pregnancy. Beyond the medical expertise, MSK also offers emotional support for expectant mothers facing a heartbreaking circumstance.
“We are seeing this situation more often because of the rise in certain cancers among younger people,” says MSK psychologist Dr. Amanda Balakirsky. “Being pregnant with cancer can cause a lot of grief and feelings of isolation. We try to normalize the experience as best we can, to help them adjust from what they were expecting in their pregnancy and feeling different from their peers.”
Learn more about how they helped one patient and her now 1.5-year-old son: www.mskcc.org/news/cancer-during-pregnancy-how-msk-protec… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
We're proud to share that Dr. Ross Levine, Chief Scientific Officer at MSK and Dr. @dana_peer, Chair of the Computational and Systems Biology Program at the Sloan Kettering Institute (SKI) at MSK, have been elected to the @theNAMedicine.
With these latest appointments, 30 MSK faculty members have now received this prestigious honor.
Learn more about these two elections: www.mskcc.org/news-releases/two-mskcc-leaders-in-cancer-r… -
Memorial Sloan Kettering Cancer Center reposted
James J. Harding, MD
@HardingJJMD
Great to see this work out, Aruj Dhyani. Great to see #adc target expression in #btc, supports several ongoing clinical trials. @MSKCancerCenter @MSK_DeptOfMed
aacrjournals.org/clincancerres/article/doi/10.1158/1078-0… -
Memorial Sloan Kettering Cancer Center reposted
Joshua Budhu
@JoshuaBudhu
So excited that Scotty is presenting our work in TWO posters today! Exploring financial toxicity among patients with limited English proficiency and those participating in clinical research. Stop by posters B4 & B8 to learn more!
@ASCO @MSKCancerCenter @WeillCornell -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Researchers at MSK and their collaborators are gaining new insights into cancer cachexia, a wasting syndrome that affects nearly half of all patients.
Findings in @NatureMedicine could help predict which patients are most at risk and help facilitate timely support and interventions. Learn more: www.mskcc.org/news/insights-about-cachexia-one-of-cancers… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
#lungcancer, both small cell lung cancer (#sclc) and non-small cell lung cancer (#nsclc), is the second-most common cancer in the United States.
"Lung adenocarcinoma, a type of NSCLC, is the most common type of lung cancer, and when caught at an early stage, it can be highly treatable. And for patients with stage one disease, surgery can often be curative," says Dr. David Jones (@JonesDavid2013), MSK's Chief of Thoracic Surgery. "If the cancer has spread to nearby lymph nodes, additional treatment may be recommended to reduce the risk of recurrence."
Learn more about advances in lung cancer treatments and the advantages of coming to MSK when you are first diagnosed: www.mskcc.org/news/new-lung-cancer-treatments-aim-to-redu… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
DYK: The most common signs and symptoms of lung cancer are the same in men and women? To name a few:
🔹 A persistent cough, including coughing up blood
🔹 Wheezing or shortness of breath
🔹 Chest pain
🔹 Hoarseness
🔹 Unexplained weight loss
MSK thoracic oncologist Dr. Helena Yu also shares why lung cancer is more common in women than men in younger age groups and why people get lung cancer even if they’ve never smoked: www.mskcc.org/news/lung-cancer-in-women-and-nonsmokers-wh… -
Memorial Sloan Kettering Cancer Center reposted
VJ Oncology
@VJOncology
Watch our interview with Ghassan Abou-Alfa (@GABOUALFA) at #asco26 to hear efficacy and safety results from the EMERALD-3 study of STRIDE + lenvatinib + TACE in unresectable embolization-eligible #hcc 💉💥
🔗: www.vjoncology.com/video/_ls45ufokss-emerald-3-efficacy-a…
#oncology #trialupdates #livercancer #hpbcsm #immunoonc @ASCO @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A new MSK study co-authored by MSK's @StadlerZsofia and Dr. Luis Diaz Jr., published in @CC_AACR, found that limiting genetic testing to patients under 50 would have missed 72% of those with inherited cancer mutations.
Knowing about these mutations can help guide treatment and help family members understand their cancer risk.
Learn more: www.mskcc.org/news/study-suggests-every-cancer-patient-sh… -
Memorial Sloan Kettering Cancer Center reposted
Himanshu Nagar
@HimanshuNagarMD
@BehfarEhdaieMD kicking off @MSKCancerCenter Advances in Prostate Cancer Management Symposium. Great 2 days ahead.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congrats to MSK's most recent awards and appointments, including @StadlerZsofia for being appointed Chief of MSK’s Clinical Genetics Service, @seungjaylee for being named a finalist for the 2026 @BlavatnikAwards for Young Scientists, Dr. Abigail Xie for receiving the 2026 @IMPvienna International Birnstiel Award, and more: www.mskcc.org/news-releases/msk-awards-and-appointments-s…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to gastrointestinal medical oncologist and clinical geneticist Dr. Zsofia Stadler (@StadlerZsofia), who has been appointed Chief of the Clinical Genetics Service at MSK.
Dr. Stadler has served as Clinical Director of the Clinical Genetics Service since 2017, helping expand genetics-driven cancer care, clinical operations, and translational research at MSK. Her work has advanced the understanding and clinical application of inherited cancer risk, including research in Lynch syndrome, germline genetic testing, cancer prevention, and precision oncology.
Join us in welcoming Dr. Stadler to her new role by commenting below. 👏 -
Memorial Sloan Kettering Cancer Center reposted
Society of Hematologic Oncology (SOHO)
@SocietyofHemOnc
"It will be a better experience... easier logistics to get this drug to patients," says @szusmani from @MSKCancerCenter on the iberdomide approval by the FDA. #soho2026
Featuring @thanosdimop @AjayNookaMD
Watch the video: sohoinsider.com/meetings-conferences/saad-usmani-md-discu… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🎉 Congratulations to MSK radiation oncologists Dr. Christopher Barker, Dr. Daphna Gelblum, and Dr. Abraham Wu on being named 2026 ASTRO Fellows, recognizing their contributions to radiation oncology! @MSK_RadOnc #astro2026
-
Memorial Sloan Kettering Cancer Center reposted
Targeted Onc
@TargetedOnc
Eytan M. Stein, MD (@MSKCancerCenter) explains how real-world data complements #aml trials and where targeted agent combinations and immunotherapy research must go next.
🎥 WATCH: www.targetedonc.com/view/stein-on-real-world-data-targete…
#leukemia #hematology #oncology #rwd #cancerresearch -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Lobular breast cancer is the second most common type of breast cancer, but it can be harder to detect on mammograms and during breast exams.
MSK experts @SherryShenMD, @FresiaPareja, and Dr. Anita Mamtani explain its symptoms, diagnosis, and treatment. Learn more: -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The @FDA recently approved a targeted therapy called lirafugratinib (Lyrfigtu) for people with advanced cholangiocarcinoma (bile duct cancer) that has a genetic change called an FGFR2 fusion or an FGFR2 rearrangement.
The clinical trial that resulted in the drug’s approval was led by MSK early drug development specialist Dr. @AliSchram.
“Cholangiocarcinoma is a rare cancer that is almost always caught after it has spread, making it extremely challenging to treat,” Dr. Schram says. “Any time we find a new treatment for patients with this disease, it can make a meaningful difference to them and their families.”
Learn more about this approval: www.mskcc.org/news/fda-approves-lirafugratinib-for-treati… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A new study from MSK and collaborators (@jonasschluter and @DrMvandenBrink) suggests that consuming high levels of sugar while taking antibiotics may worsen gastrointestinal side effects in patients receiving bone marrow transplants.
The study, co-led by Dr. Jonathan “Tsoni” Peled (@tsonipeled) and published in @Nature, tracked the diets and gut microbiomes of 173 hospitalized transplant patients. The data showed that high-sugar foods and antibiotics appeared to compound damage to the microbiome.
Learn more about what these findings could mean for nutrition during cancer treatment: www.mskcc.org/news/study-suggests-sugar-can-worsen-common… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK scientists from @LoweLabMSKCC and @Dan_A_Heller's lab engineered nanoparticles to target cells driving scarring around many liver and lung tumors. In mice, this reduced scarring and helped immunotherapy shrink tumors that resisted treatment.
The laboratory findings, published in @ScienceMagazine, potentially pave the way for new approaches against immunotherapy-resistant tumors, as well as for a host of other fibrotic and inflammatory diseases. Learn more: www.mskcc.org/news/using-nanoparticles-to-target-fibrosis… -
Memorial Sloan Kettering Cancer Center reposted
MSK ScienceEducation
@MSKEducation
To all #mskpostdocs - THANK YOU for your significant contributions to the @MSKCancerCenter research community! @MSKPDA we are proud to celebrate you!
#npaw2026 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK experts Oct. 2, 8:25 a.m.–1 p.m. ET, for a complimentary virtual symposium on multidisciplinary care for pediatric brain and spinal tumors.
Participants will hear practical updates on the latest advances in multidisciplinary neuro-oncology care, including emerging diagnostic approaches and the newest therapeutic options.
Learn more and register: mskcc.cloud-cme.com/course/courseoverview?P=5&EID=62966 @MSKCME -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The @FDA has approved the drug belzutifan in combination with lenvatinib for patients with a type of #kidneycancer called clear cell renal cell carcinoma (#ccrcc).
The approval was based on a clinical trial led by Dr. @motzermd, a genitourinary medical oncologist at MSK.
“When a patient’s cancer stops responding to immunotherapy, it’s a really difficult time,” Dr. Motzer says. “We’ve had limited options to offer in that situation. Anytime there is a new treatment approved, it’s exciting news.”
Learn more about this approval: www.mskcc.org/news/fda-approves-belzutifan-lenvatinib-for… -
Memorial Sloan Kettering Cancer Center reposted
UroToday.com
@urotoday
Real-world evidence across prostate radiotherapy modalities: Utilization shifts, toxicity, and BCR in genomic classifier-scored patients. Presentation by Thomas Kole, MD, PhD @MSKCancerCenter. #astro26 written coverage by @zklaassen_md > www.urotoday.com/conference-highlights/astro-2026/astro-2… @ASTRO_org
-
Memorial Sloan Kettering Cancer Center reposted
Kidney Cancer
@KidneyCancer
🎉 FDA approves belzutifan + lenvima combo to treat advanced #ccrcc pts who stop responding to IO. Approval based on PI @motzermd @MSKCancerCenter LITESPARK-011 trail data.
We're excited to see expanding treatment options for patients and families! www.curetoday.com/view/fda-approves-welireg-plus-lenvima-… -
Memorial Sloan Kettering Cancer Center reposted
Chris Jackson, MD, MS
@Chris_JacksonMD
Stellar @MSK_RadOnc / @MSKCancerCenter Resident @Elisa_Liu_ will present on Renal Cell Spinal metastases treated with SBRT this morning at 10:15AM at @ASTRO_org 2026.
@DanHigginsonMD @MattMcMillanMD.
www.sciencedirect.com/science/article/pii/S0360301626011132 -
Memorial Sloan Kettering Cancer Center reposted
Diana Roth O’Brien, MD MPH
@drothens
@DrPaulRomesser and I are so lucky to have the most innovative, dedicated, and accomplished mentees/CRAC fellows. Very proud of Drs. Elisa Liu and Revathi Ravella!
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
At #astro26, MSK researchers presented studies on organ preservation and circulating tumor DNA (ctDNA) monitoring in rectal and anal cancers. Their work examines how treatment and follow-up care could be tailored to each patient.
Read about the studies and their findings: -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Coming up at #astro26: MSK radiation oncologist @brandon_imber will present research on bridging radiotherapy and systemic inflammation before CAR T-cell therapy for B-cell lymphomas.
🗓️ Wednesday, September 30 | 9:15 a.m. ET
Learn more: amportal.astro.org/sessions/sh-08-22967/bridging-radiothe… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Tomorrow at #astro26: MSK radiation oncologist @kevinmboehm will present research using pathology images and clinical tumor sequencing from more than 60,000 patients to model cancer subtypes and molecular features.
🗓️ Wednesday, September 30 | 8:20 a.m. ET
Learn more: -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
At #astro26, MSK researchers presented studies on organ preservation and circulating tumor DNA (ctDNA) monitoring in rectal and anal cancers. Their work examines how treatment and follow-up care could be tailored to each patient.
Read about the studies and their findings: -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Can #testicularcancer cause pain, or is a painless lump the only sign?
In our latest MSK Explains, MSK genitourinary medical oncologist Dr. Samuel Funt is giving us the real facts: who gets it, what to look out for, and why spotting it early makes all the difference.
Because here's the thing… it's also one of the most treatable — IF you catch it early.
Watch and share to help others recognize the symptoms.This media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Coming up at #astro26: MSK radiation oncologist Dr. Marsha Reyngold will present two- and three-year overall survival findings after ablative MR-guided radiotherapy for localized pancreatic cancer without surgery.
🗓️ Tuesday, September 29 | 5:20 p.m. ET
Learn more: -
Memorial Sloan Kettering Cancer Center reposted
C. Jillian Tsai, MD, PhD
@CJTsaiMDPhD
🚨👏Congrats to Drs Daphna Gelblum, Christopher Barker, Abe Wu of @MSK_RadOnc @MSKCancerCenter for being awarded #astro26 @ASTRO_org fellows!
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Coming up at #astro26: MSK radiation oncologist @seanmmcbride will present “Intensify, Shorten, or Personalize? Modern Approaches to Post-prostatectomy RT.”
🗓️ Tuesday, September 29 | 12:30 p.m. ET -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
💭 Myth: Older men are at highest risk for #testicularcancer.
✔️ Fact: Testicular cancer is considered a ‘young man’s disease,’ usually affecting males under 40. In reality, people in their teens, 20s, and 30s are more likely to get testicular cancer.
MSK genitourinary oncologist @DrDarrenFeldman and urologic surgeon Dr. Richard Matulewicz share 7 other common myths and facts about testicular cancer: www.mskcc.org/news/testicular-cancer-myths -
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
The best part of #aacrpanc26: the people. 💜 
Mentors and mentees.
Friends and collaborators.
Scientists, clinicians and patient advocates.
Different perspectives, one ☝️united front🛡️against #pancreaticcancer.
Science brings us together.
Friendship and shared purpose keep us moving forward.
Grateful for this community. @AACR
#pdac #kras #teamscience
💜 @MSK_DeptOfMed @MSKCancerCenter @CpcrMsk @PanCAN @lustgartenfdn @NatPancFdn @Pankind_Aus
@EileenMOReilly @Jonathanwlee23 @BenWestphalen @GIcancerDoc Collin Weekes @OncoDailyGI @oncodaily -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK shows how a metabolite boosts immune cells against cancer; adds to the understanding of how colorectal cancer spreads; reveals tumor CD19 levels may predict the success of CAR T cell therapy; and finds a new targeted drug combination shows promise in early trial for small cell lung cancer. Learn more: www.mskcc.org/news/msk-research-highlights-september-14-2026
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today at #astro26: MSK radiation oncologist @alexgoglia will present five-year outcomes from a trial of MR-guided SBRT with a focal DIL boost for intermediate-risk prostate cancer.
🗓️ Monday, September 28 | 3:10 p.m. ET
Learn more: amportal.astro.org/sessions/qp-09-22890/five-year-outcome… -
Memorial Sloan Kettering Cancer Center reposted
PharmaMar
@PhrmMar
The next presentation features Dr. Marc Ladanyi (@MLadanyi), with “Synovial sarcoma: the search for targetable vulnerabilities informed by clinical cancer genomics and epigenomics”, from Memorial Sloan Kettering Cancer Center (@MSKCancerCenter).
#synovialsarcoma -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Coming up at #astro26: MSK radiation oncologist @George_E_Naoum will present a validated tool that predicts the risk of invasive breast cancer recurrence for patients with N1mic disease treated with or without nodal radiotherapy.
🗓️ Monday, September 28 | 8:30 a.m. ET
Learn more: amportal.astro.org/sessions/qp-05-22838/validated-nomogra… -
Memorial Sloan Kettering Cancer Center reposted
Michael May
@MichaelMayMD
Phenomenal oral and poster presentations by rising star Kate Ryan on the impact of selective ablation of basal-like and classical pancreas cancer cells on the TME. @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @dana_peer @TuomasTammela
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Coming up at #astro26: MSK radiation oncologist @imrtlee will present a pooled analysis of trials studying FMISO PET-guided, lower-dose radiation for HPV-positive oropharyngeal cancer. @ASTRO_org
🗓️ Sunday, September 27 | 3 p.m. ET
Learn more: amportal.astro.org/sessions/ss-03-22898/pooled-analysis-o… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Sunday Weather Update: All MSK locations are on their normal schedule today. Please allow extra time to get to your visit.
-
Memorial Sloan Kettering Cancer Center reposted
ASTRO
@ASTRO_org
#astro26 is in full swing! Start planning your Annual Meeting experience now and explore the sessions you won't want to miss.
View the Daily Schedule: amportal.astro.org/sessions -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Weather Update: All MSK locations plan to be on their normal schedule Sunday, September 27.
Please allow extra time to get to your visit. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Weather Update: All MSK locations are on their normal schedule today. Please allow extra time to get to your appointment.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Tomorrow at #ims26: MSK myeloma specialist @UrviShahMD will present research on targeting a metabolic-epigenetic axis to improve CAR T therapy in multiple myeloma. @Myeloma_Society
🗓️ Saturday, September 26 | 11 a.m. BT / 6 a.m. ET -
Memorial Sloan Kettering Cancer Center reposted
AATS
@AATSHQ
Gaetano Rocco gives the #itsos2026 Master Surgeon Lecture showing his #thoracic journey from Italy to @MSKCancerCenter.
-
Memorial Sloan Kettering Cancer Center reposted
AATS
@AATSHQ
#itsos2026 Concurrent Sessions D, E, and F start now.
🔹 Technical Aspects of Pulmonary Lung Cancer Resections featuring the Invited Master Surgeon Lecture from Gaetano Rocco @MSKCancerCenter
🔹 Update on Clinical Trials in Thoracic Oncologic Surgery
🔹 Rapid Fire Orals I -
Memorial Sloan Kettering Cancer Center reposted
Targeted Onc
@TargetedOnc
Geoffrey Y. Ku, MD (@MSKCancerCenter) discusses the state of biomarkers in gastric/gastroesophageal junction cancers and where precision medicine still falls short.
🎥 WATCH: www.targetedonc.com/view/dr-ku-biomarker-testing-gastric-…
#gastriccancer #gejcancer #gicancers #oncology #precisionmedicine -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK is heading to Boston for #astro26, starting Saturday! We look forward to connecting with colleagues and sharing our work in radiation oncology.
ASTRO
@ASTRO_org
There's still time to register: Join us in Boston or online from Sept. 26–30 for #astro26!
Connect with colleagues, explore the latest research and innovations in radiation oncology, and discover new ideas shaping the future of cancer care.
We can't wait to see you in Boston—or have you join us virtually!
Register now: www.astro.org/meetings-and-education/micro-sites/2026/ann…This media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center reposted
ASTRO
@ASTRO_org
There's still time to register: Join us in Boston or online from Sept. 26–30 for #astro26!
Connect with colleagues, explore the latest research and innovations in radiation oncology, and discover new ideas shaping the future of cancer care.
We can't wait to see you in Boston—or have you join us virtually!
Register now: www.astro.org/meetings-and-education/micro-sites/2026/ann…This media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Coming up at #ims26: MSK's @aksimhal will present an AI model that uses information from each clinical visit to predict progression in smoldering multiple myeloma. @Myeloma_Society
🗓️ Friday, September 25 | 11 a.m. BT / 6 a.m. ET -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Starting at 11 a.m. BT at #ims26 in Glasgow: Dr. Theresia Akhlaghi will present new findings that point to CD4-dominant, T-helper-skewed T cell state as a contributor to movement and neurocognitive toxicity after BCMA-directed CAR T therapy in multiple myeloma.
@TAkhlagh @Myeloma_Society @szusmani @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Research led by Dr. Agnel Sfeir’s lab at MSK identified a hidden structural weakness in rogue DNA found in aggressive cancers.
In lab studies, blocking the protein that repairs this DNA caused it to become unstable and gradually disappear from cancer cells.
Learn more: -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Over the next three days, learn about the latest myeloma research advances during #ims26 poster sessions!
Join @hhashmi87 and @CarlynRTanMD to explore their latest findings:
•Real-world analysis on early vs. late line cilta-cel for R/R multiple myeloma
• Pilot study on romosozumab for myeloma-related bone disease in postmenopausal patients
• Prior BCMA exposure outcomes with teclistamab & elranatamab for R/R multiple myeloma
• Hematology-oncologists’ perspectives on an on-body injector for subcutaneous dosing in multiple myeloma
Poster sessions: Sept. 23, 24, & 25 | 12 p.m. BT | Hall 4
@MSKCancerCenter @szusmani -
Memorial Sloan Kettering Cancer Center reposted
Francesco Maura
@FrancescoMaura4
This is a clinical practice-changing study showing how to identify patients without GPRC5D who are therefore refractory to anti-GPRC5D therapies. The great news is that this is based on IHC ➡️easy to use in clinic. #ims26 @MSKCancerCenter @szusmani
Juanjo Garcés
@juanjogrcs
(TODAY) Stop by our poster to learn how to better treat patients with #gprc5d-related therapies!
#mmsm #ims2026 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Happening at #ims26, MSK myeloma specialist @FrancescoMaura4 will take part in a Meet the Experts session on genomics and genetics. @Myeloma_Society
🗓️ September 23, 2026 | 12 p.m. BT / 7 a.m. ET -
Memorial Sloan Kettering Cancer Center reposted
Hamza Hashmi
@hhashmi87
🔬 #ims26: Is "lines of therapy" really the right way to decide who gets CAR-T?
At #ims26, we present real-world data on cilta-cel as early vs. late-line therapy in RRMM challenging a metric built for trial design and not biology.
This matters as CAR-T access debates intensify, real-world evidence like this could reshape how we define "eligibility" beyond a simple line count.
Swing by our poster, ask questions, let's talk data
📋 Poster PA-079 | Wed, Sept 23 | 12–1 PM
'Ciltacabtagene Autoleucel as Early Versus Late Line of Therapy for Patients with Relapsed Refractory Multiple Myeloma: A Real World Analysis'
#mmsm #multiplemyeloma #cart #medtwitter -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Looking forward to #ims26 and the conversations ahead about myeloma research and care. See you there! 👋
Myeloma Society
@Myeloma_Society
Here’s a first look at #ims26. 👀 We look forward to welcoming you tomorrow morning!
-
Memorial Sloan Kettering Cancer Center reposted
Karlo Perica
@PericaKarlo
Now online @NatureComms, our manuscript describing why the myeloma CAR T cell cilta-cel is more effective than a very similar CAR, ide-cel.
Led by the very talented Kevin Herrera and Sneha Mitra, and in collaboration with the Leslie Laboratory.
@MSKCancerCenter @szusmani -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨 The @FDA has approved imlunestrant (Inluriyo™) in combination with abemaciclib (Verzenio®) for patients with ER-positive, HER2-negative advanced #breastcancer with an ESR1 gene mutation who were previously treated with hormone therapy.
The approval is based on results from the EMBER-3 clinical trial. MSK breast medical oncologist @jhaveri_komal was International Study Chair and member of the steering committee for the trial.
Learn more: www.mskcc.org/news/imlunestrant-stops-progression-of-er-h… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to Zaza Gelashvili, a graduate student in the lab of cell biologist Dr. Philipp Niethammer at the @GSKGradSchool, who recently received the 2026 Chairman’s Prize, an annual award established by Louis V. Gerstner Jr., GSK Board of Trustees Chair Emeritus and namesake of the school, to recognize an outstanding GSK student who is the first author of research published in a scientific journal.
Zaza's work has uncovered new ways that cells sense physical change and turn that information into coordinated responses.
“This award encourages me to continue pursuing fundamental questions in basic research, where some of the most revealing results emerge when biological systems do not behave as predicted," says Zaza.
Congratulate Zaza below and learn more about his research here: www.mskcc.org/news/2026-gsk-chairmans-prize-recognizes-re… -
Memorial Sloan Kettering Cancer Center reposted
Himanshu Nagar
@HimanshuNagarMD
Dr. Matt Dallos from @MSKCancerCenter on the ABCs of immunotherapy and its role in #prostatecancer
-
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
🧵 1/10 The arc: POLAR - MDF – TIE
Pancreatic cancer is profoundly resistant to immune checkpoint inhibitors.
Yet, POLAR (pembrolizumab plus olaparib) trial showed that a subset of patients, especially with HRD (gBRCA2/1m or gPALB2m) tumors, can achieve remarkably durable control.
That led us to two questions:
#1 👆🏼what makes these tumors immunogenic?
#2 ✌️what makes that immunity actually work?
👑 #2. POLAR TIE @biorxivpreprint
www.biorxiv.org/content/10.64898/2026.09.17.752426v1
#1. MDF www.biorxiv.org/content/10.64898/2026.03.15.711961v1
#0. POLAR @NatureMedicine www.nature.com/articles/s41591-026-04299-5
#cancer #immunotherapy #pancreaticcancer #ici #brca #hrd #3episodes @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @ldiaz1971 @debschrag
@PanCAN @oncodaily @OncoDailyGI @OncoAlert @OncBrothers @brunolarvol -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
This week, MSK recognized Nursing Professional Development (NPD) Week. 👏
Our NPD specialists support nurses throughout every stage of their professional journey, from welcoming new nurses and supporting transition to practice to developing competencies, facilitating simulation, and preparing our teams for the future of cancer care.
Our work is grounded in a bold vision: to help MSK become the world’s leading authority on cancer by investing in our people and building the next generation of oncology nursing experts. Through education, professional development, mentorship, and innovation, we are preparing nurses not only for today's practice, but to lead the cancer care of tomorrow.
We are proud to support the incredible nurses of MSK as they learn, grow, lead, innovate, and transform cancer care.💙
#npdweek2026 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK's Basking Ridge location in New Jersey recently recognized its 20th anniversary, offering specialized care, including chemotherapy, radiation, and immunotherapy, closer to home.
The celebrations included food, sweet refreshments, a photo booth, and more.
Learn more about our MSK Basking Ridge location: www.mskcc.org/locations/directory/mskcc-basking-ridge -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK identifies a tumor-secreted protein that primes the lungs for metastasis; shows how a new drug combination improves survival in patients with advanced clear cell renal cell carcinoma; and more: www.mskcc.org/news/msk-research-highlights-august-31-2026
-
Memorial Sloan Kettering Cancer Center reposted
MSK ScienceEducation
@MSKEducation
🎉 Congratulations to our 10 Slam finalists! 👏 You were all fantastic and it was truly inspiring to learn about the incredible and diverse work happening at @MSKCancerCenter. Our #mskpostdocs @MSKPDA gave the judges a real challenge… choosing winners was no easy task! 🤗
-
Memorial Sloan Kettering Cancer Center reposted
UroToday.com
@urotoday
Is the best yet to come in #kidneycancer? @MVossMD @MSKCancerCenter joins @zklaassen_md @GACancerCenter breaking down 3 kidney cancer abstracts in this discussion on UroToday:
- RADICAL: Radium‑223 + cabozantinib in bone‑metastatic RCC closed early for futility (~90 pts) with more symptomatic skeletal events on the combo arm, though KM curves hint at possible late benefit in some.
- Non‑clear cell RCC: Cadonilimab (CTLA‑4/PD‑1 bispecific) + axitinib showed ~50% ORR with no primary progressive disease in a phase 2 study.
- KEYNOTE‑564 ctDNA: Baseline ctDNA+ in only 5–10% of patients, but >95% specificity; ctDNA+ patients had a 20% absolute 2‑year recurrence risk reduction with adjuvant pembrolizumab.
#watchnow > www.urotoday.com/video-lectures/asco-2026/video/5728-is-t… -
Memorial Sloan Kettering Cancer Center reposted
NYClimate
@NYClimate
Ahead of #nycclimateweek, we’re recognizing three institutions leading the way on building decarbonization through the #nyccarbonchallenge: @FITNYC, @MSKCancerCenter, and @ESRTsocial. 1/2
-
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
Join us next week for the 2026 Pulmo-Oncology Symposium @MSKCancerCenter, a state-of-the-art interdisciplinary program focused on the evolving care of patients with cancer who experience pulmonary comorbidities and complications of cancer and its therapies. Attend live on Sept. 25 — in person at MSK or virtually — or register for on demand access.
Topics will cover:
— Pulmonary complications, including treatment-related pulmonary hypertension, graft-versus-host disease, and bronchiectasis
— Advances in lung cancer care, including novel systemic therapies and bronchoscopic ablation
— Treatment-related toxicities, including radiation-induced lung injury and severe immune checkpoint inhibitor pneumonitis
— Emerging technologies and approaches, including AI, telehealth, and health education in the age of social media
🔗 mskcc.cloud-cme.com/course/courseoverview?p=1&eid=62266
@EldenVan @IP_DOC @TLChaunzwaMD -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Memorial Sloan Kettering Cancer Center (MSK) and @OpenEvidence have partnered to bring cutting-edge AI and precision oncology expertise closer to the point of care. By integrating OpenEvidence into MSK's Epic workflow and embedding MSK's @OncoKB™ precision oncology knowledge base directly into OpenEvidence, clinicians can access trusted, evidence-based insights within their existing clinical workflows.
“We're excited that OpenEvidence will widen OncoKB's reach, bringing MSK's expert interpretation of a patient's unique cancer genetics to cancer care providers across the U.S. to help them make molecularly informed treatment decisions,” says Dr. Debyani Chakravarty (@CDebyaniPhD), a lead scientist for OncoKB at MSK.
Learn more about this new collaboration: www.mskcc.org/news-releases/mskcc-msk-and-openevidence-pa… -
Memorial Sloan Kettering Cancer Center reposted
OpenEvidence
@OpenEvidence
Today, Memorial Sloan Kettering Cancer Center (MSK) and OpenEvidence announced a partnership to advance precision oncology. This partnership includes integration of OpenEvidence within MSK’s Epic workflow, and bringing OncoKB™, MSK's precision oncology knowledge base, directly into OpenEvidence for its broader use by physicians outside of @MSKCancerCenter.
“AI has the potential to fundamentally change how we translate an increasingly complex and rapidly expanding body of knowledge into better decisions for patients,” – Anaeze Offodile, M.D., Chief Strategy Officer at MSK.
Full press release:
www.mskcc.org/news-releases/mskcc-msk-and-openevidence-pa… -
Memorial Sloan Kettering Cancer Center reposted
YSM Department of Radiology & Biomedical Imaging
@YaleRadiology
Many thanks to @lisabodei of @MSKCancerCenter for presenting our Sept. 15 #radiology Grand Rounds on, “From a Mono Isotopic Therapy to a Multi-Modal ‘Imagenomic’ Future.” Here’s Dr. Bodei, left, with her host, Georges El Fakhri, PhD, DABR of @YaleMed.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
💙 We're proud to be ranked among the Top 10 children's cancer centers in the nation and the best cancer center for children in New York by @USNews. Together, we're advancing pediatric cancer care through research, innovation, and compassionate support.
Learn more: -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Employee Spotlight | Dr. Andrew Kobets, a pediatric neurosurgeon, is a new member of MSK Kids, the pediatric program at MSK.
Dr. Kobets is a specialist in pediatric brain and spine tumors, including medulloblastoma, astrocytoma, and ependymoma. He also has a genuine passion for helping children and families to navigate the most challenging time that most of them will ever face.
Dr. Kobets sees patients at MSK’s main hospital and at MSK Westchester.
Here, Dr. Kobets shares what gives him hope and drives him every day to be there for the kids and families in his care:
www.mskcc.org/news/meet-andrew-kobets-pediatric-neurosurg… -
Memorial Sloan Kettering Cancer Center reposted
AUB SAANA
@AUB_SAANA
Join us in congratulating the recipients of the 2026 AUB-SAANA Awards!
The Academic Achievement Award - Dr. @TabarViviane - Chair of the Department of Neurosurgery at @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
Moving to mROS1 🎯! @alexdrilon @MSKCancerCenter presents the 1L results of ARROS-1. Zidesamtinib demonstrated impressive ORR, CNS ORR, PFS. Half the rates of dose reduction compared to taletrectinib, cognitive effects not seen but peripheral edema, even grade 1/2 can have a QOL impact.#wclc26
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Don't miss this #wclc26 Presidential Symposium: @MSKCancerCenter lung cancer expert Dr. Alexander Drilon will present efficacy and safety data on a treatment for TKI-naive advanced ROS1+ non-small cell lung cancer.
September 14, 2026, at 9:38 a.m. KST
Presentation details: cattendee.abstractsonline.com/meeting/21487/Session/48
@alexdrilon -
Memorial Sloan Kettering Cancer Center reposted
OncoDaily
@oncodaily
As we continue our special OncoDaily tradition - the 𝟭𝟬𝟬 𝗜𝗻𝗳𝗹𝘂𝗲𝗻𝘁𝗶𝗮𝗹 𝗪𝗼𝗺𝗲𝗻 𝗶𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 - We’re proud to introduce the third part of our 2026 list, highlighting the next 10 remarkable women who are making a lasting impact in oncology.💫
🪄Eileen M. O’Reilly, MD, FASCO (@EileenMOReilly) is an internationally recognized gastrointestinal oncologist and Winthrop Rockefeller Endowed Chair of Medical Oncology at Memorial Sloan Kettering Cancer Center (@MSKCancerCenter), where she co-directs the David M. Rubenstein Center for Pancreatic Cancer Research and leads the HPB and Neuroendocrine Cancers Section.
In 2026, O’Reilly led a phase 3 clinical trial of the KRAS-targeted therapy daraxonrasib in pancreatic cancer, research that contributed to the FDA approval of the drug for metastatic pancreatic adenocarcinoma. Her contributions have been recognized with the 2023 Giants of Cancer Care Award, election as Fellow of ASCO in 2024, and MSK’s 2025 Willet F. Whitmore Award for Clinical Excellence.
Read the third part below.
🔗oncodaily.com/100/100-influential-women-583646
#oncology #oncodaily100 #oncodaily #cancer #100influentialwomen #womeninoncology -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK researchers are using AI to design better proteins for CAR T cell therapy and other cancer treatments.
In mouse models, an AI-designed binder from @CalebLareau’s lab controlled tumor growth significantly better than binders used in FDA-approved CAR T therapy targeting BCMA.
“We’re changing what was traditionally educated guesswork with more informed, evidence-based design.”
Learn more: www.mskcc.org/news/using-ai-to-design-better-cancer-thera… -
Memorial Sloan Kettering Cancer Center reposted
Klebanoff_Lab
@KlebanoffLab
🚨 New collaborative paper with the Thompson lab in @CellCellPress!
Mitochondrial ATP shapes T cell fate by fueling chromatin remodeling.
Congrats to 1st author Charles Ng & Craig—and to @Korbinian_NK, who led the @KlebanoffLab contribution!
www.cell.com/cell/fulltext/S0092-8674(26)00996-7 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Leading experts in #cancerresearch, including Dr. @AndreaCercek, a gastrointestinal medical oncologist at MSK, reflected on the significant strides made in tackling the disease, along with the work that remains to be done toward finding a cure, at the TIME100 (@TIME) Health Leadership Forum in New York.
Dr. Cercek, who was also a 2025 TIME100 Health honoree, highlighted the growing potential of #vaccines and immunotherapy to harness the immune system to fight cancer.
“The hope … between vaccines and immunotherapy as well is that they harness the immune system, which is really the most powerful drug we have,” she said. “It can fight anything as long as it’s equipped to do so and it recognizes something is foreign, and so it’s really that combination that needs to happen for therapy to work.”
Read more: time.com/collection/time100-leadership-forums/2026/from-t… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Don't miss the Third Annual Kyle Barlogie Plasma Cell Disorders Symposium from October 9–12, 2026. Register by September 11 to get the early-bird reduced rate!
Register here: cvent.me/7lkMy2
@MSKCancerCenter @MayoClinic @szusmani -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨 The @FDA has granted “Breakthrough Therapy” designation to FMISO, a specialized imaging tracer that can help identify patients with #hpv-positive #throatcancer who may safely receive less-intensive radiation treatment.
“This has been an absolute game changer for treating certain people with throat cancers caused by the human papillomavirus or HPV,” says MSK radiation oncologist @imrtlee, who pioneered the approach.
Learn more: www.mskcc.org/news/low-dose-radiation-possible-game-chang… -
Memorial Sloan Kettering Cancer Center reposted
Caleb Lareau
@CalebLareau
Three years ago, my lab at @MSKCancerCenter set out to see if we could harness AI for new therapeutic proteins.
Today in @natBME, our first step in developing these AI-designed molecules as anti-tumor therapies is online.
Read more here: 1/n www.mskcc.org/news/using-ai-to-design-better-cancer-thera… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The @FDA has recently approved #zanidatamab (Ziihera®) as an additional medication for newly diagnosed patients with HER2-positive cancers of the stomach and esophagus who are getting chemotherapy. Patients may receive another drug called tislelizumab (Tevimbra®) at the same time.
“These combination treatments offer hope for patients with this aggressive disease,” says Dr. Geoffrey Ku, a gastrointestinal medical oncologist at MSK.
“For patients with HER2-positive cancers of the esophagus, gastroesophageal junction, and stomach, the combination of zanidatamab and chemotherapy — with or without the immunotherapy drug tislelizumab — improves outcomes compared with older therapies.”
Learn more about this approval: www.mskcc.org/news/fda-approves-zanidatamab-for-her2-posi… -
Memorial Sloan Kettering Cancer Center reposted
New York Yankees
@Yankees
Tonight we were honored to welcome 6 year-old Vincent Diaz, his family, and Director of @MSKCancerCenter’s Pediatric Department Rachel Corke 💛
Vincent was diagnosed with Acute Lymphoblastic Leukemia in the Spring of 2024. After completing his treatment last month, he rang the bell tonight at Yankee Stadium in recognition of the end of his treatment! 👏🔔
To find out more about how you can support this important cause, visit www.mlbtogether.com/childhoodcancer. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🎉 Congratulations to MSK's most recent awards and appointments, including @TuomasTammela for receiving a 2026 Stephenson Global Scholar Grant by @sgpcri, @ZedaZhang for receiving a @PCFnews Young Investigator award, and more:
www.mskcc.org/news-releases/msk-awards-and-appointments-a… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
#peptides are having a moment in the wellness world, but how much is actually backed by science?
“We don’t know what these products actually do in the body because there have not been appropriate scientific experiments,” shares Dr. Larry Norton, a breast medical oncologist at MSK.
Read more about what is currently known — and what remains unknown — about peptides and your health: www.mskcc.org/news/reality-check-what-you-should-know-abo… -
Memorial Sloan Kettering Cancer Center reposted
OncoDaily
@oncodaily
We are pleased to announce Guillem Argilés, colorectal cancer researcher at @MSKCancerCenter, as a Speaker at Immunõ 2026!
Join us virtually from September 24–30, 2026.
oncodaily.com/immuno-2026-global-virtual-congress-on-immu… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Some call it chic. We call it our mission.
-
Memorial Sloan Kettering Cancer Center reposted
AUbreastcancer
@AUbreastcancer
Join @AUbreastcancer for Eating Well During Breast Cancer Treatment on 11.10.26, 12–1 PM on Zoom. Learn nutrition strategies to help manage side effects and support your well-being during breast cancer treatment. @MSKCancerCenter
Register: app.etapestry.com/onlineforms/AdelphiBreastCancerProgram/… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨 New research published in @NEJM shows daraxonrasib is showing early but strong signs it could be effective against lung cancer.
In a phase 1/2 clinical trial led by MSK thoracic medical oncologist @KCArbourMD, more than 30% of patients with previously treated metastatic #lungcancer responded to the targeted therapy.
“Daraxonrasib could really expand our treatment options for people with lung cancer, especially those who do not respond well to chemotherapy and immunotherapy,” says Dr. Arbour.
Learn more: www.mskcc.org/news/potential-new-treatment-for-lung-cance… -
Memorial Sloan Kettering Cancer Center reposted
MedEdge MEA
@MedEdgeMEA
In an exclusive interview, @MSKCancerCenter’s Dr. Andrew Kobets discusses advances in minimally invasive paediatric brain and spine tumour surgery.
✍🏻 By Sumayya Parveen A.
🔗 Read more: mededgemea.com/memorial-sloan-kettering-cancer-centers-mi…
#braintumours #childrenshealth #mededgemea -
Memorial Sloan Kettering Cancer Center reposted
BackTable Urology
@_backtableUro
In this collaborative episode of BackTable Urology, Dr. Sam Funt, Dr. Rich Matulewicz (@RichMatulewicz), and Dr. Sean Kern talk through treatment of testicular cancer with an evolving case discussion of a 32-year-old presenting with a testicular mass.
A great listen covering the nuances of patient selection with treatment-specific pros and cons!
Listen to the episode here: na2.hubs.ly/H07zMfL0
This podcast was developed in collaboration with the Society of Urologic Oncology (@UroOnc).
#uro327 #sou #testicularcancer #urology #urologiconcology @WRNMMC_DHA @MSKCancerCenter @RuchikaTalwarMD -
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
Nearly 40% of men and women will be diagnosed with cancer in their lifetime, yet fewer than 20% of cancers are detected through recommended preventive screening. From recognizing the earliest signs of cancer to managing the long-term needs of survivors, general practice providers play a critical role across the cancer care continuum.
This new, intensive course from @MSKCancerCenter is designed for PCPs, APPs, and nurse navigators and will provide practical guidance on cancer screening and early detection, diagnostic testing and triage, incidental findings and surveillance, treatment-related complications, and survivorship care. Learn more: mskcc.cloud-cme.com/course/courseoverview?P=5&EID=62937
Course Planners:
@PamelaJohnsonMD
@lonnyyarmus
@DrScalabrino -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
What if a blood test could detect lymphoma more precisely than an imaging scan?
MSK lymphoma specialist Dr. Mark Roschewski is studying how blood-based tests for circulating tumor DNA may help guide treatment decisions and determine whether cancer remains after therapy. Learn more: www.mskcc.org/clinical-updates/beyond-scan-see-how-blood-… -
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
Thank you @wolfblitzer and @CNN for highlighting this milestone for #pancreaticcancer 💜
For more than four years I’ve had the privilege of helping develop daraxonrasib clinically and leading translational research while caring for patients with previously treated advanced disease.
Some have had exceptional responses lasting years. Children’s weddings. Grandchildren’s graduations. Long-planned travels. Seeing these moments become possible has been a true joy in my clinic.
That is what more time means.
Now I lead MSK’s participation in RASolute-303 to test daraxonrasib as initial treatment for metastatic disease. Across the field we are also developing next-generation RAS inhibitors and degraders and testing novel combinations and treatment in earlier-stage disease.
Our goal is to make this benefit deeper and longer-lasting for our patients.
Grateful to fellow investigators including @EileenMOReilly and all the international investigators, our clinical and research teams and above all our courageous patients and families.
This is why we do this work.
And this is just the beginning.
@CpcrMsk @MSK_DeptOfMed @RevMedicines @PanCAN @OncBrothers @OncoAlert @oncodaily @OncoDailyGI @lustgartenfdn
Jeff Storobinsky
@JeffStorobinsky
MAJOR Pancreatic Cancer Advancements. @wolfblitzer w/ @CentralParkWMD
8.27.26 5 MinutesThis media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
Now FDA finally delivered!!
Please welcome 🎂 the new birth of 💫 “RASONque”
Congrats 🎉🎊 to every investigator, nursing teams, research teams and courageous patients! #pancreaticcancer #pdac
@MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @EileenMOReilly @MichaelMayMD @MarcHilmi @FiyinfoluB @schoenfeld_j @AnupriyaSingha9
www.fda.gov/news-events/press-announcements/fda-approves-… -
Memorial Sloan Kettering Cancer Center reposted
Joshua Budhu
@JoshuaBudhu
Excited to share our new paper in Equity Neuroscience @SEQUINS24
We reviewed the landscape of patient navigation in neuro-oncology 🧠
🔗 doi.org/10.1016/j.neuros.2026.100067
@MSKCancerCenter -
Memorial Sloan Kettering Cancer Center reposted
VJ Oncology
@VJOncology
It was lovely to speak with Darren Feldman (@DrDarrenFeldman) at #asco26 to hear the results of a Phase III trial of cabozatinib + nivolumab in advanced #nccrcc 📊🩺
Watch his interview here: www.vjoncology.com/video/ffgffi7nkng-phase-ii-trial-of-ca…
#oncology #trialupdate #kidneycancer #kcsm #uroonc @ASCO @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The @FDA has approved #daraxonrasib for certain patients with metastatic pancreatic cancer. MSK’s @EileenMOReilly led the phase 3 trial at MSK showing it doubled median survival compared with chemotherapy.
“To date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease."
Learn more about the approval and what it could mean for patients: www.mskcc.org/news/how-daraxonrasib-could-improve-pancrea… -
Memorial Sloan Kettering Cancer Center reposted
UroToday.com
@urotoday
Radiopharmaceuticals in #prostatecancer: Payloads, Carriers, Targets, and Combinations. Michael Morris, MD @MSKCancerCenter & @DrRanaMcKay @UCSanDiego join @DrPhilKantoff @ConvergentRx to discuss isotope and carrier selection, combination strategies, and emerging targets in radiopharmaceutical therapy. #watchnow on UroToday > www.urotoday.com/video-lectures/radiopharmaceutical-thera…
-
Memorial Sloan Kettering Cancer Center reposted
Michael May
@MichaelMayMD
Looking forward to joining Dr. Huffman @DanaFarber today for a meaningful discussion on extending therapeutic breakthroughs in pancreatic cancer to older adults, and what we are doing @MSKCancerCenter to refine our treatment algorithm for these people. @CpcrMsk @EileenMOReilly
Brandon Huffman, MD
@BHuffmanMD
Join us at 12PM EST for a patient-centric webinar on the landscape for RAS inhibitors in older individuals with pancreatic cancer.
“Understanding RAS Inhibitors: New Cancer Therapies for Older Adults”
@MichaelMayMD @DanaFarber @letswinpc @KRASKickers
dfci.zoom.us/webinar/register/WN_aOcfDdC3TFa9OTESUu_8tQ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New clinical trial data led by MSK’s Dr. Robert Motzer supports a novel combination therapy for patients with advanced clear cell renal cell carcinoma whose disease progressed after immunotherapy.
The findings, published in @TheLancet, point to a potential new treatment option. Learn more: www.mskcc.org/clinical-updates/msk-researchers-demonstrat… -
Memorial Sloan Kettering Cancer Center reposted
UroToday.com
@urotoday
Pluvicto® approval in androgen pathway modulator naive #prostatecancer and the origins of #psmaddition. Michael Morris, MD @MSKCancerCenter joins @sartor_oliver @EJHospital discussing the origins and clinical implications of PSMAddition. The study returned an rPFS hazard ratio of 0.72 for lutetium-177 PSMA-617 added to an ADT plus ARPI doublet. Dr. Morris views lutetium as a clearer intensification option than docetaxel; no controlled trial has established docetaxel's benefit when added to an ADT plus ARPI backbone. #watchnow > www.urotoday.com/video-lectures/radiopharmaceutical-thera…
-
Memorial Sloan Kettering Cancer Center reposted
Hamza Hashmi
@hhashmi87
Hot off the Press: Fortunate to be a part of this massive effort led by #alexandradrefuss from @MSKCancerCenter now published in @BloodCancerJnl 🎇🎆🙌
Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma | Blood Cancer Journal
rdcu.be/fA8M3
#mmsm #medtwitter #meded #onctwitter #cartcell #openaccess -
Memorial Sloan Kettering Cancer Center reposted
ACS Journal Cancer
@JournalCancer
Outpatient administration of cycle 2 of blinatumomab can be administered safely with no unexpected, severe, or life-threatening toxicities according to conclusions of a new study led by Yannis K. Valtis MD of @MSKCancerCenter.
Read more: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70566
@OncoAlert -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK uncovers why some leukemia patients stop responding to new drugs; examines how bone’s hardness shapes the immune battle against metastasis; shows how a telehealth tobacco treatment program helps cancer patients quit smoking; and more: www.mskcc.org/news/msk-research-highlights-july-30-2026
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨 Bad News for Cancer: Hear from MSK cancer biologist Dr. Scott Lowe and MSK senior scientist Dr. Aveline Filliol as they share research about an early stage #cart cell technique designed to target a cell surface protein called #upar that shrank solid tumors in laboratory experiments.
"Our research really has been trying to understand the principles of cancer development, the idea that you have to know the enemy if you're going to attack it," says Dr. Lowe.
While this research is still in early stages, it reflects a growing understanding of how tumors shape their local environment to survive, and how that information can be harnessed to develop new treatments.
Learn more about the research: www.mskcc.org/news/cell-surface-protein-upar-may-hold-key… -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
With lutetium Lu 177 vipivotide tetraxetan–based therapy now approved in the hormone-sensitive setting, Michael J. Morris, MD, of @MSKCancerCenter discusses how this new indication impacts prostate cancer management #pcsm #oncology
Read more: www.onclive.com/view/lutetium-lu-177-vipivotide-tetraxeta… -
Memorial Sloan Kettering Cancer Center reposted
AATS
@AATSHQ
We are proud to announce that the #itsos2026 invited lecturers include Haiquan Chen, Gaetano Rocco @MSKCancerCenter, and David H. Harpole Jr. @DukeCTSurgery. View lecture topics below. Register by August 26 to save: events.aats.org/international-thoracic-surgical-oncology-…
-
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
We’re excited to announce that the fall @MSKCancerCenter CME course lineup is now open for registration! Explore a diverse range of topics shaping cancer care, with many programs available in person, live virtually, or on demand. Multiple continuing education credit types are available for healthcare professionals across disciplines.
Explore the full fall lineup and register at msk.org/cme. -
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
The management of #rhabdomyosarcoma requires a highly coordinated, multidisciplinary approach. Jointly presented by the Departments of Pediatrics and Surgery at @MSKCancerCenter, Rhabdomyosarcoma 2026: Advancing Science, Improving Outcomes will bring together experts across disciplines to share the latest scientific advances, evidence-based practices, and emerging strategies shaping the future of care.
Join us October 19 in person or virtually, or register for on-demand access following the live symposium.
🔗 mskcc.cloud-cme.com/course/courseoverview?P=0&EID=62451
Course Directors
J. Ted Gerstle, MD
Leonard H. Wexler, MD
Mariel Marrano, MSN, RN, FNP-BC
Rochelle D. Smithingell, MHA, MBA, BSN, RN -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The @US_FDA has expanded approval of Pluvicto® (¹⁷⁷Lu-PSMA-617) as an initial treatment for people with metastatic prostate cancer whose tumors are positive for the PSMA protein.
The approval is based on results from the phase 3 PSMAddition trial, led in the U.S. by MSK genitourinary medical oncologist Dr. Michael Morris.
Learn more: www.mskcc.org/news/fda-approves-promising-therapy-advance… -
Memorial Sloan Kettering Cancer Center reposted
ASTRO
@ASTRO_org
2026 ASTRO Fellow Spotlight Series:
Congratulations to Daphna Y. Gelblum, MD, from Memorial Sloan Kettering Cancer Center on being named a 2026 ASTRO Fellow!
We look forward to recognizing you at #astro26.
View the list of 2026 Fellows: www.astro.org/about-astro/recognition-awards/fellows-list
@MSKCancerCenter @MSK_RadOnc -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
(1/2) MSK researchers have identified ZFP36L2, a protein that connects the gut’s damage-sensing system to the ability of cells to change identities and repair an injury.
The study, published in @Nature, was led by @KarunaMDPhD and @Qingwen_J. www.mskcc.org/news/msk-scientists-find-molecular-switch-h…
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
(2/2) “For a long time, we studied the ways in which cells were changing identities — but this is the first time we've been able to explain the mechanism behind how it happens,” says @KarunaMDPhD.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Inherited #brca1 and #brca2 mutations may affect how breast tumors evolve and respond to treatment, according to a study from MSK and collaborators involving genomic data from more than 5,800 patients.
MSK breast medical oncologist @PedramRazaviMD spoke with @TargetedOnc about the findings and how they could inform future treatment strategies. Learn more: www.targetedonc.com/view/how-inherited-brca-mutations-sha… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Top news! MSK is ranked #2 in the nation for cancer care, the #1 cancer center in New York, and #1 for urology care for the 4th year in a row, via the @usnews 2026-2027 Best Hospitals list.
Learn more: www.mskcc.org/news-releases/mskcc-ranked-top-cancer-cente… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's most recent awards and appointments, including Dr. Joan Massagué for receiving the Kennedy Award from @IENBarcelona; @Dan_A_Heller for being named a Gray Foundation Grant Recipient; Dr. Alexander Gitlin for being named a Pew-Stewart Scholar for Cancer Research, and more: www.mskcc.org/news-releases/msk-awards-and-appointments-j…
-
Memorial Sloan Kettering Cancer Center reposted
Science Translational Medicine
@ScienceTM
The expansion of CD4+ #cart cells drives unusual neurotoxicities in patients with #multiplemyeloma who are taking #ciltacabtagene autoleucel (cilta-cel), according to new work in a new special issue. @MSKCancerCenter scim.ag/4w011tW
-
Memorial Sloan Kettering Cancer Center reposted
David H Aggen, MD PhD
@Dr_Aggen
Fantastic to see rising stars Dr. Aditi Gupta and Dr. @patmcgillivray from @MSK_DeptOfMed presenting their work - so much more to explore about the immunogenic effects of enfortumab vedotin - informing how we build on the EV+PD-1 backbone @BladderCancerUS @BCAN_Research
Brendan Guercio
@BrendanGuercio
Congratulations to Dr. Aditi Gupta (@MSKCancerCenter) and mentors @DrRosenbergMSK @Dr_Aggen on fantastic @BladderCancerUS YIA results! Her research on biomarkers of response and resistance to enfortumab vedotin ± pembrolizumab is a critical step toward improving patient outcomes. #bladdercancer #bcantt26
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The @US_FDA has approved zidesamtinib for advanced ROS1-positive non-small cell #lungcancer that stopped responding to other #ros1 drugs.
MSK thoracic medical oncologist @alexdrilon led the clinical trial. Overall, 44% of patients responded, with 69% still responding after one year.
Learn more: www.mskcc.org/news/fda-approves-zidesamtinib-for-lung-can… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The FDA has approved #zenocutuzumab for adults with advanced, inoperable, or metastatic cholangiocarcinoma driven by an NRG1 gene fusion.
The approval is based on a clinical trial led by MSK’s @AliSchram giving patients with limited treatment options a new choice. Learn more: -
Memorial Sloan Kettering Cancer Center reposted
Brendan Guercio
@BrendanGuercio
Exceptional research shared at #bcantt26 by @patmcgillivray (@MSKCancerCenter).
His @BladderCancerUS YIA investigates treatment resistance and drivers of differentiation in micropapillary #bladdercancer. Understanding this aggressive subtype is critical to improving outcomes.
Huge congratulations to Dr. McGillivray & mentors @IyerGopa & @DrRosenbergMSK on this vital work! -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
🎙️On this episode of #oncliveonair, @mjmauroMD of @MSKCancerCenter discusses his approach to TKI use in chronic myeloid leukemia and how new FDA approvals inform his practice.
Listen here ➡️: www.onclive.com/view/tkis-continue-to-move-forward-and-ex…
#leusm #oncology -
Memorial Sloan Kettering Cancer Center reposted
eMedEvents
@eMedEvents
HER2-directed therapies are transforming the treatment of HER2-positive breast cancer and advancing personalized cancer care.
Join Shanu Modi, MD, of @MSKCancerCenter , at #herhealth2026: Updates in Breast & Gynecologic Cancer Therapeutics as she shares the latest evidence and clinical insights on HER2-directed therapies for breast cancer.
Learn from faculty at leading U.S. cancer centers as they cover precision oncology, immunotherapy, ADCs, biomarker-driven treatment strategies, AI in oncology, and more.
💰 Save 20% on in-person registration with code: HERHEALTH20
⏳ Offer ends July 31.
🔗 Register Now:
www.emedevents.com/herhealth-oncology-cme-conference-newy…
📅 October 9–10, 2026
📍 New York City + Virtual
🎓 Earn up to 10 AMA PRA Category 1 Credits™, 10 ABIM MOC Credits, and 10 Nursing Contact Hours.
Organized by eMedEd and presented by eMedEvents.
#her2positivebreastcancer #breastcancer #medicaloncology #breastoncology #precisiononcology #oncologycme #mskcc #cancercare -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A major challenge in cancer #immunotherapy is #tcell exhaustion, when the immune system's cancer-fighting cells become too fatigued to keep attacking tumors.
New research from the lab of Dr. @SantoshVardhana at MSK has identified a key signaling molecule, #mek, that helps drive this exhaustion. The findings suggest that blocking MEK could help T cells stay active longer and enhance the effectiveness of immunotherapy.
“A tragic part of T cell exhaustion is that the immunotherapy seems to be working for patients, and then it fades,” says Dr. Vardhana, an MSK physician-scientist who treats people with lymphoma. “Many of them experience a brief wisp of promise only to have it taken away.”
Even more promising is that FDA-approved MEK inhibitors already exist, potentially accelerating the path to clinical testing and improved patient outcomes. “We’re excited about applying this finding to enhance multiple forms of immunotherapy,” Dr. Vardhana says.
Read more about how this insight into T cell exhaustion could lead to new ways to boost the effectiveness of immunotherapy: www.mskcc.org/news/new-strategy-could-prevent-cell-exhaus… -
Memorial Sloan Kettering Cancer Center reposted
CancerWorld
@CancerWorldmag
🧬𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝘄𝗵𝗲𝗻 𝗼𝗻𝗲 𝗼𝗳 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆’𝘀 𝗺𝗼𝘀𝘁 𝗲𝗹𝘂𝘀𝗶𝘃𝗲 𝘁𝗮𝗿𝗴𝗲𝘁𝘀 𝗳𝗶𝗻𝗮𝗹𝗹𝘆 𝗯𝗲𝗰𝗼𝗺𝗲𝘀 𝘁𝗿𝗲𝗮𝘁𝗮𝗯𝗹𝗲?
For decades, 𝗥𝗔𝗦 was considered “undruggable.” The Phase III 𝗥𝗔𝗦𝗼𝗹𝘂𝘁𝗲 𝟯𝟬𝟮 trial is now challenging that belief—and reshaping the future of metastatic pancreatic cancer.
In this exclusive interview, 𝗗𝗿. 𝗘𝗶𝗹𝗲𝗲𝗻 𝗢’𝗥𝗲𝗶𝗹𝗹𝘆 explains why 𝗱𝗮𝗿𝗮𝘅𝗼𝗻𝗿𝗮𝘀𝗶𝗯 represents more than a breakthrough drug. It signals a new era of precision oncology for one of medicine’s most challenging diseases.
📖 Read the full interview: cancerworld.net/when-ras-becomes-treatable-eileen-oreilly…
@oncodaily | @ASCO | @MSKCancerCenter | @amalsargsyan -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The @US_FDA recently announced full approval for the drug, selpercatinib (Retevmo®), for treating patients ages 2 and older who have advanced cancer carrying a rare genetic change called RET fusion.
@alexdrilon, a thoracic oncologist and Chief of the Early Drug Development Service at MSK, led one of the two clinical trials that resulted in the FDA granting full approval. It’s the latest example of treating cancer based on a specific genetic alteration, rather than the location of the tumor.
“The full FDA approval of selpercatinib marks a pivotal moment in precision oncology — not simply because it validates this therapy, but also because it extends hope across a broad landscape of tumor types, from lung and thyroid to pancreatic, ovarian, and even rare pediatric tumors,” says Dr. Drilon.
Dr. Drilon led one of the two clinical trials that resulted in the FDA granting full approval.
Read more about how selpercatinib and the key takeaways: www.mskcc.org/news/fda-grants-full-approval-to-targeted-t… -
Memorial Sloan Kettering Cancer Center reposted
Santosh Vardhana
@SantoshVardhana
Thank you to @MSKCancerCenter for highlighting recent published work from @tanmana_mitra!
www.mskcc.org/news/new-strategy-could-prevent-cell-exhaus… -
Memorial Sloan Kettering Cancer Center reposted
AATS
@AATSHQ
This month's member spotlight features general #thoracic surgeon Gaetano Rocco from @MSKCancerCenter. Read Dr. Rocco's bio and learn about his first experience with AATS at the 72nd Annual AATS Meeting in Los Angeles in 1992: www.aats.org/gaetano-rocco?hss_channel=tw-75062801
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Calling all fourth-year medical students interested in #radonc! 🩺
Join the Chief Residents from MSK for a virtual info session about MSK's @MSK_RadOnc Residency Program. Learn more about our training program, clinical training, research opportunities, and resident life.
Register: www.mskcc.org/teaser/radiation-oncology-residency/residen… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Five years after her passing, the final study from the lab of the late MSK developmental biologist and department chair Dr. Kathryn Anderson has been published, revealing how a critical signaling molecule called WNT tells cells in the embryo what they will become.
Colleagues worked together to bring her final scientific contribution to publication.
Learn more: www.mskcc.org/news/final-discovery-from-lab-of-dr-kathryn… -
Memorial Sloan Kettering Cancer Center reposted
Melanoma Research Foundation
@CureMelanoma
#mrfresearchwednesday -- Today's campaign amplifies @Joshua_M_Weiss of @MSKCancerCenter - recipient of a Resident/Fellow Award presented in memory of Lynn Kessler.
Dr. Weiss's project titled, "Targeting development lineage programs in melanoma," explores melanocytes, the pigment cells of the skin and other tissues from which melanoma is derived and how blocking these genes once melanoma is already established may impact disease progression.
Related to the project's research aims, Dr. Weiss offers, "During early development there are genes that instruct the creation of melanocytes, which are the pigment-containing cells of the skin and body. Previous research has shown that these same genes play a critical role in promoting melanoma formation. Our research strives to investigate whether these genes could serve as novel therapeutic targets to improve the standard of care for melanoma patients."
To learn more about Dr. Weiss's work, visit -- melanoma.org/news-press/research-grant/joshua-weiss/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Curiosity, focus, and commitment are essential qualities for an aspiring scientist. But speak to any accomplished researcher and they will tell you strong mentorship matters most of all.
That’s why, nearly 20 years ago, the @GSKGradSchool was founded through the generosity of the late Louis V. Gerstner, Jr. — a visionary leader, philanthropist, and longtime champion of science and education — to train young scientists as a critical pillar of MSK.
Hear from three graduates — Drs. Robert Bowman, Elizabeth Wasmuth, and Zhong-Min Wang who are among the 144 PhD scientists who have graduated from GSK since its founding nearly 20 years ago: www.mskcc.org/news/gsk-alumni-on-what-makes-great-scientist -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New follow-up data from clinical trials confirms that a powerful treatment for bladder cancer provides lasting survival benefits: People receiving #enfortumabvedotin plus #pembrolizumab lived twice as long as those receiving standard chemotherapy.
"As an oncologist treating bladder cancer for more than two decades, this feels like a huge sea change and hopefully a turning point toward longer survival from this difficult disease," says MSK's @DrRosenbergMSK.
Learn more: www.mskcc.org/news/bladder-cancer-therapy-padcev-provides… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
What do cancer cells eat? That exact question is the focus of the lab of MSK biologist Dr. Lydia Finley.
At its most fundamental level, cancer is a disease of cells doing things they’re not supposed to do, she says. Dr. Finley and her fellow researchers study cell metabolism, aka how cells convert nutrients into the various molecules that they need to function.
“In simple terms, it’s how cells use food to grow,” she says. “And without access to the right food, cancer cells won’t be able to survive.”
By shedding new light on fundamental biology, the researchers aim to find new strategies that could work against cancer.
“Many of the drugs we use against cancer target fundamental processes in cells that have gone haywire — affecting how they function, how they grow, how they stay alive,” Dr. Finley says. “So we have to know, in great detail, how these processes work if we want to develop new therapies.”
Read more: www.mskcc.org/news/what-cancer-cells-eat-cancer-metabolis… -
Memorial Sloan Kettering Cancer Center reposted
Vumedi Oncology
@VuMediHemOnc
🧬 What did the GLEAM trial teach us about targeting CLDN18.2 in pancreatic cancer?
Dr. Wungki Park @CentralParkWMD @MSKCancerCenter reviews ESMO GI 2026 results from the phase II GLEAM study, highlighting why zolbetuximab fell short on overall survival while uncovering promising biomarker signals that could shape the next generation of CLDN18.2-targeted therapies.
🎥 Watch on #vumedi: www.vumedi.com/video/esmo-gi-2026-insights-zolbetuximab-g…
#pancreaticcancer #precisiononcologyThis media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Scientists from MSK and @WeillCornell found that a small subset of T cells, called stem T cells, are responsible for making new T cells and continuously replenishing them in chronic disease.
"We've identified what we believe is a fundamental mechanism, one that the immune system uses broadly to sustain itself in chronic disease," says MSK cancer immunologist Dr. Andrea Schietinger.
Learn more: www.mskcc.org/news/rare-stem-cells-may-hold-key-to-fighti… -
Memorial Sloan Kettering Cancer Center reposted
DAVA Oncology
@DAVAOnc
Screening nonsmokers with family history: Dr. Jamie Chaft (@MSKCancerCenter) reviews LUNG-CARE and TALENT data, the adenocarcinoma in situ question, and Sybil AI via LEGACY trial, and concluded that there is no role for early screening in the US today. #davalung
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The @US_FDA has granted full approval for an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial #sarcoma.
The clinical trials resulting in the drug’s approval were led by MSK sarcoma specialist and immunotherapy expert Dr. @sandrapdangelo.
“This treatment offers a meaningful new option for people with this rare cancer,” Dr. D’Angelo says. “It is also an important step forward in the development of T cell therapies for solid tumors, which has been a major challenge.”
Read more about this treatment: www.mskcc.org/news/immunotherapy-clinical-trial-shows-pro… -
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
We’re pleased to announce an inaugural two-day virtual symposium @MSKCancerCenter highlighting the latest advances in surgical oncology across the cancer care continuum. Explore perioperative optimization, minimally invasive approaches, enhanced recovery, complex surgical emergencies, technology and innovation, workforce development, and health equity.
Attend live October 28–29 or register for on demand access. Learn more: mskcc.cloud-cme.com/course/courseoverview?P=5&EID=62793 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK investigates how a natural antifungal compound produced by helpful gut bacteria might help protect vulnerable patients; finds that a protein “fingerprint” in blood could predict dangerous clots in cancer patients; and more: www.mskcc.org/news/msk-research-highlights-june-19-2026
-
Memorial Sloan Kettering Cancer Center reposted
James J. Harding, MD
@HardingJJMD
Congratulations @CowzerDarren. Great deep dive #biliarytractcancer #genomics outcomes and resistance! @MSK_DeptOfMed @MSKCancerCenter @MskccCMO @DSolit @GABOUALFA @EileenMOReilly
Clinical Cancer Research
@CCR_AACR
Now online: Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer doi.org/10.1158/1078-0432.CCR-26-0428
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today, we’re celebrating the strength of our MSK patients, families, caregivers, and staff alike. Wishing you a safe and meaningful Fourth of July. 🇺🇸
-
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
Thrilled 🤩 to join this 🔋Powerhouse session at #esmogi2026.
Incredible to witness so many advances in pancreatic cancer presented on one stage and to share it with leaders including Brian Wolpin, Nilo Azad, Eric Van Cutsem and
@MacarullaTeresa
The era of K/RAS inhibitors, rational combinations and biomarker-driven therapeutics is here. #daraxonrasib #zoldonrasib Unprecedented response rates in this disease ever!
We keep learning from the positive and negative work.
Search and REsearch!
I really appreciate the team so dedicated to learn the science from the #gleam trial #cldn18 #zolbetuximab
We’re finally moving the field forward.
The future of pancreatic cancer has never looked brighter 💡
#pancreaticcancer #kras #ras #teamscience @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @PanCAN @letswinpc @Pankind_Aus @OncoAlert @OncBrothers @oncodaily @OncoDailyGI @NatPancFdn -
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
Team science 🧬 at its best.
Great to catch up with the MSK family and honorary MSK friends at #esmogi26
The future of GI oncology will be built through collaboration, bold ideas and friendships that span institutions and continents.
Onward.
#pancreaticcancer #gioncology #kras #ras #cldn18 #translationalresearch #grit @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @myESMO @EileenMOReilly @BenWestphalen @graokane @BasGrootKoerkam @nasca_vincenzo @wei_ac -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Advances in #prostatecancer care are making treatment more personalized than ever. At MSK, experts evaluate each person's disease to better understand their level of risk, helping guide treatment decisions while offering advanced surgery, radiation therapy, targeted therapies, and clinical trials when needed.
“At MSK, we’ve made many advances in prostate cancer treatment,” says MSK’s Dr. Massimiliano Spaliviero. “But just as important, we developed more personalized evaluations to better understand each person’s disease.” Learn more: www.mskcc.org/news/new-prostate-cancer-treatments-aim-to-… -
Memorial Sloan Kettering Cancer Center reposted
Nature Medicine
@NatureMedicine
#cart cell therapy shows promise in treating #precancers like smoldering myeloma, but requires careful patient selection due to potential risks.
News & Views from Sham Mailankody & Eric Jurgens @MSKCancerCenter.
dlvr.it/TTJKw8 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK decodes how mesothelioma evades #immunotherapy; shows why a common kidney cancer treatment combination falls short; and supports a free, open-source #ai-driven drug discovery initiative. Learn more: www.mskcc.org/news/msk-research-highlights-june-11-2026
-
Memorial Sloan Kettering Cancer Center reposted
Targeted Onc
@TargetedOnc
Could CAR T redefine treatment for AL #amyloidosis? 💡 Heather J. Landau, MD (@MSKCancerCenter) discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL amyloidosis.
🎥 Watch: www.targetedonc.com/view/rapid-hematologic-clearances-and…
#hematology #oncology -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨 The @US_FDA has approved datopotamab deruxtecan (Dato-DXd) for patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for immunotherapy.
The approval was based on results from the international Tropion-Breast02 clinical trial, led in the U.S. by MSK breast medical oncologist Dr. Tiffany Traina. Learn more: www.mskcc.org/news/fda-approves-new-treatment-for-triple-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Spotlighting research from MSK gynecologic medical oncologist and #asco26 Conquer Cancer grant recipient @AliSchram ⬇️
Conquer Cancer, the ASCO Foundation
@ConquerCancerFd
By focusing on genetic blueprints instead of tumor locations, Conquer Cancer grant recipient Dr. Alison Schram unlocked a historic FDA "double win" for rare, aggressive cancers. 🔬 Early-career funding accelerates life-changing discoveries. Read how her targeted therapy research is giving patients like Ahmet their lives back: www.conquer.org/cancer-research/meet-researchers/alison-s…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK researchers are helping advance #morphic, an international effort to determine the biological functions of the roughly 20,000 protein-coding genes in the human genome.
The work aims to transform the human genome from a list of parts into an instruction manual, helping researchers better understand what our genes do and how they shape human development.
Learn more about how MSK researchers are contributing to this effort: www.mskcc.org/news/morphic-inside-ambitious-project-to-un… -
Memorial Sloan Kettering Cancer Center reposted
Elizabeth McKenna
@ElizSMcKenna
Now in @CD_AACR: Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-related Survival - by Justin Jee, @SawyersLabMSKCC, @nikolausschultz, et al. @MSKCancerCenter - these findings suggest that the previously reported survival advantage may be explained by selection bias.
Cancer Discovery
@CD_AACR
Now online: Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival doi.org/10.1158/2159-8290.CD-26-0403
-
Memorial Sloan Kettering Cancer Center reposted
Michael May
@MichaelMayMD
Already giving patients daraxonrasib off trial only 21 days after the practice-changing results were presented at @ASCO 2026. Thank you to @MSKCancerCenter and @RevMedicines for allowing us to fill this unmet need safely and efficiently. @EileenMOReilly @CentralParkWMD @CpcrMsk
-
Memorial Sloan Kettering Cancer Center reposted
Coach Matt Rotonda
@rotonda21
To Linds: I love you, and I never blinked.
Lindsay rang the bell at 10:55AM EST at @MSKCancerCenter.
4 months- unexpected diagnosis, surgery, radiation… behind us because you are a champion.
To all who are fighting, or know someone who is… we see you. We support you. -
Memorial Sloan Kettering Cancer Center reposted
HemeHub
@HemeHub
📚 🚀Catch up on the latest insights in Multiple Myeloma from our session with Saad Z. Usmani, MD (@szusmani) and Adeel Khan, MD (@khancology)!
➡️Watch the full session: youtu.be/5Nt9T02Fyy4?t=1
#multiplemyeloma #plasmacelldisorders #hematology #oncology #medicaleducation #patientcare #immunotherapy #celltherapy #noveltherapies #clinicaltrials #hemehub #hematologyeducation
@MSKCancerCenter @UTSWHemeOnc @MM_Hub @llmcongress @theMMRF @RareDiseases -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
A new study by @RShouval and team evaluated the frequency of second primary malignant neoplasms among those with #lymphoma or #myeloma who received T-cell–engaging bispecific antibodies. @MSKCancerCenter
Learn more: jamanetwork.com/journals/jamaoncology/article-abstract/28… -
Memorial Sloan Kettering Cancer Center reposted
Selwyn M. Vickers
@DrVickersMSK
On Juneteenth we honor a defining moment in our nation’s history and reflect on the ongoing work of expanding opportunity, dignity, and justice for all. I am grateful for the many colleagues, patients, and community partners who help us move forward with purpose and compassion.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK gastrointestinal medical oncologist @EileenMOReilly on being honored with the Hope Through Compassion Award from the @lustgartenfdn. The award recognizes her dedication to patients and her leadership in developing innovative clinical research for #pancreaticcancer.
Watch to learn more about her approach to advancing pancreatic cancer research: www.youtube.com/watch?v=yMiu7lLSSQQ -
Memorial Sloan Kettering Cancer Center reposted
Francesco Maura
@FrancescoMaura4
Together with @RossFirestone and @szusmani
we are happy to share our thoughts on SUCCESSOR-2 clinical trial published few days ago on @TheLancet
#mmsm #mezigdomide @MSKCancerCenter @MSK_DeptOfMed www.thelancet.com/journals/lancet/article/PIIS0140-6736(2… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Results from the phase 3 #rasolute302 trial found that #daraxonrasib significantly improved overall survival compared with chemotherapy in previously treated metastatic #pancreaticcancer.
Learn more about the findings and what MSK's @EileenMOReilly says they could mean for the future of pancreatic cancer treatment: www.mskcc.org/news/how-daraxonrasib-could-improve-pancrea… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🎉Congratulations to MSK pathologist Dr. Alexander Gitlin for being named a 2026 Pew-Stewart scholar!
Dr. Gitlin will uncover how cell signaling controls the nature and magnitude of inflammation in normal physiology and in disease, focusing on the intersection of inflammatory signaling and cell death pathways.
The Pew Trusts
@pewtrusts
And finally, meet the 2026 Pew-Stewart scholars.
These five scientists are tackling some of cancer research’s biggest questions, from pioneering new strategies to engineering lifesaving treatments.
www.pew.org/en/about/news-room/press-releases-and-stateme… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK scientists have uncovered a hidden role for RNA.
Researchers led by MSK molecular and cell biologist @Mayr_Christine found that #rna can act as a protein chaperone, helping critical regulatory proteins fold into the correct shape as they are being made.
The findings reveal a previously unknown function of RNA and suggest this mechanism may be used by more than 2,700 human genes. Learn more: www.mskcc.org/news/msk-scientists-uncover-rnas-hidden-rol… -
Memorial Sloan Kettering Cancer Center reposted
ACS Journal Cancer
@JournalCancer
New editorial by Drs. Gleneara E. Bates-Pappas Jamie S. Ostroff of @MSKCancerCenter | Breaking barriers: Opt-out tobacco dependence treatment in oncology care
acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr…
@OncoAlert -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
For years, patients with triple negative #breastcancer (#tnbc) have had limited treatment options beyond chemotherapy.
Now, based on results from the MSK-led TROPION-Breast02 trial, Dato-DXd was FDA approved in May 2026 as first-line therapy for adults with advanced HER2 negative breast cancer who have already received endocrine-based therapy and chemotherapy, making it the first TROP2-directed ADC to gain FDA approval as first-line in this patient population.
“Dato-DXd significantly improved overall survival for this challenging subtype of breast cancer, where historic median overall survival has been about 12 months,” said Dr. Tiffany Traina, lead and senior author of the study and MSK breast medical oncologist.
Read more about the study: www.mskcc.org/clinical-updates/landmark-study-makes-dato-… -
Memorial Sloan Kettering Cancer Center reposted
Stanford Cancer Institute
@StanfordCancer
Can pancreatic cancer be “cold yet vaccinable”? @TheVinodLab from @MSKCancerCenter shares insights on RNA vaccines at the SCI Breakthroughs in Cancer Series. Watch the full seminar: www.youtube.com/watch?v=Jv57Mb9PXnc #pancreaticcancer
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🗓️ Save the date! Join MSK’s annual Survivorship Celebration: Resilience in Motion on June 12 at 4pm ET. This event features survivorship stories, wellness practice, and expert guidance to navigate life after cancer.
Featured speakers include: MSK integrative medicine specialist Dr. @JunMaoMD; MSK thoracic medical oncologist Dr. Cardinale Smith; and MSK exercise physiologist Dr. Jessica Scott, who will share science-based evidence to guide and manage survivorship.
Register here: meetmsk.zoom.us/webinar/register/WN_jEtHjOyUT2uiC6BUbxgnZA -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK radiation oncologist Dr. Nancy Lee (@imtrlee) presented new findings at the 2026 @asco suggesting some people with HPV-related #throatcancer may be able to receive significantly lower doses of radiation while maintaining excellent outcomes.
The approach could help reduce treatment-related side effects while preserving effectiveness. Learn more: www.mskcc.org/news/low-dose-radiation-possible-game-chang… -
Memorial Sloan Kettering Cancer Center reposted
Melanoma Research Foundation
@CureMelanoma
#mrfresearchwednesday – we are honored to highlight Sarah Kim of @MSKCancerCenter, recipient of an MRF Medical Student Award, with funding support provided in Memory of Peter Looney and the Looney Legacy Foundation.
Sarah’s work titled, “Benign Dermoscopic Morphology by Skin Tone and Anatomic Site”, will create a diverse image database of benign skin lesions across all skin tones to improve diagnosis, reduce unnecessary biopsies and help ensure future AI tools work effectively for everyone.
Of her work, Sarah offers, “This research aims to build a diverse image database of benign skin lesions seen through dermoscopy, helping dermatologists better recognize these common skin findings across different skin tones and body sites. By improving our understanding of what benign lesions look like in diverse patients, we hope to support more accurate melanoma detection, reduce unnecessary biopsies, and help ensure that patients of all skin tones receive thoughtful, equitable skin cancer care."
To learn more about Sarah’s work, click here: melanoma.org/news-press/research-grant/benign-dermoscopic… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's most recent awards and appointments, including @YJanjigianMD, Dr. Samuel Cytryn, and Dr. Jeremy Tchack for being awarded funding by the Torrey Coast Foundation; Dr. Scott Lowe for receiving the 2026 Lotus Award from the @PershingSqFdn; Dr. Kathleen Foley for being inducted into the Giants of Cancer Care Class of 2026; and more: www.mskcc.org/news-releases/msk-awards-and-appointments-m…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
On June 8–9, Dr. Carol Brown, the Associate Cancer Center Director for Diversity and Outreach at MSK, will meet with experts at the #prescancerpanel to explore the evidence linking modifiable risk factors to cancer and discuss opportunities to reduce cancer risk.
MSK breast surgeon Dr. Neha Goel will also present at this event.
Learn more: prescancerpanel.cancer.gov/reports-meetings/prevention-op… -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
WATCH 👀: @ggardnermd of @MSKCancerCenter discusses the importance of elevating the national conversation surrounding gynecologic cancers through collaborative efforts.
See the whole video here ➡️: www.onclive.com/view/dr-gardner-on-the-infrastructure-nee…
#gyncsm #oncology -
Memorial Sloan Kettering Cancer Center reposted
Luis G Parra L
@luisgparral
Honored to have completed my observership at @MSKCancerCenter under the mentorship of @GABOUALFA. Grateful for the opportunity to learn from leaders in GI oncology at one of the world’s top cancer centers.
Thank you to the 2026 IDEA @ConquerCancerFd and @ASCO
@icesi @FVLCali -
Memorial Sloan Kettering Cancer Center reposted
Lasker Foundation
@LaskerFDN
In a randomized, international phase 3 trial, @EileenMOReilly et al. at @MSKCancerCenter and Dana Farber Institute gave previously treated metastatic pancreatic cancer patients either chemotherapy or the experimental oral medication daraxonrasib. Treatment with daraxonrasib led to significantly longer overall survival and progression-free survival than chemo, per @NEJM study: www.nejm.org/doi/full/10.1056/NEJMoa2605555
-
Memorial Sloan Kettering Cancer Center reposted
Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰
@szusmani
Finally some warm weather, beautiful evening out at our annual Myeloma Service picnic in the park this week!! #mmsm @MSKCancerCenter @MSK_DeptOfMed
-
Memorial Sloan Kettering Cancer Center reposted
The ASCO Post
@ASCOPost
🆕 #asco26 data in unresectable #hcc.
Ghassan K. Abou-Alfa, MD, PhD, FASCO, of @MSKCancerCenter discusses efficacy and safety findings from the phase III EMERALD-3 trial evaluating immunotherapy-based combinations with TACE.
🎥 Watch here: ascopost.com/videos/asco-2026/ghassan-k-abou-alfa-on-unre… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's @Joshua_M_Weiss for being selected as a 2026 @CureMelanoma Grant Recipient! 🎉
Melanoma Research Foundation
@CureMelanoma
We are proud to announce this year's outstanding Resident/Fellow Research Grant Awardees! Each of the 12 awardees selected are enabling innovative research for the cutaneous and rare melanoma subtypes that will advance the melanoma treatment landscape.
Grantees will explore topics ranging from vision loss after plaque radiotherapy for uveal melanoma, trends in acral melanoma, how circadian rhythms and immunotherapy outcomes are improved by light therapy and more.
View the MRF's funded researcher webpage to learn more and stay tuned for our awardee spotlights through the #mrfresearchwednesday campaign -- melanoma.org/research-science/research-grants-rfps/funded… -
Memorial Sloan Kettering Cancer Center reposted
Rebecca Scalabrino, DO
@DrScalabrino
Congratulations to our @MSKCancerCenter graduating body imaging fellows and cardiac imaging 🫀fellow!
-
Memorial Sloan Kettering Cancer Center reposted
The ASCO Post
@ASCOPost
🆕 #asco26 data in dedifferentiated #liposarcoma.
Mark A. Dickson, MD, of @MSKCancerCenter, discusses SARC041 findings showing a statistically significant progression-free survival benefit with abemaciclib in advanced dedifferentiated liposarcoma.
🎥: ascopost.com/videos/asco-2026/mark-a-dickson-on-advanced-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Thank you to everyone who participated in Memorial Sloan Kettering Cancer Center (MSK)'s #nycformsk and made the event so special.
On May 29, 35 iconic New York City brands came together to celebrate MSK’s 142nd anniversary and support lifesaving research and care.
Thank you to all of our partners and for everyone who shopped, donated, or even brought your pup to Madison Avenue, every act of generosity made a difference.
Learn more and donate here: giving.mskcc.org/programs/nyc-for-msk -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to Dr. Martin Weiser, who has been selected to serve serve as the next Chair of the Department of Surgery at MSK.
Dr. Weiser currently holds the Stuart H.Q. Quan Chair in Colorectal Surgery, is a world-renowned academic colorectal surgeon, and has held a number of important leadership roles in his 25 years on the faculty at MSK, including serving for the past 10 months as the Acting Department Chair.
Join us in welcoming Dr. Weiser to the role of Chair of the Department of Surgery by commenting below. 👏 -
Memorial Sloan Kettering Cancer Center reposted
SEOM
@_SEOM
🏙️ Desde Chicago, en #asco26 @ASCO
⭕️ Vídeo de highlights #cáncerdePulmón en onconexion.es
🩺 El Dr. Jaime Rubio, de @MSKCancerCenter, resume las novedades más relevantes: avances en terapias dirigidas para RET, ALK y EGFR (LIBRETTO-432, LORIN, CROWN y WU-KONG28), nuevos datos de inmunoterapia en HARMONi-6 y estrategias innovadoras con ADCs en enfermedad metastásica
#onconexion26 👇🏻This media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center reposted
Trinity St James's Cancer Institute
@CancerInstIRE
A landmark moment for pancreatic cancer, these findings highlight what transformative progress can look like. Congratulations to @EileenMOReilly & team @MSKCancerCenter advancing this research driving forward a new standard of care in a disease that has long needed breakthroughs
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
⚠️ New findings presented in the plenary session at #asco26 suggest daraxonrasib could help usher in a new era of treatment for metastatic pancreatic cancer.
In a phase 3 study led by @EileenMOReilly and colleagues, patients receiving #daraxonrasib lived a median of 13.2 months compared with 6.7 months for those treated with chemotherapy.
"To date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease."
Learn more: www.mskcc.org/news/how-daraxonrasib-could-improve-pancrea… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Missed some of the research presented by MSK experts at #asco26?
We've rounded up selected highlights spanning sarcoma, liver cancer, lung cancer, prostate cancer, blood cancers, and more: www.mskcc.org/clinical-updates/msk-research-roundup-at-as… -
Memorial Sloan Kettering Cancer Center reposted
Amy Xu, MD PhD
@AmyXuMDPhD
🧬 Can tumor genomics be used to personalize radiation dose?
Grateful to present results from our phase II trial on dose de-escalated radiation therapy for ATM altered tumors at #asco2026
Great to see ☢️ #radiation in the early-phase #precisiononcology space! -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Presented at #asco26 and published in @NEJM, findings from the phase 3 RASolute 302 trial showed that #daraxonrasib significantly improved overall survival and progression-free survival compared with chemotherapy in previously treated metastatic pancreatic cancer.
MSK's @EileenMOReilly was among the leaders of this research.
World News Tonight
@ABCWorldNews
New data from the company Revolution Medicines shows people with advanced pancreatic cancer who took daraxonrasib nearly doubled their overall survival. David Muir has details on the clinical trial. abcworldnewstonight.visitlink.me/7iPJS_
-
Memorial Sloan Kettering Cancer Center reposted
-
Memorial Sloan Kettering Cancer Center reposted
Amy Xu, MD PhD
@AmyXuMDPhD
✨ Inspiring to see @imrtlee representing ☢️ radiation oncology on the ASCO main stage.
Practice changing work reducing treatment toxicities and integrating radiographic biomarkers to personalize radiation
@MSK_RadOnc @MSKCancerCenter
#asco26 #radonc
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today at #asco26: MSK radiation oncologist Dr. Nancy Lee (@imrtlee) shared long-term results showing that many patients with HPV-positive #oropharyngeal cancer were able to receive lower-dose radiation while maintaining durable outcomes and experiencing fewer side effects.
-
Memorial Sloan Kettering Cancer Center reposted
Yelena Y. Janjigian MD
@YJanjigianMD
Are you an early-career pathologist 🦠 looking to break into translational cancer research? Join our GEC accelerator 🚀team at drive the next generation of therapies for GE cancer. Pathology. Biomarkers. Clinical trials. Discovery. Apply here:
www.linkedin.com/jobs/clinical-fellow-jobs -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
An important moment for sarcoma research at #asco26. 👏
Congratulations to MSK’s Dr. Mark Dickson and the SARC041 investigators on the plenary presentation of these findings.
Patrick Schöffski
@schoffski
Liposarcoma in the holy grail of oncology - the Plenary Session at the ASCO Annual Meeting 2026. Congratulations to Mark A. Dickson and all SARC041 investigators!
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Findings published in @NEJM and featured at #asco26 showed that #daraxonrasib significantly improved overall survival and progression-free survival compared with chemotherapy in previously treated metastatic #pancreaticcancer.
We’re proud of MSK’s contribution to this research, including the work of @EileenMOReilly and colleagues.
NEJM
@NEJM
Presented at #asco26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: www.nejm.org/doi/full/10.1056/NEJMoa2605555
@ASCO -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Insights from yesterday’s session with MSK’s @GABOUALFA at #asco26 ⬇️
HemOnc Today
@HemOncToday
🤝 #tremelimumab & #durvalumab with transarterial chemoembolization may help address an unmet need in advanced #livercancer, #asco26 data show.
💬 “I am beyond excited to see that there are more options for our patients,” @GABOUALFA @MSKCancerCenter says. vist.ly/56brk -
Memorial Sloan Kettering Cancer Center reposted
Trinity St James's Cancer Institute
@CancerInstIRE
Exciting momentum in precision oncology, congratulations to @MSKCancerCenter @MichaelMayMD on advancing three first‑line metastatic KRAS inhibitor trials opening at @MSKCancerCenter in the coming weeks. A powerful signal of what’s ahead, with many more studies on the horizon.
Michael May
@MichaelMayMD
Three first line metastatic KRAS inhibitor trials open at @MSKCancerCenter in the next few weeks. Many more here and coming soon in almost every disease setting. @CpcrMsk @EileenMOReilly @CentralParkWMD @AnupriyaSingha9
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Highlighting research co-led by MSK gastrointestinal medical oncologist @EileenMOReilly presented at #asco26. ⬇️
CBS News
@CBSNews
New drug nearly doubles survival rates in some pancreatic cancer patients, study says. www.cbsnews.com/news/pancreatic-cancer-treatment-daraxonr…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
We're excited to share Memorial Sloan Kettering Cancer Center (MSK)'s bold new advertising campaign “This Is What We Do.”
From a jazz musician whose life was saved by precision oncology, to a prostate cancer patient who has become an advocate for early detection, the stories we share throughout this campaign reflect our shared mission and the extraordinary outcomes we achieve together.
🔹 This is treatment on a cellular level.
🔹 This is care on a personal level.
🔹 This is hope on another level.
When someone receives a cancer diagnosis, we want them to know exactly what to do next: come to MSK. And when patients choose MSK, they’re choosing better, longer lives.
Learn more: www.mskcc.org/care-at-msk -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Closing out strong, join MSK radiation oncologist Dr. Amy Xu (@AmyXuMDPhD) at #asco26 as she presents results from a phase II study evaluating genomically personalized radiation dose de-escalation in patients with pathogenic ATM mutations.
🕒 Tuesday, June 2 | 10:39 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The final push at #asco26. 💙
We’re proud of the many MSK experts who have shared their research and expertise throughout the meeting, but we’re not done yet!
Stay tuned as we bring you highlights from the final day in Chicago. -
Memorial Sloan Kettering Cancer Center reposted
Vivek Subbiah, MD
@VivekSubbiah
⭐️What an amazing session at #asco26 👉🏼“To Boldly Deliver Where No Drug Has Gone Before: Antibody‑Drug Conjugates in Sarcoma.” 👉🏼Such a delight to speak on this topic, and even more fun seeing the amazing Bob Maki @MSKCancerCenter on stage fully in Star Trek theme🖖🏼
A perfect blend of science, creativity, and joy @ASCO @OncoAlert @PTarantinoMD @OpenMedicineHQ -
Memorial Sloan Kettering Cancer Center reposted
Trinity St James's Cancer Institute
@CancerInstIRE
Truly a landmark moment, incredible leadership from Dr Eileen O’Reilly @EileenMOReilly @MSKCancerCenter @CancerInstIRE driving progress that will change lives. #asco26
Michael May
@MichaelMayMD
Living through history! @EileenMOReilly @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @ASCO
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Spotlighting research from MSK radiation oncologist Dr. Christopher Barker at #asco26 👇
Pauline Funchain
@FunchainMD
RMAPART ph2 single arm definitive RT + peri RT cemiplimab in locally advanced, unresectable cSCC
ORR 65%
2 Y EFS 82% (comparable to resectable disease 👍)
Chris Barker @MSKCC_OncoNotes
#asco26 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Annnnnd he’s a 40 Under 40 in Cancer honoree! 🤩
Alessandro Di Federico
@DiFedericoMD
Happy to show some results at @ASCO on our study on EGFR amplification in EGFRm NSCLC treated w/ osimertinib. EGFR amp (6+ copies) correlated w/ worse PFS & OS despite similar ORR. MET alterations were found at resistance ~2.5 times more frequently in cases w/ baseline EGFR amp.
-
Memorial Sloan Kettering Cancer Center reposted
Edward Christopher "Chris" Dee, MD
@EChrisDee
Feeling hopeful and excited post @ASCO #asco2026
Each year is an opportunity for our #global group to come together, meet mentors, ideate, and break bread.
Tomorrow, the work for people with #cancer begins again.
And what a crew to do this work with 🤩
@MSKCancerCenter -
Memorial Sloan Kettering Cancer Center reposted
Ana I. Velázquez Mañana, MD, MSc, FASCO
@AnaVManana
🫁 #asco26 early stage #lungcancer and SCLC oral abstracts starting now with Dr Jamie Chaft presenting the ALCHEMIST study
@ASCO -
Memorial Sloan Kettering Cancer Center reposted
Edward Christopher "Chris" Dee, MD
@EChrisDee
So proud of my friend and co resident @RoshalP who presented work examining genomic predictors of classical leptomeningeal and nodular leptomeningeal disease @ASCO 🧠
Mentored by Dr @Luke_Pike_MD @pike_lab -
Memorial Sloan Kettering Cancer Center reposted
Wassim Daoud Khatoun
@WDKhatoun
Exciting to see some of the work on leptomeningeal disease done at @MSKCancerCenter. Posters highlighting CSF-based CTC analysis in predicting outcomes in NSCLC by @mjeng21, and genomic correlates of LMD after brain metastasis resection by @roshalp.
@ASCO #asco26 @MSK_RadOnc -
Memorial Sloan Kettering Cancer Center reposted
Fumiko Ladd Chino, MD, FASCO
@fumikochino
Dr Ali Sabbagh @MSKCancerCenter @MSK_RadOnc #asco26 presents his @ConquerCancerFd award winning work showing how a computational model can predict the OS outcome of phase Ill clinical trials of patients with metastatic #prostatecancer #pcsm using the first 4 months of PSA data.
-
Memorial Sloan Kettering Cancer Center reposted
Klebanoff_Lab
@KlebanoffLab
🚨3rd paper in our PI3Ka public neoantigen trilogy is out in @PNASNews! We show that HLA micropolymorphisms govern whether a neoantigen is visible to T cells by tuning neopeptide dynamics, not presentation or static structure. @MSKCancerCenter @parkerici
www.pnas.org/doi/10.1073/pnas.2602949123 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Spotlighting research from MSK molecular genetic pathology fellow @DDdcunha presented today at #asco26 ⬇️
Nicholas Dcunha
@DDdcunha
My first ASCO meeting and a project close to my heart "Aberant Somatic Hypermutation in Large B Lymphomas and Relation to Mutational Signatures, Inc a Novel Haloalkane Pattern." Adding a layer of complexity to cell of origin debate. Thank you @MSKCancerCenter for the opportunity!
-
Memorial Sloan Kettering Cancer Center reposted
Oncology Brothers
@OncBrothers
Why did RASolute302 get standing 👏👏? What is everyone in medicine 🗣️ about today? What does this mean for our patients?
We touch on this with @EileenMOReilly @DrShubhamPant @rachnatshroff #andrewko
⭐️Full 🗣️ on @OncUpdates & our podcast!
#onctwitter @OncoAlertThis media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK’s Dr. Michael Morris presented findings at #asco26 on CONV01-α, an investigational radioligand therapy for metastatic castration-resistant #prostatecancer.
The study showed promising activity and a manageable safety profile in patients previously treated with Lu-PSMA therapy. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK breast medical oncologist @SherryShenMD presented her poster "Clinical impact and temporal evolution of mutational signatures in metastatic lobular breast cancer" today at #asco26.
-
Memorial Sloan Kettering Cancer Center reposted
OncoDaily
@oncodaily
Dr. Emily Alouani on MSH3 as a Potential Biomarker for Immunotherapy Response | ASCO 2026
Dr. Emily Alouani from the Memorial Sloan Kettering Cancer Center (@MSKCancerCenter ) presents groundbreaking research on the clinical implications of MSH3 loss of function in cancer patients receiving immunotherapy.
The study found that MSH3 loss was associated with significantly improved overall survival in patients treated with immunotherapy, adding nearly 13 months of increse in survival.
These findings were validated in an independent Caris cohort, suggesting that MSH3 loss of function might be a predictive biomarker for immunotherapy.
www.youtube.com/watch?v=tVD1iE1XfDw -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK genitourinary medical oncologist @DrDarrenFeldman presented at #asco26 today on the management of brain metastases in patients with germ cell tumors.
The session highlighted the importance of multidisciplinary collaboration and individualized treatment planning for patients with this rare but serious complication. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Emily Wo from @pike_lab shared her poster "Impact of genomic subtype on intracranial outcomes in treatment-naive EGFR-mutant NSCLC with osilmertinib (IGnITE)" today at #asco26 ⬇️
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today at #asco26: MSK pediatric oncologist @EmilySlotkin shared her poster "A phase 1b study of xaluritamig (a STEAP1 x CD3 T-cell engager) in pediatric, adolescent, and adult patients with relapsed/refractory (R/R) #ewingsarcoma" which received an Early-Onset/AYA Research Shoutout from @ASCO.🏅
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Coming up at #asco26: Join MSK melanoma medical oncologist Dr. Alexander Shoushtari for a presentation on how new tumor-infiltrating lymphocyte (TIL) research can be translated into real benefit for patients. @MSKCancerCenter
🕒 Monday, June 1 | 5:30 p.m. CDT
Learn more: -
Memorial Sloan Kettering Cancer Center reposted
Edward Christopher "Chris" Dee, MD
@EChrisDee
Excellent work by Devon Dietrich, a future #radonc, studying early onset cancers in Chicago
#radonc PDs take note of an excellent future oncologist and health services researcher !
@ASCO @ASCOTECAG @JamesFanWu -
Memorial Sloan Kettering Cancer Center reposted
AML Hub
@AML_Hub
CONGRESS | #asco26 | POSTER
Eytan Stein shares the trial design for the phase III REVEAL-ND NPM1 trial assessing the efficacy and safety of revumenib in combination with intensive chemotherapy, in patients aged ≥12 years with ND NPM1m AML.
Approximately 468 patients will be randomized 1:1; enrollment is ongoing. Induction consists of 1–2 cycles of revumenib or placebo with IC, and consolidation consists of 1–3 cycles of revumenib or placebo with cytarabine. Patients may undergo HSCT following induction or consolidation. Maintenance consists of revumenib or placebo monotherapy for up to 2 years.
The primary endpoints are EFS and MRD-negative CR rate, and the key secondary endpoint is OS.
Follow our live feed for more updates: aml-hub.com/medical-information/congresses-asco26
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#amlsm #leusm #mednews #meded #medicalcongress @Doctor_E_Stein @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center reposted
OncoDaily
@oncodaily
Honored to Be a FASCO Inductee at ASCO26 - Komal Jhaveri (@jhaveri_komal)
oncodaily.com/voices/komal-jhaveri-512920
#oncodaily #asco26 -
Memorial Sloan Kettering Cancer Center reposted
Conquer Cancer, the ASCO Foundation
@ConquerCancerFd
Two grantees on the same plenary stage, in two different cancers, on the same day. This is not luck. It is what happens when you identify exceptional scientists early, across every cancer type, and invest in them consistently. Read the announcement: www.conquer.org/news/early-career-grants-global-stages-tw…
#asco26 #researchconquerscancer #conquercancer
Conquer Cancer, the ASCO Foundation
@ConquerCancerFd
This week at #asco26, Dr. Brian Wolpin and Dr. Mark Dickson present major updates on the Plenary Stage. Both researchers were supported early in their careers by Conquer Cancer grants and we are so proud of what they have achieved. See how early investment drives progress.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK medical oncologist Dr. Michael Morris at #asco26 as he presents results from CONVERGE-01 Part 3 evaluating Ac-225 rosopatamab tetraxetan in patients with metastatic castration-resistant prostate cancer previously treated with Lu-PSMA therapy.
🕒 Monday, June 1 | 3:48 p.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Happening now at #asco26: MSK thoracic medical oncologist Dr. Jamie Chaft (@ChaftJamie) presents new findings in resectable non-small cell lung cancer. #nsclc
-
Memorial Sloan Kettering Cancer Center reposted
Edward Christopher "Chris" Dee, MD
@EChrisDee
Proud of @MilitSPatel, who presented our work using #machine #learning to elucidate country specific drivers of global #cancer outcomes @ASCO #asco2026
Full paper in @Annals_Oncology
🔗 www.annalsofoncology.org/article/S0923-7534(25)06275-1/ab… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New findings presented at #asco26 suggest a new approach could help slow the growth of intermediate-stage liver cancer.
An international phase 3 clinical trial led by MSK's Dr. Ghassan K. Abou-Alfa (@GABOUALFA) found that adding dual immunotherapy to TACE significantly increased progression-free survival for people with hepatocellular carcinoma (HCC).
“By combining dual immunotherapy with TACE, we give patients a better chance of living longer while preserving a healthy, working liver.”
Learn more: www.mskcc.org/news/liver-cancer-progression-slowed-by-add… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
⚠️ New findings featured in the plenary session at #asco26 suggest selpercatinib may help reduce the risk of recurrence for people with early-stage #lungcancer driven by RET gene fusions.
A phase 3 clinical trial led by MSK's Dr. Alexander Drilon (@alexdrilon) found that patients who received #selpercatinib after surgery and standard treatment were 83% less likely to have their cancer return, worsen, or lead to death compared with those who received a placebo.
“This drug could transform the way we treat this group of patients.”
Learn more: www.mskcc.org/news/targeted-drug-selpercatinib-greatly-re… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK radiation oncologist Dr. Luke Pike (@pike_lab) presented findings aimed at improving the early detection of brain metastases in #breastcancer. #asco26
-
Memorial Sloan Kettering Cancer Center reposted
Edward Christopher "Chris" Dee, MD
@EChrisDee
Excellent poster by @militspatel stellar student in our group, on genomic determinants of metastatic urothelial #cancer @ASCO #asco2026
Thank you Drs @IyengarPuneeth @HimanshuNagarMD @jjnaylor02 @jonas_willmann for guidance -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A brief pause in the #asco26 coverage for Wolfgang, one of the therapy dogs making the rounds at the meeting. 😍
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK research fellow Dr. Anna Shvygin shares her poster "Treatment duration with avutometinib/defactinib in recurrent low-grade serous ovarian carcinoma by #kras mutation status" today at #asco26. @ASCO
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK's Dr. Baher Krayem shares his poster "Molecular characteristics of therapy-related myeloid neoplasms in PARP inhibitor-treated patients" today at #asco26.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK thoracic medical oncologist @ChaftJamie at #asco26 as she presents results from the phase III ALCHEMIST trial evaluating nivolumab after surgery and adjuvant chemotherapy in patients with non-small cell lung cancer.
🕒 Monday, June 1 | 1:15 p.m. CDT
Learn more: -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today at #asco26: MSK's @ZiadBakouny shares his poster: “Pan-cancer discovery of clinical and genomic determinants of immune-related adverse events" with a fellow attendee.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK medical oncologist @DrDarrenFeldman at #asco26 for an education session on optimizing treatment for patients with poor-risk testicular cancer, including a discussion on the management of brain metastasis.
🕒 Monday, June 1 | 1:51 p.m. CDT
Learn more: -
Memorial Sloan Kettering Cancer Center reposted
Sara Rothschild
@srothschild
More @ASCO news coverage of the SARC041 study of abemaciclib versus placebo in DDLPS. Median PFS of 9.7 months vs. 1.5 months. The efficacy of abemaciclib looks remarkable and we are looking forward to future studies in #liposarcoma #asco26 #sarcoma
-
Memorial Sloan Kettering Cancer Center reposted
Cycle for Survival
@Cycle4Survival
After Chase’s clear cell sarcoma diagnosis, his family found the right team at MSK Kids — and then built a team of their own, Chase the Cure, which has raised over $100,000 to fuel rare cancer research at @MSKCancerCenter. Read the full @NJBIZ story here. njbiz.com/summit-boy-raises-100k-rare-cancer-research/
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
👏👏👏
Edward Christopher "Chris" Dee, MD
@EChrisDee
So proud of @SnehaAhuja22 who presented her first author work as a college sophomore @ASCO
@ASCOTECAG #asco2026
Grateful to @LuisaJacomina, Carl, and @SaraMoufarrij1 for mentoring!
@MSKCancerCenter @MSK_RadOnc -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK’s @GABOUALFA took the podium today at #asco26 to present findings from the phase 3 EMERALD-3 trial.
The study found that adding #immunotherapy to TACE improved progression-free survival for people with intermediate-stage #livercancer. -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
WATCH: @AlanHoMDPhD, discusses the rationale for evaluating a ROR2-targeting antibody-drug conjugate in oropharyngeal squamous cell carcinoma. @MSKCancerCenter #hncsm #oncology
See our head and neck cancers page for more insights!
www.onclive.com/clinical/head-and-neck -
Memorial Sloan Kettering Cancer Center reposted
Ying Liu
@YingLiu88
So privileged to serve as study chair for this first pragmatic and streamlined phase 3 trial in #ovariancancer looking to de-escalate PARPi maintenance. Thanks to all our patients and sites for participating. Let’s keep the momentum going! @NRGonc @TeamOvary_MSK @MSKCancerCenter
MSK Department of Medicine
@MSK_DeptOfMed
Starting soon at #asco26: Gynecologic medical oncologist Dr. Ying Liu will present a poster on the NRG-GY036 trial comparing one vs. two years of maintenance olaparib (±bevacizumab) in #brca-mutated or HRD+ #ovariancancer. @MSKCancerCenter @YingLiu88
🕒 Monday, June 1 | 9 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
GRIT = GI Innovative RAS Therapeutics.
Exciting to see leaders (@EileenMOReilly @debschrag @DrVickersMSK Jeff Drebin @MHLars ) across pancreatic cancer and oncology come together as we enter a new chapter of RAS-directed therapies. 💜
Reminiscing our time in the last 4 years and all the thrills we had seeing their tumor marker and CT improving dramatically in our first patients.
From KRAS inhibition to immune modulation and more meaningful combinations, the future is being built through collaboration, innovation, and translation.
#kras #ras #pancreaticcancer #grit #asco26 @ASCO
@MSK_DeptOfMed @MSKCancerCenter @NatPancFdn @PanCAN @letswinpc @Pankind_Aus @KRASKickers @OncBrothers -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Happening NOW at #asco26! MSK gastrointestinal medical oncologist @GABOUALFA will share findings from the phase 3 EMERALD-3 trial, exploring a new approach to treating intermediate-stage #livercancer.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Day 4 of #asco26 and the momentum continues! MSK experts continue to share new research and clinical insights across a wide range of cancer types, while connecting with colleagues from around the world to discuss the latest advances in cancer care.
Stay tuned for more highlights from Chicago! -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Poster sessions continue in the Exhibit Hall! Swing by between now through 4:30pm to hear MSK experts present new findings in cancer research. #asco26
MSK Department of Medicine
@MSK_DeptOfMed
Join MSK hematology/oncology fellow Dr. Eric Jurgens at #asco26 for a poster on CAR T-cell detection and clonality in immune effector cell-associated enterocolitis after ciltacabtagene autoleucel. @MSKCancerCenter
🕒 Monday, June 1 | 9 a.m. CDT
Learn more: -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK sarcoma medical oncologist Dr. Mark Dickson at #asco26 as he participates as an expert in a case-based panel discussion on consensus and controversies in well-differentiated/dedifferentiated retroperitoneal liposarcoma.
🕒 Monday, June 1 | 11:30 a.m. CDT
Learn more: -
Memorial Sloan Kettering Cancer Center reposted
Ziad Bakouny, MD, MSc
@ZiadBakouny
Excited to present our work today. Please come by poster board #115 this morning 9 AM to 12 PM!
@ASCO #asco26
@EdReznik @CarrotJian @KotechaMD @motzermd @AdamJSchoenfeld @wesleytansey @SashaGusevPosts
MSK Department of Medicine
@MSK_DeptOfMed
Join MSK medical oncology fellow @ZiadBakouny at #asco26 for a poster on the clinical and genomic factors that drive immune-related side effects across cancer types. @MSKCancerCenter
🕒 Monday, June 1 | 9 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center reposted
ASCO
@ASCO
Room S100bc at #asco26 is popping, everyone here to learn about #melanoma and #skincancer: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1…
#melsm -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Happening NOW at #asco26 ⬇️
MSK Department of Medicine
@MSK_DeptOfMed
Starting soon at #asco26: Gynecologic medical oncologist Dr. Ying Liu will present a poster on the NRG-GY036 trial comparing one vs. two years of maintenance olaparib (±bevacizumab) in #brca-mutated or HRD+ #ovariancancer. @MSKCancerCenter @YingLiu88
🕒 Monday, June 1 | 9 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center reposted
HemOnc Today
@HemOncToday
The first positive phase 3 trial in advanced dedifferentiated #sarcoma shows #abemaciclib improves PFS by 6️⃣2️⃣% vs. placebo.
The data ‘strengthen the rationale’ for using the agent in this setting, Dr. Mark Dickson @MSKCancerCenter says. #asco26 vist.ly/566vw -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Join MSK thoracic medical oncologist Dr. Kathryn Arbour at #asco26 as she presents an overview of the latest advances in targeting #kras G12-mutant cancers. Not to be missed! @MSKCancerCenter @KCArbourMD
🕒 Monday, June 1 | 10:36 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK radiation oncologist Dr. Luke Pike (@pike_lab) at #asco26 as he presents research on a machine learning-driven model designed to help predict brain metastasis risk in patients with breast cancer.
🕒 Monday, June 1 | 9:57 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK gastrointestinal medical oncologist Dr. Ghassan Abou-Alfa (@GABOUALFA) at #asco26 as he presents efficacy and safety results from the phase 3 EMERALD-3 study evaluating tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in patients with unresectable, embolization-eligible hepatocellular carcinoma.
🕒 Monday, June 1 | 9:45 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK radiation oncologist Dr. Christopher Barker at #asco26 as he presents results from the phase II RAMPART trial evaluating response-adapted definitive radiotherapy and cemiplimab immunotherapy for locally advanced, unresectable cutaneous squamous cell carcinoma.
🕒 Monday, June 1 | 9:24 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center reposted
Multiple Myeloma Hub
@MM_Hub
CONGRESS | #asco26 | PRESENTATION
Saad Z. Usmani presents final results from a post hoc analysis of the phase III CEPHEUS trial, evaluating Dara-VRd vs VRd in patients with transplant-ineligible newly diagnosed #multiplemyeloma (N = 289; Dara-VRd, n = 144; VRd, n = 145).
At a median follow-up of 76.0 months, overall MRD negativity at 10⁻⁵ was higher with Dara-VRd vs VRd (61.1% vs 40.0%; OR, 2.35; p = 0.0004). Sustained MRD negativity at 10⁻⁵ also favored Dara-VRd vs VRd at ≥12 months (49.3% vs 29.0%; OR, 2.40; p = 0.0005) and ≥24 months (44.4% vs 23.4%; OR, 2.62; p = 0.0002). Similar results were seen at a sensitivity threshold of 10⁻⁶. At 72 months, PFS was 59.3% with DVRd vs 38.3% with VRd; median PFS was not reached vs 50.2 months, respectively (HR, 0.55; p = 0.0007). No additional safety concerns were identified with longer follow-up.
Follow our live feed for more updates: multiplemyelomahub.com/medical-information/congresses-asco26
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#mmsm #myeloma #meded #medicalcongress @szusmani @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center reposted
NRG Oncology
@NRGonc
Start off your #asco26 Monday morning with two NRG Oncology #gynecologiccancer trials highlighted during poster sessions↪️NRG-GY036 with Dr. Ying Liu @YingLiu88 and NRG-GY037 with Dr. Jyoti Mayadev.
@MSKCancerCenter @UCSDHealth -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Join MSK head and neck medical oncologist @AlanHoMDPhD
at #asco26 to learn about a phase 2 study of darolutamide plus leuprolide acetate for recurrent or metastatic AR-positive salivary gland cancer. @MSKCancerCenter
🕒 Monday, June 1 | 8:48 a.m. CDT
Learn more: -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Join MSK medical oncology fellow @ZiadBakouny at #asco26 for a poster on the clinical and genomic factors that drive immune-related side effects across cancer types. @MSKCancerCenter
🕒 Monday, June 1 | 9 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center reposted
Alm Soravis Osataphan, MD
@alm_o
Phenomenal moment for pancreatic cancer.
Hopefully cholangiocarcinoma and biliary tract cancers are next in the RAS-targeted therapy era.🙏
Congratulations to @RevMedicines, #brianwolpin @EileenMOReilly and all co-investigators!
NEJM
@NEJM
Presented at #asco26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: www.nejm.org/doi/full/10.1056/NEJMoa2605555
@ASCO -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
A huge thank you to @Latinamd of @SylvesterCancer and @jsmithymd of @mskcancercenter for stopping in for interviews to discuss tolododekin alfa in NSCLC and O102-IO103 and nivolumab-relatlimab in melanoma, respectively! Check out all of our #asco26 coverage on onclive.com #oncology @asco
-
Memorial Sloan Kettering Cancer Center reposted
Ziad Bakouny, MD, MSc
@ZiadBakouny
Really awesome poster by urologic oncology fellow extraordinaire @VinceDAndreaMD with @DrDarrenFeldman @DSolit #samfunt on genomic determinants of cisplatin resistance in germ cell tumors!
@MSKCancerCenter @UrologyMSK @MSK_DeptOfMed
@ConquerCancerFd @ASCO #asco26 -
Memorial Sloan Kettering Cancer Center reposted
Agrima Mian
@AgrimaMianMD
Moments like today at #asco26 remind you why oncology is such an extraordinary field. What an absolute privilege to witness advances like #rasolute-302 in real time. #ras_on @MSK_DeptOfMed @RevMedicines @DanaFarber #mpdac
Yüksel Ürün
@DrYukselUrun
This is not simply a new pancreatic cancer drug.
It is a reminder that even “undruggable” biology can become treatable with persistence.
Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months.
A remarkable ASCO moment.
#asco26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_OncologistsThis media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Packed room for MSK breast medical oncologist @jhaveri_komal at #asco26 today.
Dr. Jhaveri presented new findings from the phase 3 evERA Breast Cancer trial, highlighting improved chemotherapy-free survival and PFS2 with giredestrant plus everolimus in advanced #breastcancer. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today at #asco26: MSK early drug development specialist @YoninaMG shared her poster "First-line (1L) olomorasib + pembrolizumab in patients with KRAS G12C–mutant advanced NSCLC, and PD-L1 expression 0–49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01."
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Spotlighting research presented by MSK's @MichalSternsch today at #asco26.
Ziad Bakouny, MD, MSc
@ZiadBakouny
Awesome work from @MichalSternsch on changes in nectin4 expression on EV. Very important data to inform next steps!
#asco26
@DrRosenbergMSK @Dr_Aggen @IyerGopa
@MSK_DeptOfMed @MSKCancerCenter @ASCO -
Memorial Sloan Kettering Cancer Center reposted
David H Aggen, MD PhD
@Dr_Aggen
🧬 What happens to Nectin-4 expression after EV+pembro? New paired biopsy data from @MichalSternsch @MSKCancerCenter at #asco2026: some tumors retain membranous Nectin-4 post-EVP — complete target loss is seen in some cases of early progression - and in 6/6 post EV/P tumors at cystectomy Nectin-4 expression decreased in residual tumors. | Abstract 552910, Poster A56 #bladdercancer
-
Memorial Sloan Kettering Cancer Center reposted
David H Aggen, MD PhD
@Dr_Aggen
🔄 Can you rechallenge with Enfortumab Vedotin after progression? New real-world data from @MichalSternsch @MSKCancerCenter at #asco2026 says: in some yes - promising in patients with prior EV benefit & EV-free interval >6 months. 📊 55 pts, ORR 25%, median OS 15.2 months. | Abstract 547088, Poster A57 #muc #bladdercancer #immunotherapy
-
Memorial Sloan Kettering Cancer Center reposted
David H Aggen, MD PhD
@Dr_Aggen
🔬 Exciting work from @MSKCancerCenter at #asco2026! Aditi Gupta shows that EV+pembrolizumab drives early peripheral T cell activation in metastatic urothelial cancer — and CD8+ CTLA-4 expression may predict response. 🧬 | Abstract 542284, Poster A50 #muc #immunotherapy #bladdercancer
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK genitourinary medical oncologist Dr. Aditi Gupta
shared her poster "Characterizing the immune effects of enfortumab vedotin and pembrolizumab (EV+P) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)" today at #asco26 -
Memorial Sloan Kettering Cancer Center reposted
Michael May
@MichaelMayMD
So lucky to have @EileenMOReilly as a mentor. She is an extraordinary physician and is leading PDAC drug development into this new and exciting era. @MSKCancerCenter @MSK_DeptOfMed
Ghassan Abou-Alfa
@GABOUALFA
Congratulations @EileenMOReilly @MSKCancerCenter @MSK_DeptOfMed Brian Wolpin Ziv Wainberg and all colleagues on a long awaited and badly needed game changer in #pancreascancer
-
Memorial Sloan Kettering Cancer Center reposted
Rohit Thummalapalli
@rohit_thum
It’s out! Congratulations @EileenMOReilly and we are thrilled offer daraxonrasib to our patients soon - access can’t come soon enough! @MSK_DeptOfMed @MSKCancerCenter #asco26
chadi nabhan MD, MBA, FACP
@chadinabhan
Remarkable results for patients with pancreatic cancer now published in @NEJM - congrats to @EileenMOReilly @DrShubhamPant @MiteshBorad and co-authors for leading one of the most transformative trials in this disease. @RevMedicines @ASCO #asco26
www.nejm.org/doi/full/10.1056/NEJMoa2605555?query=RP -
Memorial Sloan Kettering Cancer Center reposted
Michael May
@MichaelMayMD
Living through history! @EileenMOReilly @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @ASCO
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
⚠️ New findings presented in the plenary session at #asco26 suggest daraxonrasib could help usher in a new era of treatment for metastatic pancreatic cancer.
In a phase 3 study led by @EileenMOReilly and colleagues, patients receiving #daraxonrasib lived a median of 13.2 months compared with 6.7 months for those treated with chemotherapy.
"To date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease."
Learn more: www.mskcc.org/news/how-daraxonrasib-could-improve-pancrea… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Thrilled to see this work recognized during today’s plenary session at #asco26.
Congratulations to Dr. Brian Wolpin on the presentation and to MSK’s @EileenMOReilly and the entire team whose dedication helped make this milestone possible.
Eileen M O’Reilly
@EileenMOReilly
Thrilled and honored on behalf of the whole team, patients, scientific community and more- congratulations and good luck to @BrianWolpin this afternoon @MSKCancerCenter @DanaFarber @RevMedicines - next step is translate to practice!
chadi nabhan MD, MBA, FACP
@chadinabhan
Remarkable results for patients with pancreatic cancer now published in @NEJM - congrats to @EileenMOReilly @DrShubhamPant @MiteshBorad and co-authors for leading one of the most transformative trials in this disease. @RevMedicines @ASCO #asco26
www.nejm.org/doi/full/10.1056/NEJMoa2605555?query=RP -
Memorial Sloan Kettering Cancer Center reposted
Jame Abraham, MD, FACP
@jamecancerdoc
60% less chance of dying from pancreatic cancer ! Quality of life and pain control are better in the treatment arm! Thanks to all the patients who enrolled on this global trial and congratulations to the investigators @DanaFarber , @MSKCancerCenter and around the world !
-
Memorial Sloan Kettering Cancer Center reposted
Ghassan Abou-Alfa
@GABOUALFA
Congratulations @EileenMOReilly @MSKCancerCenter @MSK_DeptOfMed Brian Wolpin Ziv Wainberg and all colleagues on a long awaited and badly needed game changer in #pancreascancer
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today at #asco26: Dr. Robert Motzer (@motzermd) shared long-term outcomes from the phase 3 TiNivo-2 trial in metastatic renal cell carcinoma.
UroToday.com
@urotoday
Final analysis of the TiNivo-2 phase 3 trial: Long-term outcome of tivozanib in patients with #mrcc. Presentation by @motzermd @MSKCancerCenter. #asco26 written coverage by @RKSayyid @UAUrology > www.urotoday.com/conference-highlights/asco-2026/asco-202… @ASCO
-
Memorial Sloan Kettering Cancer Center reposted
Ghassan Abou-Alfa
@GABOUALFA
Great news for all patients in need of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer now in New England Journal of Medicine. Congrats @MSKCancerCenter @MSK_DeptOfMed @EileenMOReilly on co-leading this global gigantic effort! www.nejm.org/doi/full/10.1056/NEJMoa2605555
-
Memorial Sloan Kettering Cancer Center reposted
Matthew Herper
@matthewherper
The mob crushing into the #asco26 plenary. Like a Who concert in 1979.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A big moment for the sarcoma community at #asco26.
TwoOncDocs
@TwoOncDocs
🤩SARCOMA AT PLENARY!🎗️
🔹 SARC041 provides the first randomized validation of CDK4 inhibition in DDLPS
📈 mPFS: 9.7 vs 1.5 mo (HR 0.39, p<0.001) — >6× improvement
🎯 ORR: 9.3% vs 0%
⏳ OS trend favors abemaciclib (HR 0.55)
🔄 Crossover activity confirmed (mPFS 3.4 mo)
#asco26 -
Memorial Sloan Kettering Cancer Center reposted
Toni Choueiri, MD
@DrChoueiri
#markdickson from @MSKCancerCenter presents the phase 3 SARC041 trial showing that abemaciclib significantly improved PFS vs placebo in advanced DDLPS (9.7 vs 1.5 months; HR 0.39), with an encouraging OS trend.
#asco26 #sarcoma @ASCO @OncoAlert @MSKSarcoma -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Spotlighting research presented by MSK myeloma specialist @szusmani at #asco26.
VJHemOnc
@VJHemOnc
How are recent trial data refining treatment approaches for transplant-ineligible patients with newly diagnosed #multiplemyeloma?
At #asco26, @szusmani (@MSKCancerCenter) discusses:
🔹 Key findings from the final analysis of the DREAMM-9 trial
🔹 Final efficacy and safety data from transplant-ineligible patients in the CEPHEUS study
🔹 Age and frailty analyses from the MAIA and CEPHEUS trials and their implications for clinical practice
Interview coming soon on vjhemonc.com 👀
@ASCO #myeloma #mmsm -
Memorial Sloan Kettering Cancer Center reposted
Oncology Learning Network
@OncLearnNetwork
Mark Dickson, MD, discusses results from #sarc041 which showed #abemaciclib improved #pfs with favorable trends toward improved #os in recurrent or metastatic dedifferentiated #liposarcoma. Learn more: www.hmpgloballearningnetwork.com/site/onc/videos/abemacic…
#medtwitter #onctwitter #ascoplenary -
Memorial Sloan Kettering Cancer Center reposted
Ghassan Abou-Alfa
@GABOUALFA
Congratulations @DrMarkDickson and @MSKCancerCenter @MSK_DeptOfMed on superb plenary presentation @ASCO . Great to see the add on of ademaciclib to the very much in need liposarcoma treatment portfolio
-
Memorial Sloan Kettering Cancer Center reposted
Moffitt Cancer Center
@MoffittNews
Happening now at the #asco26 Plenary: Mark Dickson, MD (@MSKCancerCenter), presents results from the phase 3 SARC041 trial showing that abemaciclib improved progression-free survival in people with advanced dedifferentiated liposarcoma (DDLPS), a rare and aggressive cancer with few effective treatment options.
Key takeaways:
•First positive clinical trial in dedifferentiated liposcarcoma.
•PFS was significantly improved with abemaciclib vs placebo.
•Even though most patients in the placebo group crossed over to receive abemaciclib, a positive group overall survival trend favored the abemaciclib group.
•Abemaciclib was well-tolerated.
#moffittasco26 -
Memorial Sloan Kettering Cancer Center reposted
Yelena Y. Janjigian MD
@YJanjigianMD
Mark Dickson- First time ever positive phase 3 study in lipo sarcoma! We are so proud of you!!!
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨Happening soon at #asco26: MSK sarcoma medical oncologist Dr. Mark Dickson will present results from the phase 3 SARCO41 study evaluating abemaciclib in patients with advanced dedifferentiated #liposarcoma.
-
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
All right, now the #asco26 plenary that got the room so crowded: SARC 041!🎗️
🌻 Historical ORR ~5-15% in met ddLPS
🎗️ In ~50% pretreated population, 9.7(!!) month mPFS. Median survival not reached. Some strong responders.
🔁 Almost all patients crossed over after progression, but very poor responses in second line.
❓: can this be moved to even EARLIER lines? Phase 1 ongoing with RT in preop localized setting @fredhutch
👏 HUGE accomplishment of @SARCtrials academic consortium to complete this n = 108 study in a rare cancer.
@HannahRAbrams #sarcoma -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Highlighting research presented in the plenary session today at #asco26 by MSK's Dr. Mark Dickson. ⬇️
Maurício Ribeiro, MD
@mauriciofribei1
Outstanding presentation of SARC041 data by Dr. Mark Dickson from @MSKSarcoma, during #asco26 Plenary Session, showing a statistically significant and clinically meaningful PFS improvement favoring abemaciclib in pts with treatment-naïve advanced dedifferentiated #liposarcoma. Solid and practice-changing results for the DDLPS pt population. To witness a #sarcoma trial exploring a therapeutic vulnerability and going beyond cytotoxic chemotherapy being presented during the Plenary Session is very encouraging for our community. PFS for abemaciclib vs. placebo = 9.7 mo vs. 1.5 mo, HR 0.38, 90%CI 0.25-0.59. Trend towards OS improvement (NR vs. 25.5 mo). @ASCO @MoffittNews @MSKCancerCenter @SARCtrials @ctosociety
-
Memorial Sloan Kettering Cancer Center reposted
TwoOncDocs
@TwoOncDocs
Full house for plenary! #asco26
🌟 LIBRETTO-432: adjuvant selpercatinib in stage IB-IIIA RET NSCLC
🌟 PROTEUS: apalutamide peri-op tx in PCa
🌟 RASolute 302: RAS inhibition in pancreatic cancer.
🌟 HARMONi-6: ivonescimab for NSCLC
🌟 SARC041: abemaciclib in liposarcoma -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK’s Dr. Mark Dickson took the plenary stage at #asco26 today to present findings from a phase 3 study in dedifferentiated #liposarcoma, underscoring the importance of continued research in rare cancers.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A powerhouse group representing MSK at the #asco26 plenary. 💙
Yelena Y. Janjigian MD
@YJanjigianMD
A few butterflies🦋 before the #asco26 Plenary. #2025plenary podium was unforgettable , but this seat is definitely more relaxed. Emotions are high for the PDAC and sarcoma presentations. If we can change practice in these recalcitrant diseases, anything is possible! 💜💜💜
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Research co-authored by MSK gastrointestinal medical oncologist @EileenMOReilly will be presented during the plenary session at #asco26.
The phase 3 RASolute 302 study evaluated #daraxonrasib, a RAS(ON) multi-selective inhibitor, versus chemotherapy in patients with previously treated metastatic pancreatic adenocarcinoma.
🕒 Sunday, May 31 | 3:21 p.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today at #asco26: A phase 3 clinical trial led by MSK experts found that abemaciclib, a targeted therapy already approved for certain breast cancers, can significantly slow the growth of dedifferentiated liposarcoma (DDLS), a rare and aggressive soft tissue cancer with few effective treatment options after it has spread.
The findings, which are being presented by MSK's Dr. Mark Dickson at @ASCO and featured in the meeting’s plenary program, showed that #abemaciclib kept the cancer from growing for approximately six times longer than placebo. Tumor growth stopped for an average of 10 months.
“These findings should shape how patients with this disease are treated going forward,” says @WTapMD, Chief of MSK’s Sarcoma Medical Oncology Service and senior author of the study.
Learn more: www.mskcc.org/news/targeted-therapy-shows-promising-resul… -
Memorial Sloan Kettering Cancer Center reposted
Conquer Cancer, the ASCO Foundation
@ConquerCancerFd
This morning at #asco26, @ASCOPres Dr. Eric Small shared in his presidential address the importance of the future of discovery in cancer. He urged attendees to make a donation to Conquer Cancer so the cycle of launching careers in research can continue to pave the future of discoveries. 🔬
You can support this effort by making a donation at: support.conquer.org/page/187796/donate/1
#conquercancer #researchconquerscancer -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨Happening soon at #asco26: MSK sarcoma medical oncologist Dr. Mark Dickson will present results from the phase 3 SARCO41 study evaluating abemaciclib in patients with advanced dedifferentiated #liposarcoma.
-
Memorial Sloan Kettering Cancer Center reposted
Orla Fitzpatrick
@OrlaFitz10
Fellowship @MSKCancerCenter is the best, and working with @HardingJJMD is the cherry on top! #asco2026
James J. Harding, MD
@HardingJJMD
#asco2026 @MSKCancerCenter Advanced Fellow @OrlaFitz10 2 fantastic posters, #her2 #ras #btc! Advanced Fellow Aruj Dhyani #yia #adc #btc Assistant Attending @rohit_thum #mtap #net #btc #pdac. Glad to mentor, but grateful for what you teach me too!
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today at #asco26: MSK radiation oncologist Dr. Nancy Lee (@imrtlee) shared long-term results showing that many patients with HPV-positive #oropharyngeal cancer were able to receive lower-dose radiation while maintaining durable outcomes and experiencing fewer side effects.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Research co-authored by MSK thoracic medical oncologist Dr. @alexdrilon will be presented during the plenary session at #asco26.
The phase 3 LIBRETTO-432 trial evaluated adjuvant selpercatinib in patients with stage IB-IIIA RET fusion-positive non-small cell lung cancer. #nsclc
🕒 Sunday, May 31 | 2:13 p.m. CDT -
Memorial Sloan Kettering Cancer Center reposted
Isabel Preeshagul
@ipreeshagul
Honored to join a session focused not only on discussing but ADDRESSING barriers to trial accrual 🙌
Highlights :
1) partner w/ AI for screening &navigating
2) include pts in trial design stage, not as an after thought
3)build equity into trial design at inception + more -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Spotlighting research by MSK’s @EileenMOReilly that will be presented in the plenary situation today at #asco26.
NEJM
@NEJM
Presented at #asco26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: www.nejm.org/doi/full/10.1056/NEJMoa2605555
@ASCO -
Memorial Sloan Kettering Cancer Center reposted
Michael May
@MichaelMayMD
Awesome oral presentation by Emily Alouani on MSH3 LOF as a potential independent predictor of immunotherapy benefit in pMMR/MSS cancers. @StadlerZsofia @MSKCancerCenter @MSK_DeptOfMed @ASCO
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK sarcoma medical oncologist Dr. Mark Dickson at #asco26 as he presents results from the phase 3 SARCO41 study evaluating abemaciclib in patients with advanced dedifferentiated #liposarcoma.
🕒 Sunday, May 31 | 1:39 p.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Happening now at #asco26: MSK researchers are presenting poster sessions in the Exhibit Hall👇
Ricardo Tiecher
@rdtiecher
Grateful for the opportunity to present our poster on CCNE1 amplification at #asco26. Thank you to everyone who stopped by to say hi, to my mentor Dr. Alison Schram, and to all my co-authors! @MSKCancerCenter
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Inspiring morning at #asco26 hearing about the future of cancer care. 🔬
Thank you to all the presenters and for MSK Chief Medical Officer @cardismith for chairing this session.
ASCO
@ASCO
Significant strides in oncology are taking center stage now during new Highlights of the Year I session at #asco26. From GU & ovarian cancer to hematologic malignancies, these updates are shaping the future of care. A huge thanks to our expert presenters! meetings.asco.org/meetings/2026-asco-annual-meeting/335/1…
-
Memorial Sloan Kettering Cancer Center reposted
Cancer Nursing Today
@cancer_nurses
⏰ Coming up at #asco2026: The plenary session at 1 PM CDT, with practice-shaping presentations from experts out of @DanaFarber, @MSKCancerCenter, @UCLAHealth, and more!
⭐ Don't miss this!
#asco2026 #ascoannualmeeting #oncology #asco26 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Happy day 3 of #asco26! We’re excited for another full day of cancer research and discovery.
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Join Dr. @jhaveri_komal at #asco26 for post-progression treatment analyses from the phase 3 evERA trial of giredestrant plus everolimus in ER-positive, HER2-negative advanced #breastcancer. @MSKCancerCenter
🕒 Sunday, May 31 | 12 p.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK myeloma specialist @szusmani at #asco26 as he presents results from the phase 3 CEPHEUS study evaluating daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible patients with newly diagnosed multiple myeloma.
🕒 Sunday, May 31 | 10:21 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK radiation oncologist Dr. Nancy Lee (@imrtlee) at #asco26 for a clinical science symposium on FMISO PET-guided radiation dose de-escalation in HPV-associated oropharyngeal cancer.
🕒 Sunday, May 31 | 10:09 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Join MSK genitourinary medical oncologist @DrRosenbergMSK at #asco26 as he moderates a case-based panel on biomarker-driven treatment strategies for #bladdercancer, with the patient at the center. @MSKCancerCenter
🕒 Sunday, May 31 | 8 a.m. CDT
Learn more: -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Join MSK thoracic medical oncologist Dr. Cardinale Smith at #asco26 as she chairs a "Highlights of the Year" session, spotlighting the most important advances across oncology. @MSKCancerCenter
🕒 Sunday, May 31 | 8 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center reposted
James J. Harding, MD
@HardingJJMD
#asco2026 @MSKCancerCenter Advanced Fellow @OrlaFitz10 2 fantastic posters, #her2 #ras #btc! Advanced Fellow Aruj Dhyani #yia #adc #btc Assistant Attending @rohit_thum #mtap #net #btc #pdac. Glad to mentor, but grateful for what you teach me too!
-
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
And the star 💫 having all the tractions from the crow here!
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Highlighting research from MSK’s @Dr_N_Moss presented at #asco26.
Brandon Imber
@brandon_imber
Exciting results at #asco26 from the Phase III ROADS study showing outstanding brain cavity control following surgery with Cs-131 tile based brachytherapy for newly diagnosed brain metastases @Dr_N_Moss @MSKCancerCenter @MSK_RadOnc @BrainMets_MSK
-
Memorial Sloan Kettering Cancer Center reposted
OncUpdates
@OncUpdates
⭐️Moving on to #breastcancer discussion with @hoperugo @jhaveri_komal!
#bcsm #onctwitter #oncology #medtwitter #medx #cancerresearch @SignifyMD @OncBrothers #aio26 @cityofhope @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today at #asco26: MSK’s @jsmithymd shared his rapid oral abstract “A phase 2 trial of IO102-IO103 and nivolumab-relatimab in previously untreated, unresectable #melanoma.”
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Watch this space👇 #asco26
Michael May
@MichaelMayMD
The RAS Frontier! Big changes coming to pancreas cancer shortly… @EileenMOReilly @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk
-
Memorial Sloan Kettering Cancer Center reposted
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK postdoc fellow Addison Monroe shared his poster on "Meaning, distress, and desire for hastened death in homebound adults with advanced cancer: A cluster analysis" today at #asco26.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Spotlighting research from MSK genitourinary medical oncologist @IyerGopa presented today at #asco26 ⬇️
Amanda Nizam, MD
@AmandaNizamMD
Abst 4508. NEXUS-01 identifies an early post-EV signal for LY4052031, a next-generation anti-Nectin-4 ADC with a novel Topo1 payload (Camp98). @iyergopa @MSKCancerCenter
Pts with mUC: 88% prior platinum, EV +/- P 67%, EV+P 39%, IO 94%, prior Topo1 ADCs 23%.
Efficacy in evaluable pts:
Overall: ORR 42%, DCR 79%
Prior EV (n=36): ORR 33%, DCR 75%
EV-naïve (n=12): ORR 67%, DCR 92%
Prior Topo1 ADC (n=18): 0 responses
Safety:
No or low CYP2D6 function (AS 0.0–0.25) associated with ⬆️ risk of severe toxicity incl. neutropenia.
Prospective CYP2D6 genotyping & pharmacogenomic-guided dose optimization implemented as part of future development.
Implications: NEXUS-01 provides some of the first prospective data in mUC supporting ADC resistance as largely payload-mediated. After 1L EV+P, Nectin-4 may remain an actionable target depending on other ADC components. Is optimal ADC sequencing best achieved with new payloads, improved linkers, or new targets? Importantly, with the emergence of novel ADCs, development must balance efficacy with payload-specific toxicities. Data from other novel anti-Nectin-4 ADCs also being presented at #asco26.
Congratulations to the investigators on very promising data! @OncoAlert -
Memorial Sloan Kettering Cancer Center reposted
SU2Cscience
@SU2Cscience
Dr. Eileen O'Reilly of @MSKCancerCenter gave #asco26 attendees a preview of what's on the horizon for drugs that target #kras, including combinations with #immunotherapy.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK gastrointestinal medical oncologist @EileenMOReilly presented to a packed room at #asco26 today, discussing new findings and the growing momentum behind #ras-targeted therapies in #pancreaticcancer.
-
Memorial Sloan Kettering Cancer Center reposted
James J. Harding, MD
@HardingJJMD
@OrlaFitz10 Great work! Critical foundational work for our ongoing #r01. @GABOUALFA @EileenMOReilly @YJanjigianMD.
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK research fellow @OrlaFitz10 shared her poster "Tracking genomic evolution in ERBB2-altered biliary tract cancer through longitudinal tumor profiling" during #asco26. @ASCO
-
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
@EileenMOReilly of @MSKCancerCenter with an excellent overview of #kras targeting in #pancreascancer at #asco26. A truly remarkable time with multiple strategies targeting RAS, opening new frontiers in treatment and thought about modulating the tumor microenvironment and potentials for combination strategies.
@Jonathanwlee23 @CentralParkWMD @drallysonocean @NBalmacedaMD
#meded
#oncology -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK melanoma medical oncologist Dr. @jsmithymd at #asco26 as he presents results from a phase 2 trial evaluating IO102-IO103 in combination with nivolumab-relatlimab in patients with previously untreated, unresectable melanoma.
🕒 Saturday, May 30 | 5:36 p.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center reposted
Rich Matulewicz
@RichMatulewicz
Victory! The faculty triumph in the annual Dept of Surgery faculty/fellows softball @MSKCancerCenter @UrologyMSK
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK melanoma medical oncologist Dr. Monica Chen at #asco26 as she presents results from a phase 1b study evaluating the MEK inhibitor PF-07799544 in combination with the BRAF inhibitor PF-07799933 in patients with advanced BRAF-mutant #melanoma.
🕒 Saturday, May 30 | 4:30 p.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Join MSK lymphoma specialist Dr. Alison Moskowitz at #asco26 to learn about innovative therapies for T-cell #lymphoma and relapsed #hodgkinlymphoma. @MSKCancerCenter
🕒 Saturday, May 30 | 4:36 p.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Highlighting research presented by @SherryShenMD this morning at #asco26.
Aya Mohamed | MSc, MD 🎗
@Dr_Oncologista
Metabolic Reprogramming in Early #breastcancer:
WISE Trial (ASCO26) Explores Tirzepatide as a Potential Adjuvant Strategy in HR+/HER2− Disease with Obesity
@OncoAlert @ASCO #bcsm #asco26 @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center reposted
SU2Cscience
@SU2Cscience
Charlton Tsai from @MSKCancerCenter presents work with @andreacercek, @YJanjigianMD, @Sam_Cytryn, and others on MMR-deficient #esophagogastric cancer in patients who have experienced high pathological response to immune checkpoint inhibitors. #asco2026
-
Memorial Sloan Kettering Cancer Center reposted
Edward Christopher "Chris" Dee, MD
@EChrisDee
Thrilled to be at @ASCO with many members of our research team, Collaborative Oncology Research Group International (CORGI 🐕)
So proud of @MilitSPatel for THREE posters on #global #cancer systems today
More to come! -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
#asco26 poster session with @MichaelMayMD, who shares his research about “organtropic and genomic characterization of pancreatic neuroendocrine carcinoma" with a fellow attendee. @ASCO
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A session you don’t want to miss ⬇️⬇️⬇️
MSK Department of Medicine
@MSK_DeptOfMed
Join MSK gastrointestinal medical oncologist Dr. @EileenMOReilly at #asco26 for an education session on novel approaches and future directions in targeting KRAS-driven cancers, beyond the G12C mutation. @MSKCancerCenter
🕒 Saturday, May 30 | 1:49 p.m. CDT
Learn more: -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Spotted at #asco26: MSK’s Dr. @AlanHoMDPhD and @AliSchram featured as @ConquerCancerFd grant recipients 👏
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Be sure to see MSK's Dr. Jodi Mones for her poster session today at #asco26 ⬇️
MSK Department of Medicine
@MSK_DeptOfMed
Join MSK hematologist Dr. Jodi Mones at #asco26 for a poster on global phase 3 trial results of hetrombopag for patients with chemotherapy-induced #thrombocytopenia. @MSKCancerCenter @DameofCoags
🕒 Saturday, May 30 | 1:30 p.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK breast medical oncologist Dr. Ezra Rosen at #asco26 as he presents a poster on the first-in-human phase 1/2 ERADIC8 study evaluating EXT-19477, an investigational PARG inhibitor, in patients with advanced solid tumors.
🕒 Saturday, May 30 | 1:30 – 4:30 p.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center reposted
National Cancer Institute
@theNCI
Closing message from Dr. Letai at #asco26: progress in cancer research is a shared effort, and continued partnership across the oncology community will be essential to delivering the next generation of breakthroughs for patients.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK breast medical oncologist @jhaveri_komal on becoming a #fasco inductee at #asco26! 🎉
Komal Jhaveri, MD, FACP, FASCO
@jhaveri_komal
Honored to be a #fasco inductee at #asco26. Congratulations to all my fellow inductees @MSKCancerCenter @CliffordHudis @BurrisSkip @ErikaHamilton9 @drteplinsky
-
Memorial Sloan Kettering Cancer Center reposted
UroToday.com
@urotoday
Practice patterns and outcomes by genomic risk in octogenarians with high-risk localized #prostatecancer: A national real-world data analysis. Presentation by Zachary Moore, MD, PhD @MSKCancerCenter. #asco26 written coverage by @zklaassen_md @GACancerCenter > www.urotoday.com/conference-highlights/asco-2026/asco-202… @ASCO
-
Memorial Sloan Kettering Cancer Center reposted
Michael May
@MichaelMayMD
Stop by poster board 155 to learn about clinical and genomic predictors of organotropism in pancreatic neuroendocrine carcinoma! @CentralParkWMD @FiyinfoluB @RadOncConnor @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK research fellow @OrlaFitz10 shared her poster "Tracking genomic evolution in ERBB2-altered biliary tract cancer through longitudinal tumor profiling" during #asco26. @ASCO
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK gastrointestinal medical oncologist Dr.
@YJanjigianMD's poster "First-line (1L) trastuzumab deruxtecan (T-DXd)- based regimens in advanced HER2- expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma( EA): Safety results form DESTINY-Gastric03 (DG-03) Part 2 arms D and F and Part 4" at #asco26. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
#asco26 poster session with @rohit_thum, who shares his research about “Genomic and biomarker landscape of MTAP deficiency in gastrointestinal cancers" with a fellow attendee. @ASCO
-
Memorial Sloan Kettering Cancer Center reposted
VJ Oncology
@VJOncology
We spoke to Anis Hamid (@anis_a_hamid / @MSKCancerCenter) on an update in the ENZAMET study presented at #asco26 looking at germline genetic correlates in metastatic hormone-sensitive #prostatecancer
@ASCO #gusm -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Posters are underway at #asco26!
MSK researchers are sharing new findings across a wide range of cancer types and research areas. Stop by Hall A from now until 4:30 p.m. for their poster presentations. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Spotlighting research presented by MSK’s @SherryShenMD at #asco26.
Aya Mohamed | MSc, MD 🎗
@Dr_Oncologista
Metabolic Reprogramming in Early #breastcancer:
WISE Trial (ASCO26) Explores Tirzepatide as a Potential Adjuvant Strategy in HR+/HER2− Disease with Obesity
@OncoAlert @ASCO #bcsm #asco26 @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center reposted
Michael May
@MichaelMayMD
Important (and popular) research on MTAP loss in GI cancers being presented right now at poster board 158 by @rohit_thum @ASCO 2026! @MSKCancerCenter
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Strong start to day two of #asco26!
MSK breast medical oncologist @SherryShenMD shared with an engaged room insights on optimizing #breastcancer survivorship, including weight management, lifestyle interventions, and emerging research on #glp1 medications. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Happening now at #asco26: @SherryShenMD on managing obesity after a #breastcancer diagnosis.
MSK Department of Medicine
@MSK_DeptOfMed
Join breast medical oncologist @SherryShenMD at #asco26 as she discusses managing obesity after a #breastcancer diagnosis, from behavior change to the potential role of GLP-1 therapies. @MSKCancerCenter
🕒 Saturday, May 30 | 8:24 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK gastrointestinal medical oncologist @YJanjigianMD at #asco26 as she presents a poster on first-line trastuzumab deruxtecan (T-DXd)-based regimens in advanced HER2-expressing gastric, #gastroesophageal junction, and #esophageal cancers from the DESTINY-Gastric03 study.
🕒 Saturday, May 30 | 9 a.m. – 12 p.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK gastrointestinal oncologist Dr. Neil Segal at #asco26 as he presents a poster on a phase 2 study evaluating adjuvant botensilimab and balstilimab in patients with microsatellite-stable #colorectalcancer and persistent circulating tumor DNA following surgery and chemotherapy.
🕒 Saturday, May 30 | 9 a.m. – 12 p.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Highlighting research presented at #asco26 from MSK genitourinary medical oncologist @IyerGopa 🔬
UroToday.com
@urotoday
Initial results from NEXUS-01, a phase 1 study of LY4052031, an ADC targeting Nectin-4, in participants with advanced or metastatic #urothelialcarcinoma. Presentation by @IyerGopa @MSKCancerCenter. #asco26 written coverage by @RKSayyid @UAUrology > www.urotoday.com/conference-highlights/asco-2026/asco-202… @ASCO
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Good morning #asco26! We’re excited for a full day of cancer research and discovery.
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Join breast medical oncologist @SherryShenMD at #asco26 as she discusses managing obesity after a #breastcancer diagnosis, from behavior change to the potential role of GLP-1 therapies. @MSKCancerCenter
🕒 Saturday, May 30 | 8:24 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK breast medical oncologist Dr. Mark Robson at #asco26 for the symposium “Multicancer Early Detection: Potential Versus Proof.”
🕒 Saturday, May 30 | 8:24 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK interventional radiologist Dr. Stephen B. Solomon at #asco26 as he shares an interventional #radiology perspective during a care-based panel discussion.
🕒 Saturday, May 30 | 8:00–9:00 a.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… -
Memorial Sloan Kettering Cancer Center reposted
Scot Niglio MD
@ScotNiglio
Great presentation by @IyerGopa from @MSKCancerCenter on LY4052031 that looks to be a promising post EVP therapeutic in metastatic urothelial cancer #bladdercancer
-
Memorial Sloan Kettering Cancer Center reposted
Ziad Bakouny, MD, MSc
@ZiadBakouny
Really impressive data on a next generation ADC for metastatic urothelial carcinoma. Pretty cool to see the pharmacogenomic guided dosing of the ADC too to spare patients the most severe toxcities!
@IyerGopa @MSKCancerCenter
#asco26
David H Aggen, MD PhD
@Dr_Aggen
LY405231 a topo-I nectin-4 targeted ADC retains clinical activity post EV/P. Presented by @IyerGopa #asco26
➡️ ORR 42%
➡️ Prior Topo-i exposure 0% (0/18 responses)
➡️ Increwased toxicity in the 7% of patients with low CYP2D6 activity score - one of the first markers of increased toc with a topo-I drug -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today at #asco26, MSK’s @szusmani presented findings from the DREAMM-9 study evaluating belantamab mafodotin dosing schedules in transplant-ineligible patients with newly diagnosed #multiplemyeloma.
-
Memorial Sloan Kettering Cancer Center reposted
UrologyMSK
@UrologyMSK
Congrats to our @SUO_YUO fellows @BeckySagerMDPhD (Modeling the effects of HIF2α inhibition on the ccRCC tumor microenvironment) and @aghasemzadeh1 (Understanding the Tumor Microenvironment in Non-muscle Invasive Bladder Cancer)
For their @ASCO YIAs!
www.conquer.org/cancer-research/grants-awards -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Spotlighting MSK myeloma specialist @szusmani’s research presented today at #asco26.
Targeted Onc
@TargetedOnc
DREAMM-9 final analysis defines a practical dosing strategy for belantamab mafodotin in frontline transplant-ineligible NDMM #asco26 @szusmani @MSKCancerCenter www.targetedonc.com/view/dreamm-9-identifies-preferred-do…
-
Memorial Sloan Kettering Cancer Center reposted
Brendan Guercio
@BrendanGuercio
Exciting #asco26 data from NEXUS-01! @IyerGopa presents LY4052031 (Nectin-4 ADC + Topo1i payload). In mUC:
- ORR in Topo1i naive: 42% (67% in EV-naive; 33% post-EV)
- But no responses if prior Topo1i.
- Manageable safety profile (so long as normal CYP2D6 activity)
- Significant activity post-EV suggests big implications for sequencing ADCs: we can recycle targets by switching payloads! 🔄
@MSKCancerCenter @ASCO #bladdercancer #medicaloncology -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
👇👏 #asco26
Antonio Ocejo
@ja_ocejo
Excellent discussion by my mentor Dr. Martin Voss @MVossMD at #asco26
His proposed adjuvant RCC framework uses ctDNA/MRD 🧬 to risk-stratify after nephrectomy:
🔹 MRD−: pembro vs placebo + serial ctDNA monitoring
🔹 MRD+: pembro + belzutifan vs escalation with a novel strategy
A smart path toward personalizing adjuvant therapy, but we’ll need more sensitive MRD assays, deeper sequencing, and better detection technology to make this feasible in RCC.
Exciting direction for the field 🚀
#kidneycancer #rcc #ctdna #mrd -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Important patient-centered research from MSK’s @BobbyDalyMD presented at #asco26.
Fumiko Ladd Chino, MD, FASCO
@fumikochino
Dr @BobbyDalyMD #asco26: #telehealth follow-up can help ensure that Q6 (vs Q3 week) dosing of immunotherapy is feasible. This work shows that Q6 week dosing can be safe and save patients time (and likely money).
-
Memorial Sloan Kettering Cancer Center reposted
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)
@TiansterZhang
@MVossMD @MSKCancerCenter with comprehensive discussion of bone mets, ctDNA and non clear #kidneycancer. Lots to cover — Well done! #asco26 @asco @oncoalert @urotoday @utswcancer
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Insightful discussion from MSK’s Dr. @MVossMD at #asco26. ⬇️
Thank you for sharing highlights from this session on the future of #kidneycancer research. @ASCO
Miguel Zugman, MD
@mzugman
Excellent opening kidney cancer oral session at #asco26 and outstanding discussion by @MVossMD, from @MSKCancerCenter
-
Memorial Sloan Kettering Cancer Center reposted
Multiple Myeloma Hub
@MM_Hub
CONGRESS | #asco2026 | PRESENTATION
Saad Usmani presents findings from the phase I DREAMM-9 study evaluating belantamab mafoditin + bortezomib + lenalomide + dexamethasone (BVRd) in transplant ineligible patients with ND MM (N = 118).
The ORRs were 90%, 96%, and 85% in the Q3/4W, Q6/8W, and Q9/12W cohorts, respectively. Grade 3 or high ocular events occurred in 74%, 88%, and 35% of patients in the Q3/4W, Q6/8W, and Q9/12W cohorts, respectively. Extended dosing schedules were not associated with significant deterioration in VRF compared with more frequent dosing schedules.
Follow our live feed for more updates: multiplemyelomahub.com/medical-information/congresses-asco26
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#mmsm #myeloma @MSKCancerCenter @szusmani -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
About to begin at #asco26: MSK thoracic medical oncologist Dr. Robert Daly will present a pragmatic trial using telehealth to support extended dosing of the immunotherapy pembrolizumab and reduce in-person visits. @ASCO
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK myeloma specialist @szusmani at #asco26 as he presents final results from the DREAMM-9 study evaluating belantamab mafodotin in combination with BVRd for transplant-ineligible patients with newly diagnosed #multiplemyeloma.
🕒 Friday, May 29 | 3:45 p.m. CDT
Learn more: meetings.asco.org/meetings/2026-asco-annual-meeting/335/1… @ASCO -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today kicks off #asco26! Follow along on our social channels from May 29 – June 2 for live updates and to hear from our MSK experts in attendance. @ASCO #asco26
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Join thoracic medical oncologist Dr. Robert Daly at #asco26 as he presents a pragmatic trial using telehealth to support extended dosing of the immunotherapy pembrolizumab and reduce in-person visits. @MSKCancerCenter
🕒 Friday, May 29 | 2:57 p.m. CDT
Learn more: -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
We are honored to announce the 2026 Giants of Cancer Care Visionary inductee, Sir Murray Brannan, MD, FACS of @MSKCancerCenter. #giantscc26
-
Memorial Sloan Kettering Cancer Center reposted
Isabel Preeshagul
@ipreeshagul
The calm before the @asco storm!
Just naming a FEW sessions I’m excited about tomorrow !
1) care delivery telehealth monitoring of pts on pembro @BobbyDalyMD @MSK_DeptOfMed
2) communication workshop matching prognosis & pt goals workshop
3) @asco voices -
Memorial Sloan Kettering Cancer Center reposted
Conquer Cancer, the ASCO Foundation
@ConquerCancerFd
How do you improve outcomes in a rare, aggressive cancer with limited treatment options? At #asco26 this week, Dr. Mark Dickson, a Conquer Cancer-funded researcher, will deliver promising phase 3 clinical trial results on a gene-targeting therapy. Read more about this work ahead of the meeting: www.conquer.org/cancer-research/meet-researchers/mark-dic…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Thank you to the New York Yankees Foundation for their generous donation to MSK's Ralph Lauren Center, which serves the Harlem community and surrounding neighborhoods by providing high-quality care. The gift was part of MSK's #nycformsk campaign, a citywide initiative to raise funds and awareness for cancer research and patient care.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New findings from MSK researchers that will be presented at #asco26 this weekend found that carefully selected patients with HPV-positive #throatcancer can receive significantly less radiation while maintaining excellent outcomes.
An analysis of 430 patients showed a 97% five-year overall survival rate, even among patients who received less radiation. “This has been an absolute game-changer for treating certain people with throat cancers caused by HPV,” says MSK radiation oncologist @imrtlee. “The difference in toxicity is dramatic.” @ASCO
Learn more: www.mskcc.org/news/low-dose-radiation-possible-game-chang… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Proud to see 18 MSK staff recognized as 2026 Conquer Cancer Grants & Awards recipients ahead of #asco26. Congratulations to this outstanding group helping advance the future of cancer research and care. 👏
Conquer Cancer, the ASCO Foundation
@ConquerCancerFd
We're thrilled to officially announce the 2026 class of Conquer Cancer Grants and Awards recipients! 🔬 These grants empower the next generation of physician-scientists to turn innovative ideas into clinical breakthroughs. Congratulations to the new class—see you in Chicago for #asco26!
Full list of recipients here: www.conquer.org/news/conquer-cancer-awards-more-117-milli…
#researchconquerscancer #conquercancer @ASCO -
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
Join us for a one-day multidisciplinary conference @MSKCancerCenter focused on advancing the understanding and management of adult and pediatric chronic graft-versus-host disease.
The program will feature keynote speaker Dr. Stephanie Lee on patient-reported outcomes, alongside expert talks on GVHD biology and organ-specific care, panels on AI and clinical management, a closing debate on combination therapy, and a networking reception.
Learn more: mskcc.cloud-cme.com/course/courseoverview?P=5&EID=61329
#mskgvhdcme #gvhd #cgvhd
@DrAlinaMarkova @BinniKun @Dr_vron -
Memorial Sloan Kettering Cancer Center reposted
Greater New York Hospital Association
@GNYHA
Congratulations to Selwyn M. Vickers, MD @MSKCancerCenter for becoming the new Chair of the GNYHA Board of Governors for 2026-27. 👏
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The @FDA has recently approved trastuzumab deruxtecan (T-DXd, Enhertu) for treating early-stage, #her2-positive #breastcancer based on two clinical trials, one of which was led by MSK breast medical oncologist Dr. Shanu Modi.
“HER2-positive breast cancer is an aggressive disease, even when it’s diagnosed at an early stage,” Dr. Modi says. “This approval will change the way that many patients with this type of breast cancer are treated and offer the chance for more patients to be cured.”
A drug had already transformed care for metastatic HER2-positive and HER2-low breast cancer.
Learn more about this approval: www.mskcc.org/news/trastuzumab-deruxtecan-t-dxd-treating-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The calm before #asco26.
Excited to see MSK experts join the global oncology community in Chicago this week to share research and clinical insights shaping the future of cancer care! -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Swipe through for one final look at the action from MSK Kids Prom. 🪩
And another heartfelt thank you to the Society of MSK's Children's Committee, Food & Nutrition Services, Security, Environmental Services, Child Life specialists, MSK Kids staff, and all the dedicated volunteers whose care and effort made the day truly special. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK physicians and scientists will join colleagues from around the world at the @ASCO Annual Meeting 2026, taking place May 29–June 2 in Chicago.
MSK experts will present new research and clinical insights across gastrointestinal cancers, lung cancer, sarcomas, head and neck cancer, precision oncology, targeted therapies, radiation oncology, and more.
Follow along as we share highlights from #asco26 and the latest advances in cancer research and care: www.mskcc.org/asco -
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
Celebrating 10 years of the @MSKCancerCenter Symposium on #lymphoma — a decade dedicated to advancing the diagnosis, management, and treatment of lymphoma through innovation, collaboration, and education.
We are grateful to the distinguished faculty and participants who came together this year to advance multidisciplinary learning, scientific exchange, and the future of lymphoma care.
Thank you for being part of this milestone anniversary celebration. #msklymphomacme -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Cancer of the bile duct, called cholangiocarcinoma, is a rare, aggressive type of tumor in the liver that has a notoriously poor prognosis. But a newly approved drug will give patients another option to treat cancer that is inoperable, has spread, and is caused by a particular genetic mutation.
The @FDA has recently approved zenocutuzumab (Bizengri®) for adults with advanced, unresectable, or metastatic cholangiocarcinoma driven by an NRG1 gene fusion. The approval was based results from a clinical trial led by early drug development specialist Dr. @AliSchram.
“Patients with #bileductcancer caused by an NRG1 fusion have very limited treatment options,” Dr. Schram explains. “Zenocutuzumab can make a meaningful difference for these patients, shrinking their tumors with remarkably few side effects — preserving quality of life.”
Learn more about this treatment: www.mskcc.org/news/fda-approves-zenocutuzumab-for-cholang… -
Memorial Sloan Kettering Cancer Center reposted
ASCO
@ASCO
Later this week, oncology professionals from across the globe will convene in Chicago for #asco26. Discover highlights of can’t-miss events, opportunities to connect with colleagues, and additional features to personalize your meeting experience: connection.asco.org/do/2026-asco-annual-meeting-join-conv…
-
Memorial Sloan Kettering Cancer Center reposted
Karuna Ganesh
@KarunaMDPhD
A huge thank you to our patients, patient advocates, and our collaborative team at @MSKCancerCenter, and rare cancer funding from Dalton Family Foundation & @Cycle4Survival. We hope these new models will finally open the door to precision therapies for appendiceal cancer.
-
Memorial Sloan Kettering Cancer Center reposted
Yankees Béisbol
@Yankees_Beisbol
Como parte de la campaña NYC for MSK y para honrar el servicio de @MSKCancerCenter a los neoyorquinos, la Fundación de los New York Yankees se enorgullece en donar $50,000 al Ralph Lauren Center de MSK, el cual sirve a la comunidad de Harlem y vecindarios cercanos brindando atención médica de alta calidad 💙
-
Memorial Sloan Kettering Cancer Center reposted
New York Yankees
@Yankees
To honor @MSKCancerCenter's service to New Yorkers and further support its work — and as part of the NYC for MSK campaign — the New York Yankees Foundation is proud to donate $50,000 to MSK’s Ralph Lauren Center, which serves the Harlem community and surrounding neighborhoods by providing high-quality care 💙
-
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
The 2026 Update in Hematology and Medical Oncology is now available on demand from @MSKCancerCenter. This comprehensive course provides an up-to-date review of the diagnosis, staging, and management of solid tumors and hematologic malignancies. On demand access includes recorded presentations, PDF slide decks, and a NEW study guide to support board preparation. Learn more: mskcc.cloud-cme.com/course/courseoverview?P=0&EID=62787
-
Memorial Sloan Kettering Cancer Center reposted
David H Aggen, MD PhD
@Dr_Aggen
The are likely multiple different resistance mechanisms when cancer progresses after EV/Pembro treatment.
Looking forward to @MichalSternsch @MSK_DeptOfMed presenting at #asco26 some of the first data with paired biopsies to describe what happens to nectin-4, trop-2, and HER2 post EV/P
🚨abstract: www.asco.org/abstracts-presentations/258782 🚨 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
.@CentralParkWMD led MSK's early phase clinical trial of #daraxonrasib for people with metastatic #pancreaticcancer that had stopped responding to chemotherapy.
The targeted therapy works by shutting down growth signals generated by mutated KRAS genes, which drive more than 90% of pancreatic cancers.
“For the first time, we can clinically target the dominant KRAS signals that drive most pancreatic cancers,” Dr. Park says. Learn more: www.mskcc.org/news/new-hope-for-pancreatic-cancer-with-ta… -
Memorial Sloan Kettering Cancer Center reposted
Klebanoff_Lab
@KlebanoffLab
🚨New paper: Phase 1 trail of HPV16 (E7) TCR-T cells in patients with HPV16+ cancers. First application of AKT inhibitor during cell manufacturing to promote #foxo1 stabilization & early-memory phenotype. @DrKedarKirtane @MoffittNews @MSKCancerCenter
www.frontiersin.org/journals/oncology/articles/10.3389/fo… -
Memorial Sloan Kettering Cancer Center reposted
Blood Cancers Today
@Blood_Cancers
A study published in @JCO_ASCO shows that TP53-mutated #dlbcl is not uniform—variant allele frequency and molecular context refine risk beyond standard high-risk label.
Read more, with insight from study author Gilles Salles, MD, of @MSKCancerCenter.
➡️ www.bloodcancerstoday.com/post/tp53-allele-burden-sharpen… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
“In the last two decades, different approaches to leverage the immune system have moved from being daring ideas to treatment options for many patients,” says MSK Chief Scientific Officer @rosslevinemd.
Learn how MSK researchers are building on decades of discovery to advance the next generation of immunotherapy treatments: www.mskcc.org/news/how-msk-is-tackling-immunotherapys-big… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
We’re excited to share that that Shakeeb Akhter has joined MSK as its new Chief Digital Officer (CDO). In this role, Shakeeb will be responsible for the overall design and execution of MSK’s digital strategy.
Shakeeb joins MSK following a distinguished career at Children's Hospital of Philadelphia (CHOP), where he served as Senior Vice President and Chief Digital and Information Officer. During his tenure, he built one of the most advanced healthcare digital transformation programs in the country, spanning AI, clinical informatics, cybersecurity, advanced analytics, and digitally enabled care.
At MSK, Shakeeb will serve as the architect of MSK's digital and technology future, championing an enterprise-wide strategy that connects clinical, research, and administrative domains.
Learn more about Shakeeb: www.mskcc.org/news-releases/mskcc-appoints-shakeeb-akhter… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
We're excited to share MSK's Annual Report titled: "Progress Made Personal."
In this editorial showcase, you'll read stories about what progress looks like every day at MSK — in how we care for people, in our relentless drive to discover, and in all the ways we work together to end cancer for life.
Read all of the incredible stories here: www.mskcc.org/annual-report/2025 -
Memorial Sloan Kettering Cancer Center reposted
Abdel-Wahab Lab
@AbdelWahablab
NYC area folks interested in myelodysplastic syndromes (MDS), please join July 1st for the @MSKCancerCenter & @Columbia Edward P. Evans MDS Centers Symposium July 1st. Speakers include @iannisaifantis1, @CalebLareau, @SKousteni, @Halene_lab, @rosslevinemd ! Register below:
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Potentially practice-changing research published in @JAMA_current and presented at #ats2026 today: Performing transbronchial lung biopsy using cryoprobes, compared with conventional forceps, improved diagnostic yield in patients during bronchoscopy.
The study was led by Lonny Yarmus, Head of the Division of Subspecialty Medicine in @MSKCancerCenter's Department of Medicine, and Jeff Thiboutot at @HopkinsMedicine.
Key findings:
🌟 Diagnostic yield was significantly higher with cryobiopsy than with forceps (88.6% vs 78.8%).
🌟 Yield was especially improved in patients with pulmonary nodules or masses and in lung transplant evaluation.
🌟 No patients in the cryoprobe group experienced pneumothoraces requiring chest tube placement, compared with four patients in the forceps group.
These findings suggest that cryoprobe-based transbronchial biopsy may help clinicians obtain larger, higher-quality specimens and improve diagnostic accuracy in routine practice.
Read on for more insights: jamanetwork.com/journals/jama/fullarticle/2849314 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
In an inspiring ceremony, MSK celebrated new graduates and award winners at its annual Academic Convocation and Commencement, held on May 13. 🎓
Before an excited crowd of graduates, the faculty who mentored them, and many family members and friends who supported their journey, the highest number of awards and fellowships to date were presented, recognizing promising trainees, distinguished scientists, and doctors from MSK and beyond.
Swipe for some pictures of the day, and read more about the day here: www.mskcc.org/news/msks-2026-convocation-and-commencement… -
Memorial Sloan Kettering Cancer Center reposted
Selwyn M. Vickers
@DrVickersMSK
The groundbreaking care we provide at @MSKCancerCenter is made possible by an incredible ecosystem of people. As we celebrate National Hospital Week, I am profoundly grateful to work alongside this dedicated team. Together, we are redefining what is possible in cancer care.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
An MSK team led by @DaniyanMD and @AbdelWahabLab has developed a new preclinical CAR T cell therapy approach for #aml that targets a protein found almost exclusively on #leukemia cells and not on healthy blood cells.
In animal models, the CAR T cells successfully targeted leukemia cells while sparing healthy blood-forming cells. The findings, published in @CD_AACR, may help advance future treatment approaches for AML and other types of leukemia. www.mskcc.org/news/successfully-treated-aml-patients-may-… -
Memorial Sloan Kettering Cancer Center reposted
Ghassan Abou-Alfa
@GABOUALFA
Thank you @MSKCancerCenter @MSK_DeptOfMed
Jiajia Zhang and @SteveMaronMD for a superb presentation of #gastriccancer, We all loved your measured and strategic approahc to care. Thank you all for joining. See you June 10 and help welcome @AndreaCercek -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today, 15 new PhD scientists will officially receive their degrees from @GSKGradSchool.
GSK was created to provide the next generation of biomedical investigators with a deep expertise in cancer biology and the fundamental biological processes that underlie cancer. Since 2024, GSK also has included the Pat and Ian Cook Doctoral Program in Cancer Engineering, a PhD program for those interested in developing new tools and technology to solve fundamental problems in cancer science.
The graduates will receive their diplomas as part of the 47th annual academic convocation and commencement ceremony held at MSK.
Learn more about these graduates: www.mskcc.org/news/meet-2026-graduates-of-gerstner-sloan-… -
Memorial Sloan Kettering Cancer Center reposted
Benjamin D. Greenbaum
@bengrbm
First of many great collaborations with @AbdelWahablab and our lab's first foray into spatial transcriptomics: "Ecological determinants of disease and immunity in myelodysplastic syndromes". We wanted to get into this area for a long time but were drawn to this unique ecological niche by @dewolf_susan:
www.biorxiv.org/content/10.64898/2026.05.05.720208v1.full…
The bone marrow is both difficult to derive samples from and challenging to analyze due to its lack of organized architecture compared to solid tissue. With key technological advancements and heroic effort Susan, Rob Stanley MD PhD and Kimon Argyropoulos addressed the first challenge with Ronan Chaligné. To tackle the second, Beatrice Zhang, a brilliant PhD student I am fortunate to co-mentor with Omar, under the guidance of @stephen_martis (the first fellow in @MSKCancerCenter 's Theory Group) developed a suite of analytical methods. Stephen's background in theoretical ecology was essential to our approach. They developed a paired set of methods called SAND-DUNE. SAND (Spatial Adjacency Network Detection) allowed for profiling of unique cell aggregates with awareness of immune cell specific features, while DUNE (Discovery by Unsupervised Niche Enrichment), allowed for sample to sample comparison of niche enrichment. Using these tools, we identified how hematopoetic niche enrichment stratified disease stages.
If that was not enough, we paired our analysis with customized TCR and cancer cell specific probes to uncover the spatial distribution and phenotype of cancer cells and abundant T cell clones, revealing both that early immune activation, possibly against the shared neoantigens observed by Omar's lab, may indicate favorable response, and a specific mechanism by which cancer cells can modulate immune cells to facilitate escape.
This unique team science approach led by first authors Beatrice, Rob and Kimon led to a rich analytical characterization of the hard to see microenvironment. The overarching view shows how such an approach may be able to yield clinically actionable strategies with an interpretable backbone of ecological principles based on richly characterized hard data. -
Memorial Sloan Kettering Cancer Center reposted
Cancer Immunology Research
@CIR_AACR
Congratulations to John Maciejowski, PhD, and colleagues, recipients of the 2026 Cancer Immunology Research Award for Outstanding Journal Article! Learn more: aacrjournals.org/cancerimmunolres/pages/award @J_Maciejowski @MSKCancerCenter
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK reveals how #pancreatic cancer cells organize themselves to fuel tumor growth; finds an antibody-drug conjugate shows efficacy in rare pediatric #sarcoma; develops an AI tool could accelerate identification of disease-causing genetic variants; and develops quantum nanosensors for cancer blood tests: www.mskcc.org/news/msk-research-highlights-april-27-2026
-
Memorial Sloan Kettering Cancer Center reposted
Marisol Soengas
@msmelanoma
Groundbreaking results again from @LoweLabMSKCC and his group at @MSKCancerCenter and 28 additional collaborating teams.
Wow!
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy: Cell www.cell.com/cell/fulltext/S0092-8674(26)00269-2 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to Dr. David Abramson, Chief of the Ophthalmic Oncology Service at MSK, who was honored with the 2026 Eye Research Prize from the BrightFocus Foundation and the Helen Keller Foundation in recognition of his significant contributions to vision science and advancements in the treatment of childhood eye cancers.
Dr. Abramson has developed pioneering treatments that have transformed the management of eye cancer worldwide. Established in 1994, the Helen Keller Prize for Vision Research recognizes excellence demonstrated through multiple significant research contributions to vision science or a single contribution of exceptional impact.
Learn more about Dr. Abramson's award: www.mskcc.org/news-releases/msk-awards-and-appointments-a… -
Memorial Sloan Kettering Cancer Center reposted
Targeted Onc
@TargetedOnc
What happens when standard targeted therapies for #lungcancer fail? 🫁💡
In a recent interview, Helena Yu, MD (@MSKCancerCenter) discusses unmet needs and new frontiers in lung cancer treatment.
🎥 WATCH: www.targetedonc.com/view/overcoming-egfr-resistance-new-a… -
Memorial Sloan Kettering Cancer Center reposted
Ziad Bakouny, MD, MSc
@ZiadBakouny
Thrilled to receive the Gerstner Physician Scholars’ grant!
The grant will support our work for the next 3 years on mitochondrial DNA mutations in cancer.
Very thankful for the mentorship from Craig Thompson, @EdReznik, @motzermd, @arihakimi and many others!
@MSK_DeptOfMed -
Memorial Sloan Kettering Cancer Center reposted
Ghassan Abou-Alfa
@GABOUALFA
Honored and delighted to continue the @MSKCancerCenter @MSK_DeptOfMed collaborative work with Dr Samvel Bardakhchyan and team @ Yeolyan Hematology and Oncology Center in Armenia. Thanks team!
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK computational biologist @CalebLareau on being awarded a 2026 @PershingSqFdn Sohn Cancer Prize. His work will focus on engineered protein “sponges” to absorb and neutralize chemotherapy drugs and reduce harmful side effects.
“If successful, this project will yield new combinations of treatments that would increase cancer killing while minimizing the side effects for patients.” Learn more: www.mskcc.org/news/dr-caleb-lareau-awarded-2026-pershing-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's most recent awards and appointments, including Dr. Christopher Lima for being named a 2025 Fellow of the @aaas; @SSRaj017 and Satoshi Kaito for being awarded a @DKMS_uk John Hansen Research Grant; Dr. Gregory Riely for receiving the 2026 Excellence in Engagement Award from the @NCNN; and more: www.mskcc.org/news-releases/msk-awards-and-appointments-a…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Memorial Sloan Kettering Cancer Center (MSK) congratulates Dr. Nicole B. Saphier on her nomination to become the next Surgeon General of the United States. Over her decade of service to the MSK community, Dr. Saphier has been a tireless advocate for women’s health and early cancer detection, expanding access to breast cancer screening, and raising awareness at a community and national level. We are grateful for her steadfast commitment to delivering excellent patient care and her willingness to serve our country in this capacity.
-
Memorial Sloan Kettering Cancer Center reposted
GI Oncology Now
@GiOncNow
📺 What lessons can be learned from the PROOF 301 study? Hear from @GABOUALFA of @MSKCancerCenter on the trial's challenges, and what was seen in the evaluation of infigratinib vs gemcitabine + cisplatin for #cholangiocarcinoma: www.gioncologynow.com/videos/fgfr2-targeted-therapy-in-ch…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK developmental biologist Dr. Anna-Katerina Hadjantonakis and MSK physician-scientist Dr. Robert Farese who were elected to the 2026 class of the American Academy of Arts and Sciences.
Both are members of MSK’s Sloan Kettering Institute, a hub for basic science and translational research within MSK.
Learn more: www.mskcc.org/news/drs-kat-hadjantonakis-and-robert-fares… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
MSK experts are ushering in a new era of personalized care for those with newly diagnosed multiple myeloma (NDMM) by identifying what makes everyone's cancer unique.
This review by @MSKCancerCenter's @szusmani and Kevin Miller explores how the field is evolving toward biology-driven, response-adapted care models.
What's on the horizon:
🌟Novel immunotherapy strategies, including CAR-T and bispecific antibodies moving into first-line treatment, are paving the way toward treatment-free remissions and functional cures in the majority of NDMM patients within the next decade.
🌟 Next-generation cellular therapies that reduce side effects and new small-molecule drugs that target specific disease subsets.
🌟AI-powered adaptive care models that incorporate genomics, microenvironment features, and immune profiles to identify those at high-risk of progression and those who may safely benefit from reduced or discontinued therapy.
Read on for more insights!
aacrjournals.org/bloodcancerdiscov/article-abstract/7/2/1… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to @GitlinLab_MSK!
Lupus Research
@LupusResearch
Congratulations to the newest recipients of the Lupus Innovation Award!
The award empowers scientists to pursue high-risk, high-reward approaches to major challenges in lupus research with the potential to transform our understanding of the disease.
This year’s six selected recipients aim to advance our knowledge of lupus – from examining genetic and environmental triggers to innovative disease biomarkers and pathways.
Learn more: www.lupusresearch.org/lupus-research-alliance-announces-n…
#lupus #lupusresearch -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK, published in @Nature, shows how lung cells with cancer-causing mutations recruit surrounding healthy tissue to support tumor formation. Changes to the tumor microenvironment begin early and help drive growth and progression.
Learn more: -
Memorial Sloan Kettering Cancer Center reposted
Marc Hilmi
@MarcHilmi
Just back from @AACR and honored to present our POLAR translational work led by the best mentors ever @CentralParkWMD @EileenMOReilly @ciacobu
Using single-cell, spatial transcriptomics & TCRseq, we dissect durable response vs rapid progression in PDAC @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center reposted
Blood Cancers Today
@Blood_Cancers
Researchers observed encouraging results when they paired a third-generation CDK4/6 inhibitor with a first-generation JAK inhibitor in #myelofibrosis, according to a poster presented at #aacr26 by @BrianChernak of @MSKCancerCenter.
➡️ www.bloodcancerstoday.com/post/is-cdk4-6-pairing-the-answ… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
During #aacr26, researchers from MSK presented on innovative therapeutic advances — including clinical trials showing promise for people with early-stage HER2-driven #rectalcancer and KRAS-driven #pancreaticcancer - and reported on the encouraging results from a phase 1 study of a therapeutic mRNA #cancervaccine to treat pancreatic cancer.
Learn more about this research: www.mskcc.org/news/aacr-2026-research-roundup-latest-canc… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
👏👏👏 #aacr26
SU2Cscience
@SU2Cscience
Massive congratulations to @SU2C Scientific Advisory Committee member Dr. Luis Diaz from @MSKCancerCenter for being honored with the @AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical #cancer Research. #aacr26
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK experts presented findings from their latest foundational and translational oncology research at #aacr26.
Here's a quick research roundup:
🔬 Highlights included treatment of early-stage #rectalcancer with protein inhibitors targeting HER2, alleviating the need for some patients to receive radiation and/or surgery. cc: @MichaelFoote & @AndreaCercek
🔬 Additional topics included the development of a personalized RNA vaccine for #pancreaticcancer, with almost 90% of responders still alive six years after treatment. cc: @TheVinodLab
🔬 And development of a framework to understand biomarkers and vulnerabilities during the early to late stages of transitions from #lungcancer-enabling adenomas to neuroendocrine lineage plasticity. cc: @jmchan88
Read more about these studies: www.mskcc.org/clinical-updates/msk-aacr-2026-research-rou…
@AACR -
Memorial Sloan Kettering Cancer Center reposted
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Last day of #aacr26, and don't miss @CarrotJian's presentation.
MSK Department of Medicine
@MSK_DeptOfMed
Starting soon at #aacr26: Dr. Jian Carrot-Zhang will present on germline determinants of cancer progression using multi-ancestral real-world data. @MSKCancerCenter @AACR @CarrotJian
⏰ 10:56 a.m. PDT
www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today, MSK physician-scientist Dr. Sarat Chandarlapaty shared his research on how #cancer develops resistance to #her2 antibody-drug conjugates during a session at #aacr26.
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Closing out an amazing day of #cancerresearch advances at #aacr26: Our chair Dr. Deb Schrag will share her expertise on leveraging novel technologies and knowledge bases to optimize success in clinical trials. @MSKCancerCenter @AACR
⏰ 5:25 p.m. PDT
www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Spotlighting research from @EileenMOReilly presented at #aacr26. @AACR
The Wall Street Journal
@WSJ
Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years. www.wsj.com/health/healthcare/new-drugs-for-pancreatic-ca…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK research tech Abraham Meyerson’s poster about “Integrating padeliporfin vascular-targeted photodynamic therapy with enfortumab vedotin and immune checkpoint blockade in urothelial cancer models” at #aacr26. @aacr
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK gastrointestinal medical oncologist Dr. @EileenMOReilly speaks to a crowd about her late-breaking poster research on “Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic #pancreatic adenocarcinoma (mPDAC)” at #aacr26. @aacr
-
Memorial Sloan Kettering Cancer Center reposted
Anirban Maitra
@Aiims1742
No surprise! @EileenMOReilly handling it like pro she is!
Thanks to my friend @christine_lovly for the photo. So much RAS excitement at #aacr26.
Anirban Maitra
@Aiims1742
The crowd surrounding this @EileenMOReilly late breaking poster is going to be huge!
Also today afternoon.
#aacr26 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
#aacr26 poster session recap with Dr. Jeremy Tchack, who shares his research about “Immune and clinical determinants of response to immune checkpoint blockade (ICB) rechallenge after perioperative chemoImmunotherapy in #gastroesophagealcancer” with a fellow attendee. @aacr
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK gastrointestinal medical oncologist Dr. @YJanjigianMD late-breaking poster session about “First-line (1L) trastuzumab deruxtecan (T-DXd) + rilvegostomig (rilve) + fluoropyrimidine (FP) in HER2-positive (HER2+) gastric cancer (GC), #gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) Part 4 arm A results” at #aacr26. @aacr
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK thoracic medical oncologist Dr. @AdamJSchoenfeld's poster about OBX-115 membrane-bound IL15 (mbIL15)-expressing engineered tumor-infiltrating lymphocytes (TIL) overcome target cell immune evasion related to major histocompatibility complex (MHC) silencing through both direct killing and transactivation of NK cells in patient-derived autologous non-small cell #lungcancer (#nsclc) models” at #aacr26. @aacr
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK gynecologic medical oncologist Dr. @RawiDuaa shared research from her poster about “Oncogenic transcriptional rewiring in micronuclei” during #aacr26. @AACR
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK senior research scientist Shiv Verma for his session on “STARD13-LATS2 Axis as a potential genetic modifier of BRCA2 in #breastcancer” TODAY at #aacr26. @aacr
⏱️: Tuesday, April 21 at 4:05pm PDT
Learn more: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
⚠️ New MSK research presented at #aacr26: A drug given “breakthrough designation” by @US_FDA may offer the best new option in many years for people facing #pancreaticcancer.
#daraxonrasib targets mutations in the RAS gene, which helps control cell growth — these mutations send signals that fuel cancer cells. #kras is the most common of these mutations and drives over 90% of pancreatic cancer, which is projected to be the second most deadly cancer in the U.S. by 2030.
MSK gastrointestinal medical oncologist @EileenMOReilly led a phase 1/2 clinical trial of daraxonsarib as part of a larger multidisease trial led by thoracic medical oncologist Dr. @KCArbourMD. In Dr. O’Reilly’s trial, the patients with pancreatic cancer had not yet received any form of treatment.
“This drug is potentially going to be a landmark shift in how we treat pancreatic cancer,” says Dr. O'Reilly. “The ability to target RAS mutations that drive so much of pancreatic cancer is huge and has been missing from our treatments.”
Learn more about this research: www.mskcc.org/news/new-kras-targeted-therapy-shows-promis… @AACR -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK research scholar Silvia Palladino for her session on “Combining RAS inhibitors with the clinical RNR inhibitor BBI-825 to prevent the emergence of extrachromosomal DNA (ecDNA)-driven resistance to RAS-targeted therapies in #colorectalcancer” TODAY at #aacr26. @aacr
⏱️: Tuesday, April 21 at 3:20pm PDT
Learn more: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center reposted
Clinical Cancer Research
@CCR_AACR
At the #aacr26 Dharma Master Jiantai Symposium in Targeted Therapy and interested in hearing more from Luis Diaz and colleagues? Check out the new study on molecular lineages of sporadic mismatch-repair deficient colorectal cancer. @MSKCancerCenter. aacrjournals.org/clincancerres/article/doi/10.1158/1078-0…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Insightful research on anti-HER2 ADCs from Dr. Sarat Chandarlapaty at #aacr26
Elizabeth McKenna
@ElizSMcKenna
Read the @CD_AACR paper mentioned in Sarat Chandarlapaty's #aacr26 presentation on resistance to anti-HER2 ADCs: Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding doi.org/10.1158/2159-8290.CD-25-0647 @MSKCancerCenter
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK senior research scientist Peng Li for her session on “Evasion of hepatic ILC1 immunosurveillance drives #breastcancer liver metastasis” TODAY at #aacr26. @aacr
Cc: @MingLiLab
⏱️: Tuesday, April 21 at 2:35pm PDT
Learn more: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
#aacr26 presentation recap for principal investigator @CalebLareau on #epsteinbarrvirus. @AACR
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
#aacr26 session alert: Dr. @jmchan88 shares research on #lungcancer. ⬇️
MSK Department of Medicine
@MSK_DeptOfMed
Don't miss this presentation at #aacr26: Dr. Joseph Minhow Chan on basal-state origins and genotype-specific trajectories of neuroendocrine plasticity in #lungcancer. @MSKCancerCenter @AACR @jmchan88
⏰ 3:35 p.m. PDT
www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK leukemia specialist Dr. @AbdelWahablab for his session about "RNA processing regulation of anti-tumor immune responses" TODAY at #aacr26. @AACR
⏱️: Tuesday, April 21 at 1:25pm PDT
Learn more: bit.ly/4tq8pyphttps://bit.ly/4tq8pyp -
Memorial Sloan Kettering Cancer Center reposted
AMMG
@AgeMgmtMedGroup
Investigational Pancreatic Cancer Vaccine Shows Lasting Results in Early Trial, Supporting Continued Testing via @MSKCancerCenter: www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-can…
#pancreaticcancervaccine #pancreaticcancertreatment #pancreaticcancerreserarch #longevitymedicine -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Afternoon poster sessions at #aacr26 begin at 2pm and include MSK's Dr. Jeremy Tchack.
MSK Department of Medicine
@MSK_DeptOfMed
Coming up at #aacr26: Dr. Jeremy Tchack will present a poster on immune and clinical determinants of response to immune checkpoint blockade rechallenge after perioperative chemoimmunotherapy in #gastroesophagealcancer. @MSKCancerCenter @AACR
⏰ 2 p.m. PDT -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join gastrointestinal medical oncologist Dr. Luis Diaz for his session about “Chemical engineering of mismatch repair deficiency to induce tumor immunogenicity” TODAY at #aacr26. @aacr
⏱️: Tuesday, April 21 at 1:25pm PDT
Learn more: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK breast medical oncologist Dr. Sarat Chandarlapaty for a session about “Resistance to anti-HER2 ADCs” TODAY at #aacr26. @aacr
⏱️: Tuesday, April 21 at 1:25pm PDT
Learn more here: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join principal investigator @CalebLareau for a session about “Population scale sequencing resolves the determinants and consequences of persistence #epsteinbarrvirus infection” TODAY at #aacr26. @aacr
⏱️: Tuesday, April 21 at 1pm PDT
Learn more here: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center reposted
ProfJohnCrown
@ProfJohnCrown
Brilliant!! Well done @EileenMOReilly and colleagues.
Anirban Maitra
@Aiims1742
#aacr26 late breaking abstract on early data from 1st line Daraxonrasib monotherapy in #pancreaticcancer
>90% disease control rate
aacrjournals.org/cancerres/article/86/8_Supplement/LB337/…
@EileenMOReilly @GarridoLagunaMD @DrShubhamPant
@RevMedicines -
Memorial Sloan Kettering Cancer Center reposted
Anirban Maitra
@Aiims1742
The crowd surrounding this @EileenMOReilly late breaking poster is going to be huge!
Also today afternoon.
#aacr26 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Incredible showing at #aacr26 from Dr. @BrianChernak. Catch his poster for 2 more hours.
Brian Chernak, MD
@BrianChernak
Excited to present our Late - Breaking Phase I study of Ruxolitinib + abemaciclib in Myelofibrosis at @AACR led by @BewersdorfJan & @RaajitRampal at @MSKCancerCenter @YaleMed @UTMDAnderson . Phase II in the works!
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Happening soon! @YJanjigianMD speaks about advances in cancer immunotherapy. #aacr26 ⬇️
MSK Department of Medicine
@MSK_DeptOfMed
On the #aacr26 stage this morning: Dr. Yelena Janjigian, Chief of MSK's Gastrointestinal Oncology Service, will share her expertise on the latest advances in #cancer #immunotherapy. @MSKCancerCenter @AACR @YJanjigianMD
⏰ 10:15 a.m. PDT
www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center reposted
dana_peer
@dana_peer
Amazing trailblazing super stars. I am SO lucky to work with them. CONGRATULATIONS!
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to Dr. Adrienne Boire, a neuro-oncologist at Memorial Sloan Kettering Cancer Center (MSK), and Dr. @TuomasTammela, a cancer biologist at MSK, on receiving @AACR Trailblazer Cancer Research Grants, announced during #aacr26.
Nine early-stage investigators and six mid-career investigators were awarded grants of $1 million each to support meritorious and promising cancer research. The grants will be distributed over three years.
Share a note of kudos to Dr. Boire and Dr. Tammela in the comments below! 👏 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
.@xu_jierui, a computational biologist at MSK, shared his poster on “A unified clinical and molecular framework to standardize chromosomal instability assessment in gastric, GEJ, and #esophagealcancer (GEC)” during #aacr26. @aacr
cc: @nikolausschultz Lab -
Memorial Sloan Kettering Cancer Center reposted
Jennifer Buell
@jbuell01
At #aacr26, Dr. Sam Cytryn @MSKCancerCenter reports INKT+BOT/BAL and chemo in r/r GEJ:
- 20% survival beyond 3 years in r/r GEJ
- Immune activation across assays
- Activity in active liver mets
In refractory disease, durability defines impact. @MiNK_iNKT @Agenus_Bio @YJanjigianMD -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Poster sessions start in one hour. Don't miss Dr. Brian Chernak's research. ⬇️ #aacr26
MSK Department of Medicine
@MSK_DeptOfMed
Kicking off today's poster session at #aacr26: Dr. Brian Chernak will share phase I results on ruxolitinib + the CDK4/6 inhibitor abemaciclib in previously treated #myelofibrosis. @MSKCancerCenter @AACR @BrianChernak
⏰ 9 a.m.–12 p.m. PDT
www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Hong Zhang, a pathologist at MSK, shared her poster on “Associations between #breastcancer Index and MSK-IMPACT genomic and transcriptomic profiles in HR+ breast cancer” during #aacr26 @AACR
-
Memorial Sloan Kettering Cancer Center reposted
Vinod BalachandranMD
@TheVinodLab
This is why we do the work! We’re hopeful that we can build on this progress and allow more patients to access these promising treatments.
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Donna was diagnosed with pancreatic cancer at age 66 when she and her husband were visiting one of their daughters in Australia. When they returned to the U.S., they immediately came to MSK for care, where she learned she was eligible for an investigational vaccine trial, to prevent pancreatic cancer from returning after surgery.
MSK hepatopancreatobiliary surgeon Dr. @Jeffrey_Drebin, physician-scientist @TheVinodLab, and medical oncologist @EileenMOReilly walked Donna through each step.
“They described how they would take part of my tumor to make a personalized vaccine, and it sounded amazing,” Donna says. “My husband and I had a moment of concern about delaying chemotherapy, but all the doctors made me feel so comfortable that we took the leap of faith and said, ‘Go for it.’”
Over the next few months, Donna received an immunotherapy drug and eight doses of the vaccine, followed by chemotherapy, and then a final vaccine dose.
Today, Donna is 72 and recently celebrated her 50th anniversary with her husband in Sicily and spends as much time as she can with her daughters and six grandchildren.
Learn more about this clinical trial, presented at the 2026 American Association for Cancer Research Annual Meeting: www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-can…
#aacr26 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Dr. Filemon Dela Cruz, a pediatric hematologist-oncologist at MSK, shared his poster on “Preclinical evaluation of PEG-[SN22]₄ (PEEL-224), a multivalent polymeric camptothecin prodrug, in pediatric solid tumor patient-derived xenograft models” during #aacr26. @aacr
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's Head of the Division of Solid Tumor Oncology Dr. Luis Diaz, Jr. on receiving the AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research. 👏
This evening at #aacr26, he presented an award lecture on clinical application of cancer genomics. @aacr -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK’s cellular therapist Dr. Jaeyop Lee speaks with #aacr26 attendees about his poster on “Immunopeptidomic discovery of fetal WNT-associated antigen NKD1 enables HLA-A2+ restricted TCR-T therapy for MSS mCRC.” @aacr
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK leukemia specialist Dr. @AbdelWahablab for a session about “From molecules to medicine – driving breakthroughs in blood cancer treatment” TODAY at #aacr26. @aacr
⏱️: Monday, April 20 at 6:45pm PDT
Learn more here: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Donna was diagnosed with pancreatic cancer at age 66 when she and her husband were visiting one of their daughters in Australia. When they returned to the U.S., they immediately came to MSK for care, where she learned she was eligible for an investigational vaccine trial, to prevent pancreatic cancer from returning after surgery.
MSK hepatopancreatobiliary surgeon Dr. @Jeffrey_Drebin, physician-scientist @TheVinodLab, and medical oncologist @EileenMOReilly walked Donna through each step.
“They described how they would take part of my tumor to make a personalized vaccine, and it sounded amazing,” Donna says. “My husband and I had a moment of concern about delaying chemotherapy, but all the doctors made me feel so comfortable that we took the leap of faith and said, ‘Go for it.’”
Over the next few months, Donna received an immunotherapy drug and eight doses of the vaccine, followed by chemotherapy, and then a final vaccine dose.
Today, Donna is 72 and recently celebrated her 50th anniversary with her husband in Sicily and spends as much time as she can with her daughters and six grandchildren.
Learn more about this clinical trial, presented at the 2026 American Association for Cancer Research Annual Meeting: www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-can…
#aacr26 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Happening now #aacr:
Phase 1 trial results for a therapeutic mRNA vaccine for pancreatic cancer, led by MSK physician-scientist Dr. @TheVinodLab, included 16 patients who received the investigational vaccine called autogene cevumeran after #pancreaticcancer surgery, along with an immunotherapy drug (called a checkpoint inhibitor) and chemotherapy.
Key takeaways:
🟦 Vaccines were custom-made for each patient based on unique signatures of their tumors.
🟦 In 8 patients, the vaccine activated tumor-specific immune cells, meaning the vaccine taught the immune system to recognize tumor cells as foreign. This triggered the body to produce immune cells called T cells to target and kill the tumor cells.
🟦 Of the 8 patients whose immune system responded to the vaccine, 7 (87.5%) were still alive 4-6 years after surgery.
🟦 Among the 8 patients who didn’t respond, only 2 (25%) were still alive, with a median survival time of 3.4 years.
Learn more: www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-can… @aacr -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Live from #aacr26: “The latest data from this small [16-person] study suggest vaccines can meaningfully stimulate the immune system in some patients with #pancreaticcancer – and these patients continue to do remarkably well years after vaccination,” says MSK physician-scientist @TheVinodLab.
Learn more about this phase 1 study, which tested autogene cevumeran, an investigational therapeutic #mrna #cancervaccine to prevent the disease from returning after surgery: www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-can… @AACR -
Memorial Sloan Kettering Cancer Center reposted
Selwyn M. Vickers
@DrVickersMSK
The energy at @Cycle4Survival doesn’t just fill the room, it ignites it. Every year as I jump on a bike, I’m inspired by the sheer dedication of our participants.
Since 2007, Cycle for Survival has raised more than $450 million, and behind that number are countless patient stories of determination fueled by MSK’s many advances in rare cancer treatments.
To everyone who rode, cheered, and donated, thank you for your unwavering support of rare cancer research, ensuring that tomorrow’s breakthroughs are within reach. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK’s @OncoKB scientist @MoriahNi_Phd of @DSolit Lab, shares her poster on “OncoKB, MSK’s Precision Oncology Knowledge Base: 2025 Updates” at #aacr26. @aacr
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Happening soon at #aacr26: Dr. David Solit is leading a session sharing how the @AACR international registry Project GENIE® is advancing #cancer research. @MSKCancerCenter @DSolit
⏰ 2:30 p.m. PDT
www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to Dr. Adrienne Boire, a neuro-oncologist at Memorial Sloan Kettering Cancer Center (MSK), and Dr. @TuomasTammela, a cancer biologist at MSK, on receiving @AACR Trailblazer Cancer Research Grants, announced during #aacr26.
Nine early-stage investigators and six mid-career investigators were awarded grants of $1 million each to support meritorious and promising cancer research. The grants will be distributed over three years.
Share a note of kudos to Dr. Boire and Dr. Tammela in the comments below! 👏 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Emily Pratt, a graduate student in cancer biology at @GSKGradSchool, shared her poster on “Cell division as a regulator of macrophage invasion in mammary epithelia” during #aacr26. @aacr
-
Memorial Sloan Kettering Cancer Center reposted
The Innovation | Medicine
@Innov_Medicine
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines www.cnn.com/2026/04/20/health/cancer-research-mrna-vaccines @AACR @CNN @NBCNews @MSKCancerCenter #aacr26
Vipin M. Vashishtha
@vipintukur
Personalized mRNA vaccine offers durable immune control in the deadly pancreatic cancer
➡️ An experimental mRNA vaccine for pancreatic cancer shows long-lasting immune responses in an early clinical trial.
➡️ About half of the small group of patients had durable survival (years)—remarkable for a cancer with very poor prognosis.
➡️ The vaccine works by training the immune system to recognize and attack tumor-specific targets.
👉 Findings are promising but preliminary, and larger trials are underway to confirm benefit.
www.nbcnews.com/health/cancer/pancreatic-cancer-mrna-vacc… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Don't miss Dr. Juan Osorio at #aacr26 today. ⬇️
MSK Department of Medicine
@MSK_DeptOfMed
Up next at #aacr26: Dr. Juan Osorio is chairing a session on advances in therapeutic antibodies, a rapidly evolving frontier in #cancer care. @MSKCancerCenter @AACR @juanosoriomd
⏰ 2:30 p.m. PDT
www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🎙️A sincere thank you to all of the brilliant performers and guests who made MSK's @ComedyvsCancer benefit show such a success, including @nickkroll, @hasanminhaj, @zarnagarg, @bridgeteverett, and Brett Goldstein.
While the evening was filled with laughter, the result was serious progress: every ticket sold helps fuel the breakthrough research that defines the future of oncology.
This year's event raised more than $2.5 million - with a lifetime amount of $9.8 million raised - and counting! Proceeds will support lifesaving blood cancer research at MSK.
Swipe through for some memories from the night. 💙 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The MSK Entrepreneurship & Commercialization Team made a big presence at #aacr26. Visit them at Booth 2929 to discuss business development opportunities involving MSK and AI, data resources, @OncoKB, and more.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK radiochemist @LewisLabMSKCC shared an insightful presentation about questions and new opportunities in #theranostics at #aacr26. @AACR
-
Memorial Sloan Kettering Cancer Center reposted
Ruben Sebastian
@RubenSebas_
We’re witnessing impressive advances in pancreatic cancer! A pancreatic cancer mRNA vaccine shows a very strong and durable immune response in a Phase 1 trial. New 6-year data are being presented today at #aacr2026 @MSKCancerCenter
www.nbcnews.com/health/cancer/pancreatic-cancer-mrna-vacc… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research being presented by MSK's @TheVinodLab today at #aacr26.⬇️
AACR
@AACR
Eight of 16 patients in a clinical trial of an investigational mRNA vaccine for pancreatic cancer @MSKCancerCenter had dramatic immune responses. The study, which was featured on @CNNhealth, was presented at the AACR Annual Meeting 2026. www.cnn.com/2026/04/20/health/cancer-research-mrna-vaccines @CNN #aacr26
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join @TheVinodLab, an MSK physician-scientist and Director of The Olayan Center for Cancer Vaccines, for a Major Symposium sharing new research about “Personalized neoantigen vaccines for #pancreaticcancer” TODAY at #aacr26.
⏱️: Monday, April 20 at 1:35pm PDT
Learn more: -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Count us in! #aacr26
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
-
Memorial Sloan Kettering Cancer Center reposted
Let's Win Pancreatic Cancer 💜
@letswinpc
Listen to @TheVindodLab on the #pancchat Podcast released this past Friday share.transistor.fm/s/39ffc988 and learn more about the phase 1 clinical trial presented at #aacr26 letswinpc.org/research/mrna-vaccine-effective-small-trial/
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨 An experimental, personalized vaccine using #mrna to prevent #pancreaticcancer from returning after surgery continues to show promise in a small, 16-person patient group.
New results from a phase 1 clinical trial, being presented at #aacr26, show that nearly 90% of people whose immune systems responded to the vaccine were still alive six years later.
“These early results show this new immunotherapy approach has the potential to be groundbreaking for one of the deadliest cancers,” says MSK physician-scientist Dr. Vinod Balachandran (@TheVinodLab), the trial’s principal investigator and Director of The Olayan Center for Cancer Vaccines.
Learn more about these findings: www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-can… @AACR -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK radiochemist Dr. @LewisLabMSKCC for a session about “New questions and new opportunities in theranostics” TODAY at #aacr26. @aacr
Monday, April 20 at 10:36am PDT
Learn more here: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
#aacr26 fun to be with these friends to cure cancer!! :)
#edreznik @MarcHilmi #chinatsu # Sungyong Park Sehoon Park @MikeFooteMD -
Memorial Sloan Kettering Cancer Center reposted
AACR
@AACR
Congratulations to the AACR Trailblazer Cancer Research Grants recipients, supported by @pfizer. AACR’s largest-ever grant program has awarded 15 early-stage and mid-career investigators $1million each to establish novel, highly creative research projects. www.aacr.org/about-the-aacr/newsroom/news-releases/aacr-a…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
This afternoon, MSK's @kevinmboehm shared a presentation on multimodal modeling of detailed #cancer subtypes and molecular features at #aacr26. @AACR
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK physician-scientist Dr @DSolit presented about advancing target discovery for rare cancers through institutional-scale molecular profiling and social media outreach at #aacr26. @AACR
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK's Chief Scientific Officer Dr. Ross Levine presents research about targeting epigenetic dependencies in myeloid malignancies at #aacr26. @AACR
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK's Dr. @kevinmboehm for a session about “Multimodal modeling of detailed cancer subtypes and molecular features from >60,000 patients with co-registered H&E images and clinical tumor sequencing” TODAY at #aacr26. @aacr26
⏱️: Sunday, April 19 3:05pm PDT
Learn more here: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Every medical breakthrough begins with a decades-long journey in the laboratory, a key message shared during #aacr26.
Our MSK #savedbyscience series, captures the emotional meetings between patients and the scientists, including physician-scientist and AACR presenter Dr. @DSolit, whose years of research have given them new hope.
Watch more Saved by Science stories on YouTube: www.youtube.com/watch?v=mP-ik0roidE&list=PLME9VJQhE-hut-Q… @AACR -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
#savedbyscience, a series from MSK, spotlights the lasting impact of lab research, an important message being shared at #aacr26.
Here, neuro-oncologist Dr. Adrienne Boire teamed up with computational biologist Dr. @dana_peer to find a way to stop cancer cells from surviving in the cerebrospinal fluid.
By conducting a detailed analysis of patient samples using powerful computational methods, they unearthed the secret — a discovery that also suggested a treatment strategy.
Watch more Saved by Science videos on YouTube: www.youtube.com/watch?v=h1aByfitfUE&t=3s -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Happening NOW at #aacr26: MSK computational biologist Dr. @dana_peer speaks about decoding tissue architecture. @AACR
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Happening today! MSK's Dr. Duaa Al-Rawi presenting at #aacr26.
MSK Department of Medicine
@MSK_DeptOfMed
Dr. Duaa Al-Rawi will present a poster on multimodal profiling of serous tubal intraepithelial carcinoma lesions to identify precursor states with genomic features of high-grade serous #ovariancancer. #aacr26 @MSKCancerCenter @AACR @RawiDuaa
⏰ 2–5 p.m. PDT -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Next up at #aacr: Join MSK gynecologic medical oncologist Dr. Rachel Grisham for a session about “Approaches to drug development for rare malignancies” TODAY. @aacr
⏱️: Sunday, April 19 at 1:30pm PDT
Learn more here: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK genitourinary medical oncologist Dr. @DSolit for a session about “Advancing target discovery for rare cancers through institutional-scale molecular profiling and social media outreach” TODAY at #aacr26. @AACR
⏱️: Sunday, April 19 at 1:55pm PDT
Learn more here: -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK computation biologist @dana_peer for a session about “When form meets function: Decoding tissue architecture” TODAY at #aacr26. @aacr
⏱️: Sunday, April 19 at 1:30pm PDT
Learn more here: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center reposted
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK leukemia specialist and physician-scientist Dr. Ross Levine for a session titled “Targeting epigenetic dependencies in myeloid malignancies” TODAY at #aacr26. @aacr
⏱️: Sunday, April 19 at 1:30pm PDT
Learn more here: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Don't miss the chance to meet with MSK's Dr. Luis Diaz at #aacr26. ⬇️
MSK Department of Medicine
@MSK_DeptOfMed
Coming up at #aacr26: Meet Dr. Luis Diaz, Editor-in-Chief of @CD_AACR and Head of MSK's Division of Solid Tumor Oncology, at the AACR Publications Booth 3537 in Hall D. @MSKCancerCenter @AACR @ldiaz1971
⏰ 2 p.m. PDT
www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center reposted
Jyves94 🧬
@jyves94
Un vaccin utilisant #mrna pour empêcher le #cancerdupancréas de revenir montre des résultats prometteurs dans un groupe de 16 patients.
De nouveaux résultats d’un essai clinique de phase 1, présentés à #aacr26 🇺🇸, montrent près de 90 % des patients encore en vie 6 ans plus tard.
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨 An experimental, personalized vaccine using #mrna to prevent #pancreaticcancer from returning after surgery continues to show promise in a small, 16-person patient group.
New results from a phase 1 clinical trial, being presented at #aacr26, show that nearly 90% of people whose immune systems responded to the vaccine were still alive six years later.
“These early results show this new immunotherapy approach has the potential to be groundbreaking for one of the deadliest cancers,” says MSK physician-scientist Dr. Vinod Balachandran (@TheVinodLab), the trial’s principal investigator and Director of The Olayan Center for Cancer Vaccines.
Learn more about these findings: www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-can… @AACR -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK gastrointestinal medical oncologist @YJanjigianMD for a session about “Resectable gastroesophageal cancer: Time to rewrite the standard” TODAY at #aacr26. @aacr
⏱️: Sunday, April 19 at 1:25pm PT
Learn more here: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
This morning, MSK physician-scientist shared research during the Opening Plenary Session at #aacr26 about how cancer cells escape targeted therapy by changing identity. @AACR
Key conclusions:
➡️ Adenocarcinomas with RB1 loss are at risk ("primed") to undergo NE lineage transition in response to therapelic stress.
➡️ In "primed" tumors, extracellular matrix production by cancer associated fibroblasts restrains NE lineage transition through integrin -> YAP/TEAD activation. Notch pathway activation acts as a second level of restraint.
➡️ This adeno <-> NEPC transition can be toggled in either direction using existing pharmacologic tools, with potential therapeutic implications.
➡️ New vulnerabilities arise once the NE transition is complete, notably on MYC family paralogs with co-option of TIP60/KAT5 as a coactivator. -
Memorial Sloan Kettering Cancer Center reposted
Moffitt Cancer Center
@MoffittNews
Happening now at #aacr26: Charles Sawyers, MD (@MSKCancerCenter) discusses how cancer cells evade targeted therapies through shifts in cell lineage, highlighting new challenges and opportunities for precision oncology.
Key takeaways:
•Adenocarcinomas with RB1 loss are at risk ("primed") to undergo NE lineage transition in response to therapelic stress.
•In "primed" tumors, extracellular matrix production by cancer associated fibroblasts restrains NE lineage transition through integrin -> YAP/TEAD activation. Notch pathway activation acts as a second level of restraint.
•This adeno <-> NEPC transition can be toggled in either direction using existing pharmacologic tools, with potential therapeutic implications.
•New vulnerabilities arise once the NE transition is complete, notably on MYC family paralogs with co-option of TIP60/KAT5 as a coactivator.
#moffittaacr26 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨 An experimental, personalized vaccine using #mrna to prevent #pancreaticcancer from returning after surgery continues to show promise in a small, 16-person patient group.
New results from a phase 1 clinical trial, being presented at #aacr26, show that nearly 90% of people whose immune systems responded to the vaccine were still alive six years later.
“These early results show this new immunotherapy approach has the potential to be groundbreaking for one of the deadliest cancers,” says MSK physician-scientist Dr. Vinod Balachandran (@TheVinodLab), the trial’s principal investigator and Director of The Olayan Center for Cancer Vaccines.
Learn more about these findings: www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-can… @AACR -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK physician-scientist Dr. Charles Sawyers presented the opening plenary at #aacr26.
AACR
@AACR
#aacrfellows and Past President Charles L. Sawyers discusses "How Cancer Cells Escape Targeted Therapy by Changing Identity" during the Opening Plenary Session at #aacr26.
-
Memorial Sloan Kettering Cancer Center reposted
Young Kwang Chae, MD, MPH, MBA
@youngkwangchae
Amazing plenary talk by Dr. Sawyers
🧬 #aacr25 lineage plasticity bombshell:
RB1 loss “primes” prostate cancer for NE transition. ECM→integrin→YAP keeps it adeno. Remove ECM? ASCL1 explodes → NEPC in days.
New target: TIP60/KAT5 inhibition kills NEPC via MYC dependency 🎯
Best part? It’s reversible with LATS inhibitor ↩️
@AACR @OncoAlert @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center reposted
Alastair Lamb
@LambAlastair
Excited to be at #aacr26 in sunny #sandiego
•22,000 delegates
•7400 abstracts
•Particular focus on organ-specific developments & #survivorship
🔬🧪🎗🧬
First plenary talk from #legend Charles Sawyer @MSKCancerCenter - good to see #prostatecancer front & centre!
@AACR @theNCI -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Summary of MSK's Dr. Charles Sawyers plenary session at #aacr26.
Allison Rosen, MS
@ARosen380
Today’s@AACR Plenary session kicked off with Dr. Charles L. Sawyers from @MSKCancerCenter discussing how cancer cells escape targeted therapy by changing identity! #aacr26 #aacrssp
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
This morning, Dr. @rosslevinemd, Chief Scientific Officer at MSK, and Dr. Kenneth Offit, Chief of the Clinical Genetics Service at MSK, were recognized as new members of the 2026 class of the AACR Academy of Fellows during the Opening Ceremony at #aacr26. @AACR 👏
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK leukemia specialist Dr. Charles Sawyers for a session about “How cancer cells escape targeted therapy by changing identity” TODAY at #aacr26. @aacr
⏱️ : Sunday, April 19 at 9:40am PDT
Learn more here: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center reposted
-
Memorial Sloan Kettering Cancer Center reposted
Anirban Maitra
@Aiims1742
What an honor to sit in the #aacr26 RAS education session with two legends of RAS biology - Neal Rosen (@MSKCancerCenter) and Mark Philips (@Perlmutter_CC) and to see their early work on RAS signaling come to fruition in the clinic. Enjoying the session with @rkalluriMDPhD
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Don't miss meeting MSK's Dr. Ross Levine, one of the Editors-in-Chief of Blood Cancer Discovery. #aacr26
AACR
@AACR
Attending #aacr26? Meet Ross Levine, Riccardo Dalla-Favera, and Kenneth C. Anderson, Editors-in-Chief of Blood Cancer Discovery, at 9:15 AM on Monday, April 20 at the AACR Publications Booth 3537. Learn more: www.abstractsonline.com/pp8/
@BCD_AACR -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Recap of #aacr26 session with gastrointestinal medical oncologist Dr. @MikeFooteMD.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New from #aacr26: A small clinical trial (8-person) at MSK is showing promise for people with early-stage #rectalcancer whose tumors are driven by excessive amounts of a protein called HER2 (human epidermal growth factor receptor 2).
The trial, led by MSK gastrointestinal medical oncologists Dr. @MikeFooteMD and Dr. @AndreaCercek, suggests that many of these patients may be successfully treated using targeted therapies to avoid surgery, resulting in fewer side effects and better quality of life during and after treatment.
Learn more about this research: www.mskcc.org/news/treating-her2-amplified-early-stage-re… @aacr -
Memorial Sloan Kettering Cancer Center reposted
KRAS Kickers
@KRASKickers
"The phase 2 study treated eight people fully with early-stage rectal tumors using two well-known targeted therapies — trastuzumab (Herceptin) and tucatinib (Tukysa) — that attack HER2-driven tumors. The two drugs were given alone for the first six weeks, then afterwards in combination with standard chemotherapy.
Typically, these rectal cancer patients would eventually undergo a large surgery. But in the trial, 4 of the 8 patients saw their tumors disappear using only the targeted therapies and chemotherapy. In three patients, tumors began to regrow but were managed without surgery, using radiation or a minimally-invasive procedure."
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New from #aacr26: A small clinical trial (8-person) at MSK is showing promise for people with early-stage #rectalcancer whose tumors are driven by excessive amounts of a protein called HER2 (human epidermal growth factor receptor 2).
The trial, led by MSK gastrointestinal medical oncologists Dr. Michael Foote and Dr. @AndreaCercek, suggests that many of these patients may be successfully treated using targeted therapies to avoid surgery, resulting in fewer side effects and better quality of life during and after treatment.
Learn more about this research: www.mskcc.org/news/treating-her2-amplified-early-stage-re… @aacr -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK cancer biologist @MaraShermanLab presented to a full room on identifying strongly barriers to pancreatic tumorigenesis at #aacr26. @AACR
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Research updates from MSK computational oncologist Dr. Eduard Reznik via #aacr26.
Young Kwang Chae, MD, MPH, MBA
@youngkwangchae
Brilliant talk by Dr. @EduardReznam @MSKCancerCenter #aacr26
Cancer cachexia isn’t one disease — CT-based body composition reveals 3 distinct subtypes:
Type A: liver/spleen enlargement + ↑NLR + inflammatory signaling, worst OS
Type B: widespread ↑organ density
Type C: mild -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New from #aacr26: A small clinical trial (8-person) at MSK is showing promise for people with early-stage #rectalcancer whose tumors are driven by excessive amounts of a protein called HER2 (human epidermal growth factor receptor 2).
The trial, led by MSK gastrointestinal medical oncologists Dr. Michael Foote and Dr. @AndreaCercek, suggests that many of these patients may be successfully treated using targeted therapies to avoid surgery, resulting in fewer side effects and better quality of life during and after treatment.
Learn more about this research: www.mskcc.org/news/treating-her2-amplified-early-stage-re… @aacr -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
About to start: MSK gastrointestinal medical oncologist Dr. Michael Foote will present new clinical trial research for advanced #rectaladenocarcinoma at #aacr26.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Don't miss the chance to meet with MSK's Dr. Luis Diaz, Editor-In-Chief of Cancer Discovery. #aacr26
AACR
@AACR
Attending #aacr26? Meet Luis A. Diaz, Editor-in-Chief of Cancer Discovery, at 2:00 PM on Sunday, April 19 at the AACR Publications Booth 3537. www.abstractsonline.com/pp8/
@CD_AACR -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK cancer biologist Dr. @MaraShermanLab for a session about “Identifying stromal barriers to pancreatic tumorigenesis” TODAY at #aacr26. @aacr
⏱️ : Saturday, April 18 at 1pm PDT
Learn more here: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center reposted
Al-Ola A Abdallah MD (USMIRC)
@Abdallah81MD
Kicking off #icet2026 Session 1 🚀
Honored to have Dr. Saad Usmani @szusmani from @MSKCancerCenter sharing insights on:
🔬 CAR-T in #multiplemyeloma
📊 Clinical trial outcomes vs real-world experience
⚡ Efficacy, durability & evolving patient selection
A powerful start to an exciting meeting! 👏 #car_t #myeloma #hemeonc
#ice_t #meded #medtwitter #usmirc @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK gastrointestinal oncologist Dr. Michael Foote for a session about “Genomic HER2 amplification predicts for complete clinical response in a phase II study of induction tucatinib and trastuzumab combined with chemotherapy in locally advanced #rectal #adenocarcinoma” TODAY at #aacr26. @aacr
⏱️ : Saturday, April 18 at 12:36pm PT
Learn more here: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Featuring Dr. @rosslevinemd, Chief Scientific Officer at MSK and Dr. Kenneth Offit, Chief of the Clinical Genetics Service at MSK. ⬇️👏 #aacr26
AACR
@AACR
This evening, the 24 members of the 2026 class of AACR Fellows were inducted into the AACR Academy. The distinguished scientists who comprise the AACR Academy form a global community of thought leaders who advance the AACR’s mission. #aacr26 #aacrfellows
-
Memorial Sloan Kettering Cancer Center reposted
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Don't miss this important #aacr26 session with Dr. Karuna Ganesh this morning! ⬇️
MSK Department of Medicine
@MSK_DeptOfMed
Starting soon at #aacr26! Dr. Karuna Ganesh will present on the role of pks+ E. coli in intestinal stem cell plasticity and early-onset #colorectalcancer. @MSKCancerCenter @AACR @KarunaMDPhD
⏰ 8:30 a.m. PDT
www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Research updates from @MFBerger1 at #aacr26.
Oriol Mirallas MD
@DrMirallas
📝 Methods Workshop - #ai in #cancer care @AACR #aacr26
🗣️@ca_chung @UTMDAnderson
@deniswirtz @JohnsHopkins
@MFBerger1 @MSKCancerCenter
📌 Accelerate scientific discovery 🖥️
♻️ Integrating clinical context across multiomics
🔬 Tissue and cellular level 🧫
@OncoAlert -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today kicks off #aacr26! Follow along on our social channels from April 17-22 for live updates and to hear from our MSK experts in attendance. @AACR
-
Memorial Sloan Kettering Cancer Center reposted
ASCI
@the_asci
Congratulations to Charles L. Sawyers @SawyersLabMSKCC (@MSKCancerCenter) on receiving the Harrington Prize—award lecture happening now
#jointmeeting2026 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join MSK molecular geneticist Dr. Michael Berger for a session titled “From sequencing to treatment: The role of AI in precision oncology” TODAY at @aacr. #aacr26
⏱️ : Friday, April 17 at 4:01pm PT
Learn more: www.abstractsonline.com/pp8/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
“Survivorship research has become an increasingly important topic. We now have more effective cancer therapies and, as a result, more cancer survivors,” says MSK genitourinary oncologist Dr. @DSolit.
Learn more below ⬇️
AACR
@AACR
Explore the science of survivorship and the critical value of patient perspectives in cancer research through the #aacr26 survivorship track. Learn more in AACR Annual Meeting News: www.aacrmeetingnews.org/survivorship-sessions-and-patient…
-
Memorial Sloan Kettering Cancer Center reposted
Stanford Cancer Institute
@StanfordCancer
It was an honor to host @charlesrudin, deputy director of @MSKCancerCenter, for the SCI Breakthroughs in Cancer Series. He shared insights into small cell #lungcancer, including newly defined etiologies and emerging therapies. Watch: www.youtube.com/watch?v=7SZmtE3O35U #sclc
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK, led by Dr. Scott Lowe, Dr. @dana_peer, and colleagues, shows how pancreatic cells can shift from a benign state to cancer — revealing new aspects of this process.
The study, published in @CellCellPress, identifies a critical window for early detection and prevention. Learn more: www.mskcc.org/news/from-benign-growth-to-pancreatic-cance… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
If you’re planning to attend the 2026 @aacr Annual Meeting, don’t miss the Memorial Sloan Kettering Cancer Center (MSK) Entrepreneurship & Commercialization Booth (#2929).
Meet with Jonathan Dow, PhD, about the MSK Therapeutics Accelerator, which facilitates industry collaborations leveraging MSK’s expertise to de-risk therapeutics development.
Connect with other innovation experts including Shengquan Duan, PhD, who leads MSK’s Product Development team, and Brendan Laing and Jake Cohen, Digital Health experts who can discuss business development opportunities involving MSK and AI, data resources, OncoKB, and more. #aacr26 -
Memorial Sloan Kettering Cancer Center reposted
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Physicians and scientists from MSK will join oncology experts and members of the global #cancerresearch community to present the latest advances in cancer discovery at @aacr Annual Meeting 2026, taking place April 17–22, in San Diego, California.
MSK investigators will share significant new findings and participate in high‑impact sessions spanning cancer metastasis, immuno‑oncology, molecular biology and genetics, early‑phase drug development, tumor evolution, computational oncology, and precision medicine.
Learn more: www.mskcc.org/news-releases/mskcc-experts-to-present-lead… #aacr26 -
Memorial Sloan Kettering Cancer Center reposted
K2 Integrity
@K2Integrity
@K2Integrity is proud to sponsor #comedyvscancer, benefiting @MSKCancerCenter and advancing critical #bloodcancer research.
Returning to Jazz at Lincoln Center this week, the event has raised just under $10M to advance breakthrough treatments. Learn more: www.k2integrity.com/en/events/comedy-vs-cancer-k2-integri… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A new study from MSK is testing a long-held assumption about #mesothelioma, which has long been thought of as a condition that affects older men, especially those who may have been exposed to #asbestos.
Researchers say they’ve become increasingly aware of patients with this aggressive cancer under the age of 50, including a surprising number of younger women with no self-reported potential exposures to asbestos. Learn more: www.mskcc.org/news/what-you-should-know-about-mesotheliom… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK finds skin stem cells retain long-lasting memory of inflammation; shows how a large cancer DNA study could transform personalized oncology; reveals how the protein BAF helps cancer cells hide from the immune system; and investigates how early DNA markings shape cell fate. Learn more: www.mskcc.org/news/msk-research-highlights-march-27-2026
-
Memorial Sloan Kettering Cancer Center reposted
MSKCC Team Uterus
@TeamEndo_MSK
Big moment for our colleague Sana Hatoum taking the stage at #sgoam2026 to present her work on molecular classification of endometrial carcinoma, focusing on challenging cases and the role of panel sequencing.
@SanaHatoum @AmirMomeniBr @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
MSK researchers presented new findings on #cartcelltherapy safety, treatment options for rare blood disorders, precision dosing for #bonemarrowtransplant, and patient navigation programs at the 2026 Tandem Meetings. @MSKCancerCenter #tandem26 #bloodcancer
Learn more: -
Memorial Sloan Kettering Cancer Center reposted
Ghassan Abou-Alfa
@GABOUALFA
Excited to join #dhai2026. @GABOUALFA @MSKCancerCenter will be joining @Amir Lahav and team at @Digital Health & AI Innovation (DHAI) Summit take the stage and discuss precision medicine. Looking forward to connecting with clinicians, scientists, and AI experts shaping the future
-
Memorial Sloan Kettering Cancer Center reposted
JCO Precision Oncology
@JCOPO_ASCO
Diffuse Pleural Mesothelioma in Young (Age ≤50 Years) and Very Young (Age ≤35 Years) Patients: Clinical Characteristics, Genomics, and Survival. Co-authored by @MSKCancerCenter and @MSK_Thoracic.
Read the full article. ascopubs.org/doi/abs/10.1200/PO-25-01171 -
Memorial Sloan Kettering Cancer Center reposted
Targeted Onc
@TargetedOnc
📽️ In an interview, Charles Simone, MD, @MSKCancerCenter, discusses how radiation is advancing treatment and outcomes for rare thymic tumors.
www.targetedonc.com/view/advancing-outcomes-in-thymic-mal… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's most recent awards and appointments, including Dr. Charles Sawyers for being awarded the Harrington Prize for Innovation in Medicine, @RShouval for receiving the Van Bekkum Award from the @TheEBMT, and more: www.mskcc.org/news-releases/msk-awards-and-appointments-m…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to Dr. Charles Sawyers, an investigator at Memorial Sloan Kettering Cancer Center (MSK), on receiving the 13th annual Harrington Prize for Innovation in Medicine.
Dr. Sawyers, who is Chair of Human Oncology and Pathogenesis Program at MSK and a Howard Hughes Medical Institute (HHMI) Investigator, was jointly awarded the prize with Dr. Arul Chinnaiyan, an investigator at the University of Michigan and the HHMI.
The award recognizes their transformative discoveries that defined the molecular drivers of prostate cancer and pioneered precision therapies that have reshaped the diagnosis and treatment of prostate cancer worldwide.
Together, Drs. Sawyers and Chinnaiyan have developed the contemporary framework for diagnosis and treatment of advanced prostate cancer and a basis for next generation therapies. The Harrington Prize for Innovation in Medicine recognizes their impact on improving outcomes in this deadly disease.
Dr. Sawyers also holds the Marie-Josée and Henry R. Kravis Chair in Human Oncology and Pathogenesis at MSK.
Learn more: www.mskcc.org/news-releases/msk-awards-and-appointments-m… -
Memorial Sloan Kettering Cancer Center reposted
Allergic Living
@AllergicLiving
ICYMI: Researchers may have found why early allergen exposure helps prevent food allergies. Meet Thetis Cells—newly discovered immune cells that broker long-term peace between the immune system & good bacteria + food proteins. Learn more: @MSKCancerCenter www.allergicliving.com/2025/05/17/immune-thetis-cells-lin…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK researchers and their collaborators have developed a new type of CAR T cell designed to target a cell surface protein called uPAR, which is found on cancer cells as well as supportive cells in the tumor microenvironment. (1/3)
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
“In our laboratory models, these engineered cells selectively eliminated not only solid tumor cells, but also the uPAR-positive fibroblasts and immune-suppressive myeloid cells that provide a protective environment for the tumor to grow in,” says MSK cancer biologist Dr. Scott Lowe. (2/3)
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
While this research is still in early stages, it reflects a growing understanding that tumors depend on interactions between cancer cells and nearby tissues to grow and persist. (3/3) Learn more: www.mskcc.org/news/cell-surface-protein-upar-may-hold-key…
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
In a @NEJM editorial, Department of Medicine Chair @DebSchrag reflected on 30 years of incredible progress in #coloncancer treatment and identified opportunities to harness insights from biomarker testing to customize therapies that reduce side effects. @MSKCancerCenter
📖 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
For more than 140 years, MSK has been a global leader in cancer research and scientific discovery.
Subscribe to our quarterly newsletter, MSK Discoveries, to stay up to date with the latest research news — from clinical innovations to foundational biological insights: -
Memorial Sloan Kettering Cancer Center reposted
MSK_IntegrativeMedicine
@MSK_Integrative
🌿 Build strength, balance & confidence with MSK’s 6-week Fit & Functional Movement series 🌿
Improve mobility, coordination & independence with guided functional exercises.
🗓 Mondays, Apr 6–May 11
⏰ 1–2 PM EST
📍 MSK Evelyn H. Lauder Breast Center -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
📰 “Everything needs to now be [done] with an eye towards the resistance mechanisms of EV plus pembrolizumab," said @DSolit of @MSKCancerCenter on additional ADC targets and novel therapeutics developing in urothelial cancer.
Read more here ⚛️: www.onclive.com/view/additional-targets-for-adc-and-novel…
#oncology -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
WATCH 👀: Jae Park, MD, of @MSKCancerCenter discusses real-world data for obe-cel and its role in R/R ALL.
See the whole video here ➡️: www.onclive.com/view/dr-park-on-emerging-data-shaping-the…
#leusm #oncology -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A new drug is showing promise in lung and pancreatic cancers (two of the most aggressive forms of cancer) by targeting one of the most common cancer-driving mutations.
Researchers at Memorial Sloan Kettering Cancer Center (MSK), including gastrointestinal medical oncologist @CentralParkWMD who led the global phase 1 clinical trial, shared results published in the @NEJM.
The trial tested setidegrasib, a drug that tags and destroys the cancer-causing protein produced by the KRAS G12D mutation. This new method for targeting a long-known mutation is called a KRAS degrader.
KRAS mutations are present in about 1 in 5 cancers. The G12D subtype drives about 40% of pancreatic cancers and 5% of non-small cell lung cancers.
“This drug’s potential is exciting,” says Dr. Park, “because the trial results suggest that setidegrasib can not only extend life for some patients with these aggressive cancers, it also has a very good safety profile, meaning the drug was well-tolerated with side effects that can be managed quite easily."
Learn more about this research: www.mskcc.org/news/first-in-class-investigational-drug-kr… -
Memorial Sloan Kettering Cancer Center reposted
UrologyMSK
@UrologyMSK
Special to celebrate the retirement of the legendary Pramod Sogani after his 54 (!!) year career at @MSKCancerCenter! Amongst his many accomplishment Dr Sogani served as president of the @AmerUrological
-
Memorial Sloan Kettering Cancer Center reposted
Klebanoff_Lab
@KlebanoffLab
🚨Today in @Cancer_Cell: 50,000 tumor genomes via MSK-IMPACT. We map which HLA alleles are highest yield for antigen discovery—and define when HLA LOH constrains targetability.
A framework for scaling TCR therapies.
@MSKCancerCenter @parkerici authors.elsevier.com/sd/article/S1535-6108(26)00155-8 -
Memorial Sloan Kettering Cancer Center reposted
Marc Hilmi
@MarcHilmi
🤯🤯
Huge congratulations to @CentralParkWMD for two first-author papers in NEJM and Nature Medicine - on the same day! Truly extraordinary contribution to the field. Proud to be part of this @MSKCancerCenter team! @EileenMOReilly @ciacobu
NEJM
@NEJM
Presented at #elcc26:
In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. Full trial results: www.nejm.org/doi/full/10.1056/NEJMoa2600752
@myESMO -
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
1/n Now published in @NatureMedicine : The phase 2 #polar trial of pembrolizumab + olaparib maintenance in metastatic pancreatic cancer. @CpcrMsk @MSKCancerCenter @MSK_DeptOfMed @PICIatMSK
rdcu.be/e9WmJ -
Memorial Sloan Kettering Cancer Center reposted
Samson W. Fine, MD
@rovingatuscap
Highlighting the Wednesday 3/25 Poster Presentations by @MSKPathology @MSKCancerCenter Fellows & Faculty #uscap2026
-
Memorial Sloan Kettering Cancer Center reposted
Roni Shouval
@RShouval
Great science, even better people. Grateful to experience #ebmt2026 with this amazing @MSKCancerCenter team. @TheEBMT
-
Memorial Sloan Kettering Cancer Center reposted
Blood Cancers Today
@Blood_Cancers
March is National Breast Implant Awareness Month.
Patients with breast cancer and BRCA mutations who received textured breast implants are more likely to develop a rare T-cell #lymphoma, according to research by @PaolaGhione_MD (@MSKCancerCenter).
➡️ www.bloodcancerstoday.com/videos/brca-mutations-associate… -
Memorial Sloan Kettering Cancer Center reposted
Hafsa Nebbache, MD
@NebbacheHafsa
Reposting with the complete photo this time, much better than the half-face version 😄
Honored to present our work on #digitalpathology and AI platform validation in cytology specimens at
@MSKCancerCenter
#uscap2026 #uscap26 @cytojournal #cytopathology #uscap2026 @TheBatoolMD
Hafsa Nebbache, MD
@NebbacheHafsa
#uscap2026 → Poster #38 🔬✨ Exciting discussions on digital AI validation in the cytopathology world! #cytopath #cytopathology @JCOOA_ASCO @JASCJOURNAL @CancerCytopath @IACytology #pathresidents #digipath #pathology
#uscap2026 #uscap26 -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
Phase 3 TROPION-Breast02 results are in! Tiffany A. Traina, MD of @MSKCancerCenter highlights how Dato-DXd significantly improved PFS (10.8 vs 5.6 mos) & OS vs chemo in untreated mTNBC patients ineligible for immunotherapy.
Watch her full breakdown here: www.onclive.com/view/first-line-datopotamab-deruxtecan-vs… -
Memorial Sloan Kettering Cancer Center reposted
Cycle for Survival
@Cycle4Survival
A generous donor saved her life — and today, she’s saving others as a @MSKCancerCenter nurse. Lauren Kidd was diagnosed with cancer as a teen, and the only chance of survival was a stem cell transplant. Read the powerful @Newsweek article here. www.newsweek.com/diagnosed-with-cancer-as-teen-stranger-s…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
“Think of a chatbot as a research assistant rather than a decision-maker,” says MSK radiation oncologist @jjnaylor02.
MSK experts share how to use #ai chatbots to get reliable information and emphasize the importance of confirming what patients learn with their care team. Learn more: www.mskcc.org/news/using-ai-chatbots-to-get-reliable-info… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK would like to welcome Steve Glass, our new Executive Vice President and Chief Financial Officer.
Steve brings more than three decades of experience across the healthcare provider and payer sectors and will oversee MSK’s financial strategy and operations.
At MSK, Steve will work closely with leadership across the institution to support the organization’s continued growth and mission to end cancer for life.
Learn more about Steve: www.mskcc.org/news-releases/mskcc-appoints-steve-glass-as… -
Memorial Sloan Kettering Cancer Center reposted
José P. Zevallos, MD, MPH, FACS
@jpzevallos
I was honored to visit the @MSKCancerCenter Head and Neck Service, and to meet the outstanding faculty and fellows at such a storied program. Thank you especially to Dr. Rich Wong for the invitation, and to Dr. Shah and Dr. Shaha for sharing their wisdom and perspective.
-
Memorial Sloan Kettering Cancer Center reposted
Isabel Preeshagul
@ipreeshagul
INCREDIBLE leadership development meeting @MSKCancerCenter w/ @DrVickersMSK & Ami Schmitz featuring the great Dr. Francis Collin’s.
Take 🏠pearls :
1) the best way to grow is to surround yourself by truth tellers .
2) you can still succeed with an unconventional path! -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
"We hope to convert advanced colorectal cancer into a manageable disease."
#icymi: MSK physician-scientist @KarunaMDPhD and colleagues were awarded a @CancerGrand grant — a prestigious global initiative providing up to $25 million over five years to tackle some of the toughest problems in cancer research. Learn more: www.mskcc.org/news-releases/mskcc-physician-scientist-kar… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's Dr. @AndreaCercek and Dr. Luis Diaz for being accepted into Round 3 of @statnews #statmadness. Vote for their team now: www.statnews.com/feature/stat-madness/bracket-voting-now-…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨: Memorial Sloan Kettering Cancer Center security personnel identified a potential threat in the lobby at 1275 York Ave. and promptly notified the NYPD.
The situation was quickly contained. No injuries were reported, and the NYPD has issued the all-clear.
We are grateful for the swift response of our MSK security team and the NYPD. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
With the flood of medical content readily available on our phones and other devices, how do you know what’s credible? It’s a growing challenge for patients and medical professionals alike.
“Many people come across cancer misinformation when they are at a low point in their lives and looking for answers,” says Dr. David Miller, an MSK radiation oncology resident, who recently published a study on health misinformation. “If you have just received bad news from your doctor and you find something online that promises a better outcome, it’s natural that you’ll want to believe it.”
If you’re searching for health information online, here are a few things to be aware of: www.mskcc.org/news/finding-trustworthy-information-about-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to Won Jun Kim, a student in the Tri-Institutional MD-PhD Program and training at @GSKGradSchool in the @AbdelWahablab, for being named one of the 12 recipients of the Harold M. Weintraub Graduate Student Award.
This annual award recognizes outstanding achievement by graduate students in the biological sciences. Won Jun’s thesis focuses on mis-splicing-derived #neoantigens and cognate T-cell receptors in splicing factor mutant leukemias. Learn more: www.fredhutch.org/en/news/releases/2026/02/harold-m-weint… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
RT @MSKCME: Calling all residents, fellows, and trainees: Hear from @KishKPatel on why the annual @MSKCancerCenter Symposium on #lymphoma (…
-
Memorial Sloan Kettering Cancer Center reposted
Karim Touijer
@TouijerKarim
Deeply honored to receive the @EUplatinum award for 2025’s most-cited paper. Immensely proud of my @UrologyMSK team and thankful to the patients who made this research meaningful—advancing how we think about #prostatecancer surgery. @Uroweb @MSKCancerCenter
-
Memorial Sloan Kettering Cancer Center reposted
Vumedi Oncology
@VuMediHemOnc
🧬 Precision oncology is reshaping treatment for stage IV colorectal cancer. @colontown
Dr. Michael Foote @MikeFooteMD @MSKCancerCenter reviews how biomarkers—including RAS, BRAF, HER2, and MSI status—guide therapy selection, from EGFR inhibitors to targeted combinations and immunotherapy strategies.
🎥 Watch on #vumedi: www.vumedi.com/video/treating-stage-iv-colorectal-cancer-…
#colorectalcancer #gioncology #precisiononcology #cancerresearch -
Memorial Sloan Kettering Cancer Center reposted
Abdel-Wahab Lab
@AbdelWahablab
Excited to announce a paper out today in @natgenet.nature.com identifying an approach to mitigate the risk of therapy-related myeloid malignancies in patients with cancer. Collaboration with @KellyLBolton @WashU and led by @IrenaeusChan & @PuZhang09980432
www.nature.com/articles/s41588-026-02526-w -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's most recent awards and appointments, including Dr. Luis Díaz for receiving the 2026 @GustaveRoussy Award, Dr. Cardinale Smith for being named among “252 Chief Medical Officers to Know” by @BeckersHR, Dr. Miguel-Angel Perales for being inducted into the 2026 class of fellows of the @ASTCT, and more: www.mskcc.org/news-releases/msk-awards-and-appointments-f…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Just out in @NatureGenet: Research led by Dr. Omar Abdel-Wahab of MSK and Dr. Kelly Bolton of WashU Medicine offers a new method to prevent the development of chemotherapy-induced leukemia — one of the most lethal complications of cancer therapy for solid tumors.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Memorial Sloan Kettering Cancer Center (MSK) would like to welcome Dr. Lonny Yarmus, Head of the the Division of Subspecialty Medicine in the @MSK_DeptOfMed.
A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Dr. Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.
Learn more about Dr. Yarmus: www.mskcc.org/news-releases/lonny-yarmus-named-head-of-di… -
Memorial Sloan Kettering Cancer Center reposted
Waggoner Lab
@LabWaggoner
CD4+ T cell-driven cytotoxicity, memory-biased T cell states, reduced exhaustion, and microenvironment effects linked to long-term responses to BMCA-CAR-T in multiple myeloma patients @Cancer_Cell
www.cell.com/cancer-cell/fulltext/S1535-6108(26)00056-5
www.cell.com/cancer-cell/fulltext/S1535-6108(25)00490-8 @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's Dr. @TabarViviane and Dr. Lorenz Studer for being accepted into Round 2 of @statnews #statmadness. Vote for their team now: www.statnews.com/feature/stat-madness/bracket-voting-now-…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's Dr. @AndreaCercek and Dr. Luis Diaz for being accepted into Round 2 of @statnews #statmadness. Vote for their team now: www.statnews.com/feature/stat-madness/bracket-voting-now-…
-
Memorial Sloan Kettering Cancer Center reposted
Nature Metabolism
@NatMetabolism
#natmetabpicks | In @CellCellPress led by @lydfinley (@mskcancercenter)
Citrate clearance is an essential function of the TCA cycle via the activity of aconitase 2.
www.cell.com/cell/fulltext/S0092-8674(26)00115-7 -
Memorial Sloan Kettering Cancer Center reposted
Hamza Hashmi
@hhashmi87
Proud to ride with my Team Myeloma to raise awareness and support for cancer research @szusmani @UrviShahMD @FrancescoMaura4 @HassounHani @KyleeMaclachlan @MSK_DeptOfMed #mmsm
-
Memorial Sloan Kettering Cancer Center reposted
Tara Talaie, MD, MS
@TaraTalaie
Grateful to have had the opportunity to present our @MSKCancerCenter research at the #sso2026 breast session titled ‘Is routine intraoperative sentinel lymph node frozen section necessary in clinically node negative patients treated with neoadjuvant chemotherapy?’ @SocSurgOnc
-
Memorial Sloan Kettering Cancer Center reposted
Claire Eden, MD
@Claire_EdenMD
Thank you #sso for the opportunity to present our data at the best papers session “Borderline epithelial lesions of the breast and low-grade DCIS show similar rates of subsequent ipsilateral DCIS and invasive disease: a 10-year follow-up report” #sso2026 #mskcc @MSKCancerCenter @SocSurgOnc
-
Memorial Sloan Kettering Cancer Center reposted
Christopher Cowley, PhD
@chris_cowley14
This weekend I will be cycling alongside my @KarunaGaneshLab lab mates in @Cycle4Survival to raise money for rare cancer research @MSKCancerCenter! 100% of donations go straight to research! Please support our ride and help us reach our fundraising goal: secure2.convio.net/mskcc/site/TR/CycleforSurvival/Cyclefo…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
RT @MSKCME: On behalf of Course Director Dr. Gilles Salles, we invite you to join us for the 10th Anniversary MSK Symposium on #lymphoma. T…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New from @Nature: A team led by MSK breast medical oncologist Dr. Pedram Razavi found that tumors with germline #brca2 mutations or homologous recombination deficiency (HRD) are more likely to develop RB1 loss during treatment with CDK4/6 inhibitors, leading to therapeutic resistance.
“If we look deeper and better understand the biology of tumors, we may be able to predict how they will behave on treatment,” says Dr. Razavi. “By forecasting how resistance develops, we can work to intervene earlier and potentially improve outcomes.” Learn more: www.mskcc.org/clinical-updates/predicting-breast-cancer-b… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🎉 Congratulations to MSK physician-scientist @KarunaMDPhD and colleagues, who are part of an international team awarded a @CancerGrand grant — a prestigious global award providing up to $25M over five years to tackle some of the toughest challenges in #cancerresearch.
The team will explore new ways to “rewire” cancer cells and prevent treatment resistance in #colorectalcancer, one of the leading causes of cancer-related deaths. Learn more: www.mskcc.org/news-releases/mskcc-physician-scientist-kar… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's Dr. @TabarViviane and Dr. Lorenz Studer for being accepted into Round 1 of @statnews #statmadness. Vote for their team now: www.statnews.com/feature/stat-madness/bracket-voting-now-…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK investigates harnessing the power of #ferroptosis to spread cell death; reports how an MSK artificial intelligence (AI) model could help improve patient safety; and uses #ai to reveal country-specific drivers of global cancer outcomes. Read more:
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's Dr. Andrea Cercek and Dr. Luis Diaz for being accepted into Round 1 of @statnews #statmadness. Vote for their team now: www.statnews.com/feature/stat-madness/bracket-voting-now-…
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
At @ASCO #gu26, @motzermd presented phase 3 trial results showing that belzutifan + lenvatinib achieved superior PFS and ORR compared with cabozantinib in people with advanced #kidneycancer who progressed after immunotherapy. @MSKCancerCenter #rcc
🔗 meetings.asco.org/meetings/2026-asco-genitourinary-cancer… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's most recent Awards and Appointments, including @DrVickersMSK for being named among @oncodaily's “100 Most Influential CEOs in Oncology 2025," Dr. Maximilian Merz for being awarded $2.3 Million from the Hector Foundation, and more: www.mskcc.org/news-releases/msk-awards-and-appointments-j…
-
Memorial Sloan Kettering Cancer Center reposted
pathologynews
@pathologynews
🚨 Now Live: 2026 Digital Pathology Course
Join leaders at @MSKCancerCenter and @dpatweet in New York 🍎 for a 2-day deep dive into digital pathology, AI-enabled workflows & real-world implementation.
📅 May 1–2, 2026
💲 FREE–$700
Register: www.pathologynews.com/event/2026-digital-pathology-course/
More events: www.pathologynews.com/upcoming-events/ #pathology #aiinhealthcare -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
🎙️ On this episode of #casesandconversations we were joined by @AgulnikMd of @CityOfHope and @sandrapdangelo, Mrinal M. Gounder, MD, and @sujanamovvaMD of @MSKCancerCenter to discuss all things epithelioid sarcoma.
Listen to the whole episode here ➡️: www.onclive.com/view/cases-conversations-unmasking-epithe…
#scmsm #oncology -
Memorial Sloan Kettering Cancer Center reposted
UroToday.com
@urotoday
New treatment options for patients with castrate-resistant #prostatecancer or androgen pathway modulator-resistant cancer. Presented by @DRathkopf @MSKCancerCenter. #gu26 written coverage by @chavarriagaj @PSH_Urology > www.urotoday.com/conference-highlights/asco-gu-2026/asco-… @ASCO #ascogu26
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
After the major snowstorm that struck our area, all MSK sites plan to open at their normal time on Tuesday, February 24.
If we need to reschedule or change your visit to a video visit, we will call you. If you want to reschedule, call your care team.
Check back here for updates. -
Memorial Sloan Kettering Cancer Center reposted
OncoDaily
@oncodaily
🎗️How I Treat Gallbladder and Bile Duct Cancer in 2026: OncoDaily Gallbladder Cancer Summit
📅 February 28, 2026 | Virtual | 10 AM EST
🎤 Our first speaker is Dr. Ghassan K Abou-Alfa (@GABOUALFA) - Medical Oncologist at MSKCC (@MSKCancerCenter), Weill Medical College at Cornell University.
🌍 Experts from all continents
🎓 Practical, real-world oncology insights
📝 Register: docs.google.com/forms/d/e/1FAIpQLSeq5SbqlYeJhPyO37aLMytr0…
Let’s shape the future of gallbaldder cancer care together.
#oncodaily #oncology #cancer #health #medicine #gallbladdercancer #bileductcancer #cholangiocarcinoma #medx #medtwitter -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Winter storm update: Due to severe weather, MSK Westchester is closed today, Monday, February 23. Patients will be contacted about rescheduling their appointments.
For patients with appointments at other MSK sites: If we need to reschedule or change your visit to a video visit, we will call you. If you want to reschedule, call your care team. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Winter storm update: We are monitoring the winter storm (February 22–23). If we need to reschedule or change your visit to a video visit, we will call you. If you want to reschedule, call your care team. Check back here for updates.
-
Memorial Sloan Kettering Cancer Center reposted
ACCC
@ACCCBuzz
Last call to join the first webinar in #accc 4-part series on implementing the Collaborative Care Model (CoCM) in #oncology.
Hear expert faculty from @fredhutch, @MSKCancerCenter, and @providence offer tips for securing stakeholder buy-in and identifying key staffing models. -
Memorial Sloan Kettering Cancer Center reposted
Cancer Research
@CR_AACR
New in the February 15 issue from the Cancer Research special series: Deep-Learning Tool ScVital Enables Species-Agnostic Integration of Cancer Cell States doi.org/10.1158/0008-5472.CAN-24-4889
@TuomasTammela @MSKCancerCenter #computationalmethods #openaccess -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Years of CAR T research led to a breakthrough for AL amyloidosis and a clinical trial led by Dr. Heather Landau. Dr. Karlo Perica is advancing its potential for other cancers.
Our Saved by Science series captures the emotional meetings between patients and the scientists transforming care. Watch more Saved by Science stories on YouTube: www.youtube.com/watch?v=q3yqrfvmoRU -
Memorial Sloan Kettering Cancer Center reposted
Christine Quinn
@chriscquinn
It’s annual mammogram time! If you are someone who should get a mammogram-make an appointment TODAY!!If you have someone in your life who should get a mammogram-remind them TODAY!Thank you @MSKCancerCenter !
#breast #breastcancer #mammogram -
Memorial Sloan Kettering Cancer Center reposted
JCO Precision Oncology
@JCOPO_ASCO
We are proud to name @StadlerZsofia from @MSKCancerCenter the next Editor-in-Chief of JCO Precision Oncology starting July 1st. Dr. Stadler’s expertise will drive the integration of genomics and AI into cancer research for improved patient outcomes.
Read more: www.asco.org/about-asco/press-center/news-releases/geneti…
#jcopo -
Memorial Sloan Kettering Cancer Center reposted
Brandon Mancini
@brandonmancini
Michael J. Morris, MD of @MSKCancerCenter finishes Session VII with a presentation on industry perspective and regulatory challenges for RPT clinical trials. @ASTRO_org #mrpts26
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A clinical trial led by MSK’s Dr. Heather Landau using CAR T cell therapy helped Maureen and other patients with relapsed light chain (AL) amyloidosis. In just a week, her biomarkers returned to normal. Learn from physician scientist Dr. Karlo Perica how CAR T therapy is shaping the future of patient care: www.mskcc.org/news/car-cell-therapy-for-light-chain-al-am…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
After 20 years of fighting a rare blood disease, Maureen joined an MSK clinical trial, led by Dr. Heather Landau. Dr. Karlo Perica explains how #cart therapy re-engineered her immune cells to attack the disease. Just one week after her CAR T cell infusion, Maureen’s blood tests were normal and she felt great.
Watch more #savedbyscience stories: www.youtube.com/playlist?list=PLME9VJQhE-hut-Q41iJGdBUzEJ… -
Memorial Sloan Kettering Cancer Center reposted
American Statistical Association Philadelphia
@amstatphilly
Dr. Li-Xuan Qin of @MSKCancerCenter will present Evidence-Based Practice for microRNA-seq Data Harmonization: Contextual Evaluation and Robust Benchmarking. DM us for the link to register!
🗓️ February 26 @ 11 AM EST
www.mskcc.org/profile/li-xuan-qin -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Every medical breakthrough begins with a decades-long journey in the laboratory. Our Saved by Science series, captures the emotional meetings between patients and the scientists, including physician-scientist Dr. David Solit, whose years of research have given them new hope. Watch more Saved by Science stories on YouTube: www.youtube.com/watch?v=mP-ik0roidE&list=PLME9VJQhE-hut-Q…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
After participating in an MSK clinical trial, led by gynecological oncologist Dr. Rachel Grisham and based on research by physician-scientist Dr. David Solit, Ellen, an MSK ovarian cancer patient, got early access to a treatment that has dramatically shrunk her tumors and changed her outlook on life. Read more: www.mskcc.org/news/new-drug-treatment-for-low-grade-serou…
-
Memorial Sloan Kettering Cancer Center reposted
Alliance for Clinical Trials in Oncology
@ALLIANCE_org
New publication alert! Data from Alliance A031201 by Michael Morris MD and Nadine Norton PhD has uncovered a genetic factor that may inform the dosing of abiraterone, a hormone treatment for advanced prostate cancer. www.allianceforclinicaltrialsinoncology.org/main/public/s… @MSKCancerCenter @MayoClinic
-
Memorial Sloan Kettering Cancer Center reposted
Moffitt Cancer Center
@MoffittNews
Happening now: Kayvan Keshari, PhD (@KeshariLab @MSKCancerCenter) shares how metabolic engineering can power next-generation cell-based therapies, translating insights from in vivo cancer metabolism into more precise, effective treatment strategies.
#cancerengineeringsummit -
Memorial Sloan Kettering Cancer Center reposted
Daniel Heller
@Dan_A_Heller
A pleasure to discuss our research and Cancer Engineering PhD Program at @MSKCancerCenter co-directed with Kayvan Keshari. Thank you @ProfGregSawyer for having us at the #cancerengineeringsummit!
Moffitt Cancer Center
@MoffittNews
Happening now at #cancerengineeringsummit: Daniel Heller, PhD (@Dan_A_Heller), discusses cancer engineering at Memorial Sloan Kettering, highlighting the integration of engineering into oncology research and how he helped build a PhD program that bridges engineering and medicine to train the next generation of innovators.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Ellen was diagnosed with a rare and hard to treat #ovariancancer. Everything changed when she enrolled in a clinical trial led by Dr. Rachel Grisham, based on a lab discovery years ago by @DSolit.
Watch more #savedbyscience stories on YouTube: www.youtube.com/playlist?list=PLME9VJQhE-hut-Q41iJGdBUzEJ… -
Memorial Sloan Kettering Cancer Center reposted
Pancreatic Cell News
@PancreaticCell
🧬 Dr. Jungeui Hong and team at @MSKCancerCenter provide a high-level profile of the genetic features distinguishing locally advanced from metastatic PDAC, serving as a biomarker of PDACs most likely to benefit from neoadjuvant chemoradiation.
@CD_AACR | aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159… -
Memorial Sloan Kettering Cancer Center reposted
Salomon Tendler
@Tendler_S
Proud to see our work featured: a DLL3-targeted theranostic approach from @MSKCancerCenter combining PET imaging and targeted therapy for aggressive small cell lung and neuroendocrine prostate cancers.@MSKCancerCenter @LewisLabMSKCC www.mskcc.org/news/new-imaging-detects-deadly-lung-prosta…
-
Memorial Sloan Kettering Cancer Center reposted
Fernando Martín Moro
@Fer_martinmoro
Spending some days in NYC learning from Dr. Gilles Salles and his #lymphoma team at @MSKCancerCenter
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
In a "Best Abstracts" session at #tandem26, Dr. Heather Landau will present the study, "First 23-Patient Safety and Efficacy Data from Nexicart-2, the First U.S. Trial of CAR-T in R/R Light Chain (AL) Amyloidosis, Nxc-201." @mskcancercenter
📍 Feb 6, 9:15 a.m. MST
➡️ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to Dr. Luis Diaz, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center(MSK), on receiving the @GustaveRoussy Prize.
Each year, the Gustave Roussy Foundation selects a prominent figure whose scientific breakthroughs in cancer diagnosis, treatment, or prevention have significantly improved patient care and advanced our understanding of the disease. 👏 -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Congratulations to Dr. Miguel-Angel Perales, Chief of the Adult Bone Marrow Transplant Service at @MSKCancerCenter, on being inducted into the 2026 Class of the American Society of Transplantation and Cellular Therapy Fellows Program! #tandem26
ASTCT
@ASTCT
Congratulations to our 2026 Fellows of ASTCT and past presidents Dr. Corey Cutler and Dr. Miguel-Angel Perales! #tandem26 @DrCCutler
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
At #tandem26, don't miss Dr. Mohammad Alhomoud's presentation, "Cartiac: Comparative Cardiovascular Safety of CAR T Products for Non-Hodgkin’s Lymphoma – a Propensity Score–Matched International Multicenter Study."
📍 Feb 4, 4:15 PM MST
➡️ tandem.virtual-meeting.org/programme/presentation/677659
@MSKCancerCenter @moh7madhomod @ASTCT @CIBMTR -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Neuro-oncologist Dr. Adrienne Boire teamed up with computational biologist Dr. Dana Pe’er to find a way to stop cancer cells from surviving in the cerebrospinal fluid. By conducting a detailed analysis of patient samples using powerful computational methods, they unearthed the secret — a discovery that also suggested a treatment strategy. Learn more about the research with the potential to give patients more precious time. www.mskcc.org/news/leptomeningeal-metastasis-lm-clinical-…
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Next at #tandem26, Miguel-Angel Perales, MSK's Adult Bone Marrow Transplant Chief and past @ASTCT President, will present research on new tools to help predict one-year survival for transplant recipients. @CIBMTR @MSKCancerCenter
📍Feb 4, 11:15 a.m.
➡️ tandem.virtual-meeting.org/programme/presentation/674479 -
Memorial Sloan Kettering Cancer Center reposted
Bloomberg New Economy
@BBGNewEconomy
On #worldcancerday, a historic step forward for global cancer care.
For the first time, a clinical trial using immunotherapy is now enrolling colorectal cancer patients in Nigeria, marking the first trial of its kind in sub-Saharan Africa.
This milestone reflects a global collaboration between @OAUniversity, @LUTHofficial, @Medserve @ARGOResearch, and @MSKCancerCenter —expanding access to cutting-edge cancer treatment where it is needed most.
Congratulations to @BBGNewEconomy #internationalcancercoalition members Peter Kingham and Tolulope Adewole who played a central role in the collaboration behind this effort.
As cancer cases rise globally, the challenge is no longer just scientific progress - but how innovation can reach patients everywhere. This trial is an important step in that direction.
www.mskcc.org/news-releases/first-clinical-trial-using-im… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Dr. Sergio Giralt is kicking off the Tandem Meetings for @MSKCancerCenter! Join his session to learn about the latest CAR T cell therapies for #multiplemyeloma.
📍 Feb 4, 9:05 a.m.–9:35 a.m. MST | Room 255 A-G
➡️ tandem.virtual-meeting.org/programme/presentation/674436
#tandem26 @ASTCT @CIBMTR @GiraltSergio #mmsm -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK, in partnership with @OAUniversity, @LUTHofficial, and @medservengr, has launched a ground-breaking clinical trial aimed at transforming treatment options and standard of care for patients with #colorectalcancer in Nigeria.
This is the first clinical trial in sub-Saharan Africa to utilize #immunotherapy, a treatment that uses a person’s own immune system to fight cancer.
Learn more: www.mskcc.org/news-releases/first-clinical-trial-using-im… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🔬 A treatment discovered through a collaboration between MSK computational biologist Dr. @dana_peer and MSK neuro-oncologist Dr. Adrienne Boire, has given Carlos, an MSK stage 4 #lungcancer patient, more time with his family and a much better quality of life.
Watch more stories on YouTube: www.youtube.com/watch?v=h1aByfitfUE #cancerresearch -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Just out in @Nature: MSK researchers are shedding new light on the origins of Thetis cells — which help establish immune tolerance to food and helpful gut microbes. The findings will facilitate future investigations of these enigmatic cells and efforts to harness their therapeutic potential against food allergies and autoimmune diseases.
go.nature.com/46lMnmL -
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
Join us for a two-day live virtual symposium on the latest advances in cancer treatment and care across the oncology continuum. Presented in collaboration with @MSKCancerCenter, @HartfordHealthC, and @BaptistHealthSF, this program will share practical tools to support collaborative, high-quality, patient-centered cancer care. Learn more: mskcc.cloud-cme.com/course/courseoverview?P=5&EID=59906
-
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
Join us for the 10th anniversary edition of the MSK Symposium on #lymphoma. This milestone program brings together leading experts from @MSKCancerCenter and institutions around the world to explore the rapidly evolving landscape of lymphoma research and clinical care. Sessions will highlight breakthroughs in disease biology, advanced diagnostics, and innovative treatment strategies that are driving better patient outcomes.
For full program details and to register, visit: mskcc.cloud-cme.com/course/courseoverview?P=5&EID=62231
#msklymphomacme #lymphomaawareness #bloodcancer #hematology #oncology #cancerresearch #cancercare #precisionmedicine #immunotherapy #clinicaltrials
@BachyEmmanuel, @JenCrombieMD, @DocHutchings, @MarcelaMaus, @chaudhuj, @LiaPalomba, @RoschewskiMD, @QuinlanSievers -
Memorial Sloan Kettering Cancer Center reposted
Ziad Bakouny, MD, MSc
@ZiadBakouny
It was a pleasure to virtually join @AUB_FM for their 2nd Middle East Genitourinary Oncology conference with #nizartannir @EJonasch @drjkaouk @VaessenCh to discuss first line treatment for metastatic clear cell RCC!
@AUB_Lebanon @MSKCancerCenter @MSK_DeptOfMed @DrAlbert -
Memorial Sloan Kettering Cancer Center reposted
ACS Journal Cancer
@JournalCancer
New from @MSKCancerCenter investigators 💡 Advancing depression assessment in older adults w/ cancer: Development & validation of the Older Adults w/ Cancer-Depression Scale (OAC-D), a novel, patient-reported outcome
#openaccess 🔗: acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr…
@OncoAlert #gerionc -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A new collaborative research study by researchers at MSK, @AstraZeneca, and @Baylor College of Medicine, has identified 22 specific genetic variants that are linked to both higher active levels of the Epstein-Barr virus (EBV) and risk for chronic diseases of the lung and heart, lupus, and certain cancers.
“We saw the untapped potential of this routinely discarded viral DNA and generated valuable insights at a scale previously unimaginable, turning trash into treasure,” says MSK's @CalebLareau. Learn more: www.mskcc.org/news/genomics-unlocks-how-dna-and-viruses-c… -
Memorial Sloan Kettering Cancer Center reposted
Caleb Lareau
@CalebLareau
Grateful to work everyday at @MSKCancerCenter as a home to conduct this research. A write-up of the effort in context of our group's efforts to understand the virome is covered here: www.mskcc.org/news/genomics-unlocks-how-dna-and-viruses-c…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A new study published in @Nature by researchers at MSK, led by @TuomasTammela, shows that a small number of highly plastic cancer cells drive cancer progression and the ability to evolve resistance to treatment. Learn more: www.mskcc.org/news/small-number-of-highly-plastic-cancer-…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Researchers at MSK are studying the intricacies of metastatic disease to develop new ways to treat it and improve outcomes for patients with stage 4 #cancer. Learn how MSK is making progress against #metastasis: www.mskcc.org/news/making-progress-against-metastasis
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to Dr. Kenneth Offit, Chief of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center (MSK), and @rosslevinemd, Chief Scientific Officer at MSK, on their election to the Fellows of the American Association for Cancer (@AACR) Academy. This election to the AACR Academy recognizes extraordinary scientists whose work has made a profound and lasting impact on #cancerresearch.
Learn more: www.mskcc.org/news-releases/two-mskcc-physicians-elected-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK sheds new light on how the gut protects itself by sensing gut bacteria; finds a subtype of #glioma-associated macrophages that appear to play a pivotal role in progression; and more: www.mskcc.org/news/msk-research-highlights-january-20-2026
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A winter storm is affecting our area. All Memorial Sloan Kettering Cancer Center locations are their normal schedule today, Monday, January 26. Please allow extra time to get to your appointment.
-
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
WATCH📺: @jhaveri_komal of @MSKCancerCenter shares lessons learned from the negative phase 3 ASCENT-07 trial, which evaluated sacituzumab govitecan in the first line for HR+, HER2- breast cancer.
Hear her insights ➡️: www.onclive.com/view/dr-jhaveri-on-the-implications-of-as…
#bcsm #oncology -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Storm Update: All MSK locations planning for normal operations on Monday, January 26. Please plan extra travel time. If we need to reschedule appointments, we will contact you. Please call your care team if you need to reschedule an appointment. Check back for updates.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research at MSK shows how dormant #metastatic cancer cells prevent the immune system from eliminating them by changing their shape.
Scientists uncovered how these cancer cells lower their surface tension, making it harder for patrolling immune cells to latch onto them. The findings, published in @NatureCancer, illuminate how cancer cells physically adapt to survive. Learn more: www.mskcc.org/news/dormant-cancer-cells-change-shape-to-s… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from an international team led by MSK physician-scientist Dr. Alex Kentsis suggests that disruptions caused by the gene #pgbd5 are also essential to normal brain development in mammals, including humans.
The finding, published in @ScienceAdvances, sheds more light on the origins of early onset cancers and their link to brain development. Learn more: www.mskcc.org/news/researchers-discover-pgbd5-guides-norm… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
According to a 2026 report from the @AmericanCancer, “#colorectalcancer death rates in the past decade have decreased by 1.5% per year for both men and women.”
The group credits “reductions in colorectal cancer incidence, earlier detection in screening, and improvements in treatment.”
MSK colorectal surgeon Dr. Julio Garcia-Aguilar says there are a growing number of ways to treat colon and rectal cancer including advances, developed at MSK, in targeted therapy, surgery, and immunotherapy that can also preserve quality of life.
Learn more about these latest treatments for colon and rectal (colorectal) cancer: www.mskcc.org/news/new-colorectal-cancer-treatments-at-ms… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Researchers from the lab of MSK immunologist Dr. Gretchen Diehl are shedding new light on how intestinal stem cells sense microbes and protect the gut. Read their new study, just out in @ScienceMagazine. #scienceimmunology. www.science.org/doi/10.1126/sciimmunol.adr4057
-
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
Join distinguished faculty for a current update in #hematology and #medicaloncology and the 14th Annual Board Review from @MSKCancerCenter. Delivered virtually over four streamlined days, this course provides an in-depth review of the diagnosis, staging, and management of neoplastic diseases across solid tumors and hematologic malignancies. Designed as both a high-yield refresher for practicing clinicians and focused preparation for #abim certification and recertification. Learn more: mskcc.cloud-cme.com/course/courseoverview?P=5&EID=56570
#mskhemonccme @GABOUALFA @KCArbourMD @LiorBraunstein @DrDarrenFeldman @MalinHultcrantz @LeaderAvi @anitamamtani @mjmauroMD @motzermd @michael_offin @EileenMOReilly @RaajitRampal @GunjanLShah @SherryShenMD @SoffGerald @StadlerZsofia @MCThompsonMD @AnnaVarghese4 @cywilkinsmd @CelineYehMD -
Memorial Sloan Kettering Cancer Center reposted
Selwyn M. Vickers
@DrVickersMSK
Dr. Martin Luther King Jr.’s life and leadership continue to inspire me. Today and always, we can honor his legacy by caring for those around us.
-
Memorial Sloan Kettering Cancer Center reposted
Blood Cancers Today
@Blood_Cancers
🙌 ICYMI: Sergio Giralt, MD, of @MSKCancerCenter, highlighted pivotal #myeloma research, from bispecific combinations to CAR T-cell therapy.
Check out our Multiple Myeloma Learning Lab here! ➡️ www.bloodcancerstoday.com/learning-lab/multiple-myeloma-l… -
Memorial Sloan Kettering Cancer Center reposted
Cancer Nursing Today
@cancer_nurses
⏰ ICYMI: Check out our #ash2025 interview with Amy Pierre, RN, BSN, ANP-BC, of @MSKCancerCenter, about conference updates, including key presentations, abstracts, & data nurse practitioners should know!
🌟 You don't want to miss this!
➡️ Watch Now: www.cancernursingtoday.com/videos/multiple-myeloma-update… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Congrats to @MSKCancerCenter's Eytan Stein and collaborators on receiving the "2025 Paper of the Year” award from @JCO_ASCO for their study evaluating revumenib for acute #leukemia with a KMT2A translocation. The study results led to the drug's FDA approval in 2024.
Learn more about this advance: www.mskcc.org/news/promising-new-type-drug-aggressive-leu… -
Memorial Sloan Kettering Cancer Center reposted
Blood Cancers Today
@Blood_Cancers
🙌 Myelofibrosis Year in Review: @RaajitRampal, of @MSKCancerCenter, tells us the most stand-out #myelofibrosis research from #ash25 and what's on the horizon for 2026.
📺 Watch here: www.bloodcancerstoday.com/videos/myelofibrosis-year-in-re… -
Memorial Sloan Kettering Cancer Center reposted
HemOnc Today
@HemOncToday
💉 Underserved patients with cancer who received #acupuncture or massages in a pilot program reported significant improvement in #anxiety and #fatigue.
🗨️ “There definitely is a need for this type of therapy,” @KevinLiouMD @MSKCancerCenter told Healio. vist.ly/4mtnf -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Medical oncologist Dr. Miguel-Angel Perales, Chief of the Adult Bone Marrow Transplant (BMT) Service at MSK, shares 10 reasons why MSK's BMT program continues to be a leader in the field of transplantation.
www.mskcc.org/news/why-msk-is-leader-in-stem-cell-and-bon… -
Memorial Sloan Kettering Cancer Center reposted
Jessica Altman, MD
@jaltmanmd
So very lucky to have Eytan Stein of @MSKCancerCenter share his expertise with us during @NUFeinbergMed grand rounds.
-
Memorial Sloan Kettering Cancer Center reposted
Association of American Cancer Institutes
@AACI_Cancer
The 5-year cancer survival rate has reached 70%, up from 50% in 1971, per @AmericanCancer. Experts told @statnews decades of cancer research investment drove this progress. Leaders at @SloanKettering say it’s critical to keep the momentum going. www.cancer.org/content/dam/cancer-org/research/cancer-fac…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New MSK research suggests circadian rhythms may influence how patients respond to CAR T cell therapy for large B cell #lymphoma. Patients treated before noon showed higher 1-year progression-free survival.
“The link between circadian rhythms and treatment effectiveness is a relatively new area of research,” says MSK's @RShouval. “By studying this connection, we hope to improve the way CAR T therapy is administered, so that more people can benefit from this potentially lifesaving therapy.” Learn more: www.mskcc.org/news/successful-car-treatment-for-large-cel… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to Dr. Ross Levine (@rosslevinemd), MSK's Chief Scientific Officer, who was appointment editor-in-chief of Blood Cancer Discovery (@BCD_AACR), published by @AACR.
Learn more: www.aacr.org/about-the-aacr/newsroom/news-releases/ross-l… -
Memorial Sloan Kettering Cancer Center reposted
Yale Cancer Center
@YaleCancer
Today at 12pm, we are pleased to welcome Dr. Scott Lowe @LoweLabMSKCC as our #grandrounds lecturer, presenting "Targeting the intersection between senescence and cancer."
Join us in Smilow Auditorium or online via Zoom: medicine.yale.edu/cancer/event/yale-cancer-center-grand-r….
@SmilowCancer @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center reposted
Daniel Heller
@Dan_A_Heller
Thank you @MSKCancerCenter for explaining our work to detect brain cancers earlier with nanosensor/AI “machine perception” so that they are easier to treat, and hopefully cure!
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Imagine a blood test that detects the first signs of a #braintumor when it might be treated more easily.
A liquid biopsy for brain cancers is now one step closer to reality. The laboratory of Dr. @Dan_A_Heller, a biomedical engineer at MSK, has developed an ultrasensitive diagnostic test that could potentially detect and classify different types of brain tumors with 98% accuracy.
Learn more about this research: www.mskcc.org/news/new-liquid-biopsy-using-ai-nanosensors…
#braincancer -
Memorial Sloan Kettering Cancer Center reposted
Oncology News Central
@OncNewsCentral
From perioperative strategies to adjuvant therapy: @DrRosenbergMSK of @MSKCancerCenter explores the evolving role of #ctdna and MRD in bladder cancer and the studies driving change.
Watch: www.oncologynewscentral.com/video/bladder-cancer/whats-ne…
#esmo25 #oncology #bladdercancer #mrd -
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
#kras Big time! Early signals for finally #precision therapies that may change how we treat #pancreaticcancer
Single agents work and combos show promising responses. 🔑 = Durability and tolerability = long 😊 QoL
#gi26 @ASCO @MSKCancerCenter @MSK_DeptOfMed @myESMO @KRASKickers
Grainne O'Kane
@graokane
Abstracts #gi26 released! With dedicated KRAS session, 👇select KRAS abstracts #pancreaticcancer - more to come this yr!
➡️ combos I feel 🔑
Looking forward full presentations
@ASCO @myESMO @OncoAlert -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Imagine a blood test that detects the first signs of a #braintumor when it might be treated more easily.
A liquid biopsy for brain cancers is now one step closer to reality. The laboratory of Dr. @Dan_A_Heller, a biomedical engineer at MSK, has developed an ultrasensitive diagnostic test that could potentially detect and classify different types of brain tumors with 98% accuracy.
Learn more about this research: www.mskcc.org/news/new-liquid-biopsy-using-ai-nanosensors…
#braincancer -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Love to see a collaborator reunion! @YJanjigianMD, Eric Van Cutsem, & @KoheiShitara caught up at #gi26. Dr. Janjigian presented about a trial in progress of first-line trastuzumab deruxtecan with volrustomig and fluropyrimidine in patients with HER2-low #gastriccancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma. @ASCO @MSKCancerCenter.
Learn more: meetings.asco.org/meetings/2026-asco-gastrointestinal-can… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Coming up at @ASCO #gi26, Dr. Geoffrey Ku will give a medical oncologist's perspective on the role of local and systemic treatments in metastatic #gastriccancer and #gastroesophagealcancer @MSKCancerCenter #gicancers
3:45 – 5 p.m. PST | Level 3, Room 3001 -
Memorial Sloan Kettering Cancer Center reposted
NU Internal Medicine
@NU_IntMed
Please join us on Jan. 14th for our next #medicalgrandrounds ! We will be joined by Eytan Stein, MD from @MSKCancerCenter for our Distinguished Alumni Lectureship sponsored by @Landsberg_Soc !
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
We're excited for @ASCO #gi26! Stop by @SteveMaronMD's poster to learn about a phase 2 trial of amivantamab for EGFR- or MET-amplified #gastroesophageal #adenocarcinoma. @MSKCancerCenter #gicancer
TODAY | 11:30 – 1 p.m. PST
Learn more: www.asco.org/abstracts-presentations/255864 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from MSK shows that bacteria inside tumors may limit the effectiveness of #immunotherapy. Targeting those bacteria could help more patients benefit. Learn more: www.mskcc.org/news/treatment-for-head-and-neck-squamous-c…
-
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
Join us in three weeks for a one-day virtual symposium exploring foundational principles and emerging advances in cancer #immunotherapy. Expert faculty from @MSKCancerCenter will address clinical applications across solid tumors and hematologic malignancies, with a focus on recognizing and managing treatment-related toxicity. Learn more and register at mskcc.cloud-cme.com/course/courseoverview?P=5&EID=59528
@RossFirestone @lynnalidomide @ROCearbhaill @BSantomasso @JessicaWilcoxMD @carollct @sandrapdangelo #mskimmunoonccme #mskcme -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK surgeons have extensive experience performing radical #prostatectomy and use advanced imaging and precision techniques to support safe, effective care and individualized treatment planning.
MSK urologic surgeon Dr. Jonathan Fainberg discusses what to expect when a patient is considering prostate cancer surgery, including potential side effects and prospects for recovery. Learn more: www.mskcc.org/news/prostate-surgery-complications-what-pa… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Scientists have known for decades that there are gene mutations that increase your risk of developing cancer. But there is also a genetic variant that could reduce the risk of developing certain #bloodcancers, according to new research co-led by scientists from MSK.
“We’ve discovered the mechanism by which a change within the MUSASHI2 (MSI2) gene region appears to protect people from blood cancers related to clonal hematopoiesis,” says cancer biologist @KharasLab, a member of the Molecular Pharmacology Program in the Sloan Kettering Institute and co-corresponding author of the paper.
Learn more: www.mskcc.org/news/new-research-finds-genetic-variant-in-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK researchers are investigating the relationship between dietary patterns and cancer. Clinical trials like #nutrivention test how high-fiber, minimally processed plant-based food affects weight and metabolic biomarkers in people with precursor blood disorders. Learn more:
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's most recent Awards & Appointments honorees, including @DrVickersMSK for being named “61 CEO Influencers to Know” by @BeckersHR, Dr. Jason Lewis for being elected as a Fellow of the @AcadofInventors, Dr. Piro Lito for being selected for the 2025 Pew Charitable Trusts’ Class of Innovation Fund Investigators, Dr. Thomas Atkinson for being awarded funding from @PCORI, and more: www.mskcc.org/news-releases/msk-awards-and-appointments-d…
-
Memorial Sloan Kettering Cancer Center reposted
Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰
@szusmani
It’s a privilege to be part of the #mmsm community and humbled to be acknowledged in this way, big shoutout to the myeloma crew @MSKCancerCenter and former team @LevineCancer , and to all my friends and collaborators.
@IMFmyeloma @theMMRF @HealthTree @BloodCancerUtd
OncLive.com
@OncLive
From Pakistan to the Front Lines of Multiple Myeloma Research @szusmani @MSKCancerCenter #oncology #myeloma
www.onclive.com/view/from-pakistan-to-the-front-lines-of-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The @FDA approved 10 #cancer drugs in 2025, based on #clinicaltrials in which MSK played a pivotal role.
These approvals spanned therapies for a range of solid tumors and blood cancers and included treatments for both common and rare types of tumors.
Learn more: -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Ozempic, Zepbound, Wegovy, and related weight loss drugs have become some of the world’s most talked about medications in a remarkably short time.
Dr. Sherry Shen is a breast cancer oncologist at MSK who studies the relationship between obesity, metabolic health, and cancer. Here, she shares what these weight loss drugs mean for cancer risk and treatment.
www.mskcc.org/news/cancer-benefits-and-risks-from-ozempic… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
In 2025, MSK researchers made some exciting scientific discoveries that are reshaping our understanding of cancer biology and treatment, from a new AI model that predicts immunotherapy response using routine blood tests to groundbreaking advances in CAR T cell therapies and more.
Learn more about the top research breakthroughs from MSK this year: www.mskcc.org/news/top-cancer-research-advances-at-msk-in… -
Memorial Sloan Kettering Cancer Center reposted
Blood Cancers Today
@Blood_Cancers
In an interview from #ash25, Dr. Lorenzo Falchi (@MSKCancerCenter) discusses emerging frontline treatment strategies for patients with high-risk #dlbcl and the rationale behind combining novel immunotherapies with standard chemotherapy.
📺 Watch here! www.bloodcancerstoday.com/videos/beyond-r-chop-improving-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Festive fits, cocoa sips, and a whole lot of MSK cheer! ☕️✨ Our teams took a well-deserved breather last week to celebrate the season and light up the hospital with some holiday magic.
Who knew our staff had such a competitive sweater game? ❄️ 🧣 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in a variety of #cancer treatments in 2025 — including new approaches to #immunotherapy, targeted therapy, and surgical imaging. Highlights this year also included a stem cell–based therapy for Parkinson’s disease and several clinical trials looking at the benefits of integrative medicine.
Learn more: www.mskcc.org/news/top-cancer-treatment-advances-at-msk-i… -
Memorial Sloan Kettering Cancer Center reposted
OncoDaily
@oncodaily
Yelena Janjigian (@YJanjigianMD) recognized among The 100 Most Influential People in Oncology in 2025
oncodaily.com/community/yelena-janjigian-427857
@MSKCancerCenter @WeillCornell
#oncodaily #oncology #cancer #health #medicine #100influentialpeopleinoncology #oncodaily100 -
Memorial Sloan Kettering Cancer Center reposted
Fresia Pareja
@FresiaPareja
Thrilled and incredibly grateful to @AACR and @BCRFcure for supporting our work in lobular breast cancer, a biologically distinct and understudied entity. @LobularBCA @MSKCancerCenter @MSKPathology
AACR
@AACR
Congratulations to Fresia Pareja Zea, MD, PhD, recipient of the 2025 BCRF–AACR Career Development Award to Promote Diversity and Inclusion. Dr. Pareja's research aims to advance antibody-drug conjugate therapies for lobular breast cancer.
#aacrgrants @bcrfcure @FresiaPareja -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
👏 Congratulations to Dr. @debschrag, a gastrointestinal medical oncologist at MSK and Chair of the @MSK_DeptOfMed, on being elected as the 2027-28 President of @ASCO.
Dr. Schrag will take office as President-Elect following the conclusion of the ASCO Annual Business Meeting in Chicago on June 1, 2026.
“ASCO is at the forefront of cancer care and empowers the global oncology community by bringing us together to drive innovation and discovery and tackle challenges that enable us to improve outcomes for our patients” said Dr. Schrag. “I thank ASCO’s membership for trusting me with this important responsibility and look forward to advancing ASCO’s strategic plan and championing the shared values of the oncology workforce to accelerate progress in partnership with the Society’s members.”
Read more: www.mskcc.org/news-releases/deb-schrag-md-mph-chair-of-de… -
Memorial Sloan Kettering Cancer Center reposted
Medical Digest & Congress Report
@MedicalDigestCR
Lorenzo Falchi discusses the results of phase 3 EPCORE FL-1 trial presented at ASH25. Link is in the comments! 👇
@MSKCancerCenter @ASH_hematology -
Memorial Sloan Kettering Cancer Center reposted
The ASCO Post
@ASCOPost
🩸 Phase III EPCORE FL-1: Epcoritamab + lenalidomide/rituximab delivered deeper, more durable responses and markedly longer PFS vs the doublet alone in second-line #follicularlymphoma.
🔹 Lorenzo Falchi, MD of @MSKCancerCenter
🔗 ascopost.com/news/december-2025/epcoritamab-added-to-seco… -
Memorial Sloan Kettering Cancer Center reposted
Breastcancer.org
@Breastcancerorg
Have you experienced “chemo brain” during or after breast cancer treatment? New research suggests acupuncture could help.
At SABCS25, Dr. Jun Mao, Chief of the Integrative Medicine and Wellness Service at @MSKCancerCenter, shared new research exploring whether acupuncture could ease this kind of brain fog. In a carefully designed Phase 2 clinical trial, people who received acupuncture reported improvements in cognitive symptoms compared to those who did not.
🎧 Listen now to our podcast to hear Dr. Mao explain the findings, what they mean, and how this research could help people navigate this common chemotherapy side effect. www.breastcancer.org/podcast/acupuncture-eases-chemo-brain
#breastcancer #sabcs25 #breastcancersurvivor #breastcancerwarrior #breastcancerresearch -
Memorial Sloan Kettering Cancer Center reposted
Immune Regulation News
@Immune_News
The Rudensky lab at @MSKCancerCenter examined the heterogeneity of tumoral Treg cells in colorectal cancer and identified two distinct tumoral #treg subsets with differential Il10 expression.
See the abstract in @CellPressNews: www.cell.com/immunity/fulltext/S1074-7613(25)00516-3 -
Memorial Sloan Kettering Cancer Center reposted
Klebanoff_Lab
@KlebanoffLab
🚨Today in @NatureComms: We resolve an enduring enigma in T cell biology—how TCR binding to p/HLA triggers intracellular signaling. CryoEM in native environment reveals a 'jack-in-the-box' mechanism! Collab btw @RockefellerUniv @MSKCancerCenter @parkerici rdcu.be/eUPPl
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The @US_FDA approved a combination of two drugs — enfortumab vedotin and an immunotherapy drug pembrolizumab, to be given before and after surgery for people with muscle-invasive urothelial carcinoma — a cancer that usually starts in the bladder and can also appear in other parts of the urinary system.
MSK genitourinary oncologist Dr. Rosenberg has led multiple clinical trials testing enfortumab vedotin alone or in combination with others for #bladdercancer. Learn more ⬇️ www.mskcc.org/news/new-metastatic-bladder-cancer-therapy-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨 UPDATE: The @US_FDA has approved a new therapy for #marginalzonelymphoma. The approval is based on results from a phase 2 clinical trial led by Dr. @LiaPalomba, a hematologist-oncologist at MSK.
“People with this type of lymphoma have desperately needed a treatment that has lasting effects without toxicity,” Dr. Palomba says. “Lisocabtagene maraleucel is a critical advance and the first CAR T therapy approved to treat marginal zone lymphoma when it has relapsed after at least two previous treatments.”
Read more: www.mskcc.org/news/fda-approves-marginal-zone-lymphoma-ca… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
(1/2) Researchers from the Sloan Kettering Institute at MSK discovered that not all regulatory T cells behave the same way in tumors. Some help fight cancer, while others protect it.
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
(2/2) The results of the study, which were published in Immunity (@CellPressNews), could help improve #immunotherapy treatment for the majority of patients with #colorectalcancer, and potentially for other cancers. Learn more: www.mskcc.org/news/msk-researchers-solve-key-colorectal-c…
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Don't miss @StadlerZsofia's presentation "Identification of inherited #cancer syndromes: Re-defining early-onset cancers" at #aacrearlyonset25. @AndreaCercek is the conference co-chair. @MSKCancerCenter @AACR
TODAY | 11:30 a.m. ET
www.aacr.org/meeting/advancing-precision-medicine-2020/pr… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
At the @AACR special conference on the rise of early-onset #cancers, Dr. Luis Diaz will present in a session about opportunities for early interception. @AndreaCercek is the conference co-chair. @MSKCancerCenter #aacrearlyonset25
TODAY | 11:10 a.m. ET
www.aacr.org/meeting/advancing-precision-medicine-2020/pr… -
Memorial Sloan Kettering Cancer Center reposted
Blood Cancers Today
@Blood_Cancers
🙌 @RaajitRampal, of @MSKCancerCenter, reflects on the phase 3 MANIFEST-2 trial of pelabresib plus ruxolitinib in JAK inhibitor–naive #myelofibrosis presented at #ash25.
Read here! ➡️ www.bloodcancerstoday.com/post/ninety-six-week-manifest-2… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Updated results from #sabcs25 from a clinical trial, reported by MSK breast cancer medical oncologist @jhaveri_komal, show that a new treatment continues to be effective at stopping advanced #breastcancer from progressing in some people with tumors that have grown resistant to standard therapy.
The new data, presented by Dr. Jhaveri at @SABCSSanAntonio, also suggests that overall survival can be improved by giving the drug, #imlunestrant, alone or in combination with a second drug, #abemaciclib, to patients with #erpositive, #her2negative advanced breast cancer who had previously been treated with hormone therapy.
“These results will change how many breast cancers are treated,” says Dr. Jhaveri, chair of the international study and its principal investigator at MSK.
Read more about this research: www.mskcc.org/news/imlunestrant-stops-progression-of-er-h… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
.@JunMaoMD, the Integrative Medicine and Wellness Service Chief at MSK, presented research on the benefits of acupuncture for #breastcancer patients who experience cancer-related cognitive impairment at the 2025 @SABCSSanAntonio.
Cancer-related cognitive impairment, often called “brain fog” or “chemo brain,” has been shown to affect about 40% of breast cancer survivors. But acupuncture may help alleviate this brain fog, according to a rigorous phase 2 clinical trial led by Dr. Mao.
“These results are good news for patients,” says Dr. Mao. “At a time when there’s a lot of speculation and misinformation about wellness therapies for cancer patients, we are conducting research to offer evidence-based therapies that may help them.”
Learn more: www.mskcc.org/news/acupuncture-may-ease-brain-fog-in-brea… #sabcs25 -
Memorial Sloan Kettering Cancer Center reposted
Margaret Van Meter, MD
@MVanMeterMD
Real and sham accupuncture for cognitive difficulties in breast cancer survivors. 10 weekly sessions, 20-30 min, focused on sleep, cognition, other symptoms. Subjective improvement in both groups vs usual care; objective improvement in real.
@JunMaoMD @MSKCancerCenter #sabcs25 -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
We're excited for @AACR Special Conference in Cancer Research: The Rise in Early-Onset Cancers! @KarunaMDPhD will discuss the role of pks⁺ E. coli in early-onset #colorectalcancer. @MSKCancerCenter #aacrearlyonset25 @AndreaCercek
TODAY | 3:20 p.m. ET
www.aacr.org/meeting/advancing-precision-medicine-2020/pr… -
Memorial Sloan Kettering Cancer Center reposted
MSK ScienceEducation
@MSKEducation
Huge congratulations to our very own OSET lead, @LewisLabMSKCC, on receiving this prestigious and well-deserved recognition!
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to Dr. Jason Lewis, a radiochemist and Deputy Director of the Sloan Kettering Institute at MSK, for being elected as a Fellow of the @AcadofInventors, a prestigious honor recognizing individuals who have demonstrated innovation and made tangible contributions to the advancement of technology and society.
Learn more: www.mskcc.org/news-releases/mskcc-radiochemist-jason-lewi… -
Memorial Sloan Kettering Cancer Center reposted
HemOnc Today
@HemOncToday
💉 #breastcancer survivors derived clinically meaningful benefits for perceived and objective cognitive impairment from #acupuncture, according to data at #sabcs25.
“The treatment effects are persistent.” @JunMaoMD @MSKCancerCenter told @GoHealio.
www.healio.com/news/hematology-oncology/20251212/this-wor… -
Memorial Sloan Kettering Cancer Center reposted
GSK Graduate School
@GSKGradSchool
Congratulations to GSK PhD student @juldelgado22 in the lab of Andrew Koff for defending her thesis entitled "A Multi-Omics Study of Molecular Determinants
and Pathway Diversity Underlying Therapy-Induced Senescence in Cancer." -
Memorial Sloan Kettering Cancer Center reposted
MSK ScienceEducation
@MSKEducation
Calling NYC undergrads who are passionate about #biomedical sciences & are looking for #research opportunity to help them become strong PhD candidates. Applications for #mskengage are now open!
Deadline: Feb 2, 2026
For more information visit us: www.mskcc.org/engage -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
#sabcs25 posters! Dr. Tiffany Traina will present the safety analysis of first-line datopotamab deruxtecan vs chemo for locally recurrent inoperable or metastatic triple negative #breastcancer. #bcsm @SABCSSanAntonio @MSKCancerCenter
⏰ 12:30–2 p.m. CST
sabcs.org/events/2025/poster-session-5/ -
Memorial Sloan Kettering Cancer Center reposted
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
In the ENHANCE phase II trial, both real and sham acupuncture (non-penetrating needles) were more effective than usual care at improving breast cancer survivors’ perceived cognitive function, Dr. Jun J. Mao said at #sabcs25: www.aacr.org/about-the-aacr/newsroom/news-releases/acupun… @JunMaoMD @MSKCancerCenter
-
Memorial Sloan Kettering Cancer Center reposted
Lymphoma Hub
@lymphomahub
The Lymphoma Hub was pleased to speak with Lorenzo Falchi at #ash25. We asked, What do the primary results from the phase III EPCORE FL-1 trial tell us about epcoritamab + R2 vs R2 in patients with R/R FL?
Watch here: lymphomahub.com/medical-information/ash-2025-epcore-fl-1-…
#lymphoma #meded @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
TODAY at the #sabcs25: Dr. @JunMaoMD, an integrative medicine specialist at MSK, will present research on the effects of acupuncture versus sham acupuncture and usual care on cancer-related cognitive difficulties among #breastcancer survivors. @SABCSSanAntonio
🗓️: December 12 at 9 a.m. (CST) -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Coming up at #sabcs25: @jhaveri_komal will present updated results from the phase 3 EMBER-3 trial of imlunestrant with or without abemaciclib for advanced #breastcancer. #bcsm @SABCSSanAntonio @MSKCancerCenter
TODAY | 9 a.m.–11:30 a.m. CST
Learn more: sabcs.org/events/2025/general-session-3/ -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to Dr. Jason Lewis, a radiochemist and Deputy Director of the Sloan Kettering Institute at MSK, for being elected as a Fellow of the @AcadofInventors, a prestigious honor recognizing individuals who have demonstrated innovation and made tangible contributions to the advancement of technology and society.
Learn more: www.mskcc.org/news-releases/mskcc-radiochemist-jason-lewi… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Join @SherryShenMD for a presentation on adjuvant therapy decisions in HR+HER2- #breastcancer in the era of axillary de-escalation. #bcsm @SABCSSanAntonio @MSKCancerCenter #sabcs25
TODAY | 1 p.m.–2:15 p.m. CST
Learn more: sabcs.org/events/2025/clinical-controversies-management-o… -
Memorial Sloan Kettering Cancer Center reposted
HemOnc Today
@HemOncToday
#sabcs25 data drop: Sacituzumab govitecan misses PFS mark for HR+ HER2- #breastcancer 🎯
🗨️ Dr. @jhaveri_komal @MSKCancerCenter notes an early OS trend at 15 months, but based on “immature data."
www.healio.com/news/hematology-oncology/20251211/sacituzu… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
HAPPENING SOON at #sabcs25: MSK breast surgeon Dr. Giacomo Montagna will present research on the de-escalation of axillary surgery after NAC in clinically node positive patients. @SABCSSanAntonio
🗓️: December 11 at 1 p.m. (CST) -
Memorial Sloan Kettering Cancer Center reposted
ESDO
@ESDO_tweets
What are the criteria for organ preservation in Colorectal Cancer care? In our latest podcast, Dr. Randrian discusses different approaches with expert @AndreaCercek from @MSKCancerCenter
🎧 Listen here → www.esdo.eu/fileadmin/user_upload/documents/7_episode_Pod… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
TODAY at #sabcs25: Join MSK breast medical oncologist Dr. Shanu Modi as she presents research for people with high-risk, HER2+ early-stage #breastcancer. #bcsm @SABCSSanAntonio
🗓️: December 10 | 1 p.m.–2 p.m. CST -
Memorial Sloan Kettering Cancer Center reposted
MPN_Hub
@MPN_Hub
CONGRESS | #ash2025 | POSTER
Raajit Rampal presents survival outcomes from a post hoc analysis of the phase III SIMPLIFY-1 study, applying the RR6 prognostic model to ruxolitinib-treated patients with myelofibrosis who crossed over to momelotinib (N = 196), compared with patients enrolled in RUXOREL-MF (N = 209)
Among ruxolitinib-treated cohorts with similar RR6 risk distributions, those in SIMPLIFY-1 who crossed over to momelotinib had superior overall survival compared with patients who discontinued ruxolitinib in RUXOREL-MF. These data suggest that momelotinib may mitigate risk following ruxolitinib discontinuation and improve survival outcomes.
Follow our live feed for more updates: mpn-hub.com/medical-information/ash-2025-live-congress-co…
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#mpn #mpnsm #myelofibrosis #meded #medicalcongress @RaajitRampal @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
.@jhaveri_komal, a breast medical oncologist at MSK, presented results from the ASCENT-07 clinical trial at the @SABCSSanAntonio.
The phase 3 clinical trial, which tested sacituzumab govitecan-hziy as the first treatment after endocrine therapy for people with hormone receptor (HR)-positive, HER2-negative metastatic #breastcancer, has shown mixed results. In the study sacituzumab govitecan-hziy did not appear to work better than chemotherapy in terms of slowing disease progression — the main objective of the trial.
However, there were intriguing signs suggesting that sacituzumab govitecan-hziy could lower the risk of death over time.
“These preliminary results related to survival are very interesting, and we need to continue following this closely,” says Dr. Jhaveri. “We did not see any new safety concerns giving sacituzumab govitecan-hziy earlier, which is encouraging, in addition to the fact that fewer patients stopped taking this drug compared with chemotherapy. In the meantime, sacituzumab govitecan-hziy remains an effective treatment option for patients whose cancer has progressed despite treatment with endocrine therapy and chemotherapy.”
#sabcs25
Read more about the study: www.mskcc.org/news/antibody-drug-conjugate-for-endocrine-… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Coming up at #sabcs25: Join Dr. Sarat Chandarlapaty for a session examining the evolving role of antibody-drug conjugates in #breastcancer. #bcsm @SABCSSanAntonio @MSKCancerCenter
TODAY | 1 p.m.–2:15 p.m. CST
Learn more: sabcs.org/events/2025/translational-controversies-adcs-ta… -
Memorial Sloan Kettering Cancer Center reposted
HemOnc Today
@HemOncToday
📍 Onsite at #sabcs25 : Dr. @KateIdaLathrop @mayscancer shares insights on ASCENT-07 data from Dr. @jhaveri_komal @MSKCancerCenter…
💣No PFS edge for #trodelvy 🆚 chemo in HR+/HER2- #breastcancer after endocrine therapy
Full scoop coming soon 👉www.healio.com/news/hematology-oncology/meeting-news/san-… -
Memorial Sloan Kettering Cancer Center reposted
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
The phase III trial compared sacituzumab govitecan vs. chemotherapy in patients with HR-positive, HER2-negative endocrine therapy-refractory breast cancers. @jhaveri_komal @MSKCancerCenter #sabcs25
-
Memorial Sloan Kettering Cancer Center reposted
San Antonio Breast Cancer Symposium® (SABCS®)
@SABCSSanAntonio
ASCENT-07 did not meet its primary endpoint: Patients had a median PFS of 8.3 months whether they received sacituzumab govitecan or chemotherapy as the first treatment after endocrine therapy, according to @jhaveri_komal. www.aacr.org/about-the-aacr/newsroom/news-releases/sacitu… #sabcs25 @MSKCancerCenter
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
HAPPENING SOON at #sabcs25: MSK breast oncologist and early drug development specialist Dr. @jhaveri_komal will present results from her ASCENT-07 clinical trial for patients with HR+/HER2 metastatic #breastcancer. @SABCSSanAntonio
🗓️: December 10 at 9:30 am (CST) -
Memorial Sloan Kettering Cancer Center reposted
AML Hub
@AML_Hub
CONGRESS | #ash25 | PRESENTATION
Eytan Stein shares updated findings from an open-label, phase I trial of ivosidenib plus intensive chemotherapy induction and consolidation followed by ivosidenib maintenance in patients with ND IDH1m AML(N = 60).
77% of patients achieved CR+CRh; median time to CR+CRh was 34 days; and median duration was 25 months. After 60 months of follow-up, OS was good (67% at 3-years), and 48% patients proceeded to HSCT. The safety profile was acceptable, with fewer TEAEs seen during maintenance than in induction/consolidation. The HOVON150AML randomized phase III trial is further assessing this regimen.
Follow our live feed for more updates: aml-hub.com/medical-information/ash-2025-live-congress-co…
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#amlsm #leusm #medicalcongress #mednews #meded @Doctor_E_Stein @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Recipients of the Paul Marks Prize for Cancer Research recently received their awards during a symposium event held at MSK.
The prize, named in honor of former MSK president Dr. Paul Marks, recognizes a new generation of leaders who are making significant contributions to the understanding of cancer or are improving the treatment of the disease.
The three investigators included Dr. Andrea Ablasser, of the Swiss Federal Institute of Technology Lausanne (EPFL); Dr. @cncurtis, of Stanford Medicine, and Dr. @AbdelWahablab only the second person from MSK to receive the Paul Marks Prize for Cancer Research.
Each recipient also presented their work at the event. Swipe to view some photos of the event. -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Coming up at #sabcs25: Join @PedramRazaviMD for a workshop on emerging technologies and expanding clinical applications of #liquidbiopsy in #breastcancer. #bcsm @SABCSSanAntonio @MSKCancerCenter
TODAY | 12:45 p.m.–2:15 p.m. CST
Learn more: sabcs.org/events/2025/translational-workshop-2-liquid-bio… -
Memorial Sloan Kettering Cancer Center reposted
Francesco Maura
@FrancescoMaura4
Last #ash2025 session with cool collaborative work with @LarrayozMarta #carmen_vincente and #jose_climent_martinez revealing new insight on FAM46c/TENT5C role in MM. @MSKCancerCenter @unav
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Dr. Heather Landau, a cellular therapist at MSK, recently presented findings from a phase 1 clinical trial at the 2025 @ASH_hematology Annual Meeting.
Dr. Landau reported that a chimeric antigen receptor (CAR) T cell therapy appears to be effective at stopping AL amyloidosis in these patients. The new therapy, called NXC-201, appears to be safe and to work fast: In patients receiving the therapy, key biomarkers returned to normal levels within one to two weeks, and no lingering cancer cells could be detected.
Read more about her research: www.mskcc.org/news/car-cell-therapy-for-light-chain-al-am…
#ash25 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join Dr. Eytan Stein today at #ash25 for his session: “Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation.” @ASH_hematology
TODAY | 4:45 p.m. EST
Learn more: submit.hematology.org/program/presentation/672882 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New results from a clinical trial show that giving two bispecific antibodies in combination can be effective in people with extramedullary myeloma, an especially resistant form of #multiplemyeloma.
“These are impressive results, showing that combination therapy could be a big step forward for people with extramedullary myeloma, who urgently need better treatments,” says MSK myeloma specialist @szusmani who helped lead the combination therapy trial and presented the results at #ash25. @ASH_hematology Learn more: www.mskcc.org/news/new-extramedullary-myeloma-treatment-w… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Next at #ash25: #leukemia expert @RaajitRampal will present durable efficacy and long-term safety of pelabresib plus ruxolitinib in JAK inhibitor–naive #myelofibrosis from the phase 3 MANIFEST-2 study. @MSKCancerCenter @ASH_hematology #leusm
Learn more: submit.hematology.org/program/presentation/674446 -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Coming up at #ash25: Join @IntlekoferLab for a presentation on
using enzyme hyperactivation to target oncometabolism in IDH-mutant #leukemia cells. @MSKCancerCenter @ASH_hematology #leusm #lymsm #lymphoma
Learn more: submit.hematology.org/program/presentation/670789 -
Memorial Sloan Kettering Cancer Center reposted
Hamza Hashmi
@hhashmi87
Oral Abstract 0698: @szusmani redirecting us to Tec+Talq for RRMM w ‘true’ EMD, n=90, ORR 80%, early responses (<3m), RR in both organ and non organ EMD, better RR w low EMD burden, mPFS 15m
#meetunmetneed
#ash25 #mmsm @MSKCancerCenter -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join Dr. Heather Landau today at #ash25 for her session: “First 20-patient safety and efficacy data from nexicart-2, the first U.S. trial of CAR-T in R/R light chain (AL) amyloidosis, nxc-201.” @ASH_hematology
TODAY | 5:45 p.m. EST
Learn more: submit.hematology.org/program/presentation/674671 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join @szusmani today at #ash25 for his session: “Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up.” @ASH_hematology
TODAY | 4:45 p.m. EST
Learn more: submit.hematology.org/program/presentation/679285 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join @FrancescoMaura4 today at #ash25 for his session: “Genomics define neoplastic transformation in multiple myeloma precursor conditions.” @ASH_hematology
TODAY | 4:45 p.m. EST
Learn more: submit.hematology.org/program/presentation/678391 -
Memorial Sloan Kettering Cancer Center reposted
Lymphoma Hub
@lymphomahub
CONGRESS | #ash25 | PRESENTATION
Lorenzo Falchi shares initial results from the phase II MITHIC-FL2 trial assessing mosunetuzumab in combination with zanubrutinib, in patients with newly diagnosed high-burden FL.
In response-evaluable patients (n = 51), the ORR with mosunetuzumab + zanubrutinib was 92% and CR rate was 82%. Response rates were preserved across demographic and disease characteristic subgroups. The combination resulted in a ≥50% reduction in tumor volume from baseline in 49/51 patients. In safety-evaluable patients (n = 54), most AEs were Grade 1–2, and no new safety signals for mosunetuzumab or zanubrutinib were observed. Cytokine release syndrome occurred in 61% of patients.
Follow our live feed for more updates: lymphomahub.com/medical-information/ash-2025-live-congres…
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#lymphoma #lymsm #medicalcongress
@MSKCancerCenter -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A phase 3 trial led by MSK’s Dr. Lorenzo Falchi found that adding epcoritamab to rituximab + lenalidomide significantly improves outcomes for people with follicular lymphoma. Epcoritamab received FDA approval based on these findings.
“This study focused on finding ways to prolong the benefit that patients receive from immunotherapy while also allowing them to avoid chemotherapy,” says Dr. Falchi, who presented the findings at #ash25. “It’s too soon to say whether this treatment will result in a cure, but it appears to be the beginning of a new era in lymphoma treatment.” @ASH_hematology
Learn more: www.mskcc.org/news/new-trial-shows-a-3-drug-combination-b… -
Memorial Sloan Kettering Cancer Center reposted
Cancer Research Communications
@CRC_AACR
Recently published:
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated #liposarcoma, by Evan Rosenbaum et al. doi.org/10.1158/2767-9764.CRC-25-0334
@sandrapdangelo @MSKCancerCenter @WeillCornell #sarcoma #openaccess -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
Epcoritamab Plus Rituximab and Lenalidomide Improves PFS in Pretreated Follicular Lymphoma @ASH_hematology @MSKCancerCenter #ash25 www.onclive.com/view/epcoritamab-plus-rituximab-and-lenal…
-
Memorial Sloan Kettering Cancer Center reposted
Lymphoma Hub
@lymphomahub
CONGRESS | #ash25 | PRESENTATION
Lorenzo Falchi, @MSKCancerCenter, presents primary results from the phase III EPCORE FL-1 trial of epcoritamab with rituximab + lenalidomide (R2) vs R2 in patients with R/R FL (N = 488).
Epcoritamab + R2 improved the ORR (95% vs 79%; p <0.0001) and CR rate (83% vs 50%; p <0.0001) vs R2, and resulted in a 79% reduction in the risk of progression or death. The safety profile was manageable and consistent with the known safety profile of the individual agents.
Epcoritamab + R2 is a chemotherapy-free, fixed-duration therapy suitable for outpatient administration and has the potential to become a new standard of care in 2L+ FL.
Follow our live feed for more updates: lymphomahub.com/medical-information/ash-2025-live-congres…
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#lymphoma #lymsm #medicalcongress #mednews -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join @SSRaj017 today at #ash25 for his session: “Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma” @ASH_hematology
TODAY | 12 p.m. EST
Learn more: submit.hematology.org/program/presentation/677200 -
Memorial Sloan Kettering Cancer Center reposted
Francesco Maura
@FrancescoMaura4
#ash2025 second day! Two orals from our lab in the same session. In the first we define the concept of malignant transformation in SMM (ascopubs.org/doi/10.1200/JCO-25-01733). Great collaboration with @MSKCancerCenter @MayoClinic @SylvesterCancer @MoffittNews @MDAndersonNews @LaStatale #mmsm
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Join Dr. Xiaoli Mi this morning at #ash25 for the presentation, "CAR T cells converge on a distinct transcriptional state over time in patients with diverse hematologic malignancies." #lymsm #leusm @MSKCancerCenter @ASH_hematology
Learn more: submit.hematology.org/program/presentation/678098 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join Dr. Lorenzo Falchi today at #ash25 for his session: “Primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma.” @ASH_hematology
TODAY | 10:15 a.m. EST
Learn more: -
Memorial Sloan Kettering Cancer Center reposted
Edward Christopher "Chris" Dee, MD
@EChrisDee
📜 Led by @MilitSPatel and Dr @IMRTLee, out in @NatRevClinOncol today:
👉 We highlight the importance of #synergy between #human #care and #ai-informed #medicine for people with #cancer.
👉 AI can #augment human expertise, not replace it.
🔗 www.nature.com/articles/s41571-025-01108-9 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join @UrviShahMD today at #ash25 for her session: “Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial.” @ASH_hematology
TODAY | 5:30 p.m. EST
Learn more: submit.hematology.org/program/presentation/679352. -
Memorial Sloan Kettering Cancer Center reposted
Hamza Hashmi
@hhashmi87
Oral Abstract 0250: @szusmani on KTX-1001 for heavily pre treated RRMM, 30% EMD, 30% HR, 40% w prior BCMA, 80% pent exposed, ⬇️ plt common AE, reasonable ORR in heavily treated pts w no viable options (slide 3)
#ash25 #mmsm @MSKCancerCenter
#meetunmetneed -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Coming up at #ash25: @sridevirajeeve will present a study evaluating remote patient monitoring for outpatient step-up dosing for bispecific antibodies at a large academic center. @MSKCancerCenter @ASH_hematology #mmsm
Learn more: submit.hematology.org/program/presentation/674821 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Join @szusmani today at #ash25 for his session: “Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma.” @ASH_hematology
TODAY | 2:45 p.m. EST
Learn more: submit.hematology.org/program/presentation/671663 -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
At #ash25, Dr. Mohammad Alhomoud will present a study that determined the optimal fludarabine exposure in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide. @MSKCancerCenter @ASH_hematology
Learn more: submit.hematology.org/program/presentation/680128 -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Coming up at #ash25: Dr. Xin Wang will present findings from a study that compared outcome disparities between Asian and White patients with newly diagnosed acute myeloid #leukemia. @MSKCancerCenter @ASH_hematology #leusm
Learn more: submit.hematology.org/program/presentation/677386 -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
At #ash25, @kuokaichin will present a retrospective study that evaluated outcomes of patients with acute myeloid #leukemia whose cancer stopped responding to or returned after menin inhibitor treatment. #leusm @MSKCancerCenter @ASH_hematology
Learn more: submit.hematology.org/program/presentation/677387 -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
#ash25: Divyash Shah will present the results of a study assessing the comparative incidence of venous thromboembolism in patients with chemotherapy-induced thrombocytopenia treated with romiplostim. @MSKCancerCenter @ASH_hematology
Learn more: submit.hematology.org/program/presentation/671991 -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
Hear Lauren Schaff, MD, of @MSKCancerCenter spotlight exciting data in leptomeningeal metastases presented by her colleague at #sno2025 in the video below! 🧠👇
WATCH: www.onclive.com/shorts/schaff-spotlights-key-research-in-…
@NeuroOnc #btsm -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Tomorrow morning at #ash25, Varun Iyengar, MD, will present a study evaluating venous thromboembolism risk factors found via genomic profiling cross subtypes of B-cell #lymphoma. @MSKCancerCenter @ASH_hematology #lymsm
Learn more: submit.hematology.org/program/presentation/671989 -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
At #ash25, join @QuinlanSievers to learn about molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation. #lymsm @MSKCancerCenter @ASH_hematology
TODAY | 4:32 p.m. ET
Learn more: submit.hematology.org/program/presentation/681077 -
Memorial Sloan Kettering Cancer Center reposted
Urvi Shah
@UrviShahMD
Can dietary changes delay progression from precursor disorders to a cancer - myeloma? Excited to share our manuscript is published online @CD_AACR @MSKCancerCenter @SanRaffaeleMI @Bellone_lab @DrMvandenBrink @LesokhinMD @Lauracgr001 @szusmani #mmsm #ash25
aacrjournals.org/cancerdiscovery/article-abstract/doi/10.… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
At #ash25, join @jzbos to learn how the cellular pathways that allow blood to clot can contribute to #cancer growth and spread, presenting opportunities for new treatment approaches. @MSKCancerCenter @ASH_hematology
Learn more: submit.hematology.org/program/session/116502 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Researchers at MSK are contributing meaningful advancements to cancer care.
New research from MSK finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of #foxp3; shows how cancer develops resistance to antibody-drug conjugates; and more: -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Join @DrRichardJLin today at #ash25 to learn about methods for preventing and treating age-related blood conditions, including #exercise, #nutrition, new therapies, and more. @MSKCancerCenter @ASH_hematology
Learn more: submit.hematology.org/program/session/116540 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK is excited to be in Orlando, Florida for #ash25! Follow along on our social channels from Dec. 6-9 for updates. @ASH_hematology
ASH
@ASH_hematology
A little behind the scenes at #ash25 because so much heart goes into bringing this meeting to life. #ashkudos to the crew behind the build and to the amazing attendees who make this meeting feel alive.
#hematology #hemeonc -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
A longitudinal study led by Dr. Maximilian Merz sheds new light on why cilta-cel yielded better response rates compared to ide-cel for those with relapsed/refractory #multiplemyeloma. @MSKCancerCenter #mmsm @szusmani #cartcelltherapy
Cancer Cell
@Cancer_Cell
Online Now: A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma www.cell.com/cancer-cell/fulltext/S1535-6108(25)00490-8?r…
-
Memorial Sloan Kettering Cancer Center reposted
ARGO Research
@ArgoResearch
Our Global Cancer Research and Training (GCRT) and ARGO team at @MSKCancerCenter were thrilled to host Dr. Erika Ruiz and Dr. Oscar Galindo from INCan (Instituto Nacional de Cancerologia) Mexico to build partnerships and collaborations for improving cancer care for all patients!
-
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
Since the landmark approval of #ipilimumab, rapid advancements in immunotherapeutics have transformed cancer care.
Join @MSKCancerCenter faculty on January 28, 2026 for a live virtual CME program covering foundational principles and emerging innovations in cancer #immunotherapy—including clinical applications across diseases and practical strategies for managing immune-related toxicities.
Learn more / register: mskcc.cloud-cme.com/course/courseoverview?P=5&EID=59528
@RossFirestone @lynnalidomide @ROCearbhaill @BSantomasso @JessicaWilcoxMD @carollct @sandrapdangelo #mskimmunoonccme #mskcme -
Memorial Sloan Kettering Cancer Center reposted
Ghassan Abou-Alfa
@GABOUALFA
Live from @MSKCancerCenter now. @GABOUALFA delighted to sahre and disucss with colleagues in China #hcc advances. Great honro to be invited to the International Academic Exchange Program on Hepatobiliary Oncology!
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Happy #fellowmatch day! We look forward to welcoming 18 hematology/oncology fellows to @MSKCancerCenter next summer to continue our legacy of providing outstanding #cancer care. #match2026
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK physician-scientist Dr. Omar Abdel-Wahab (@AbdelWahablab), a leader in #bloodcancer research, has been named a 2025 Paul Marks Prize winner for his contributions to the field.
Learn more about his path and what inspires his work: www.mskcc.org/news/meet-omar-abdel-wahab-2025-paul-marks-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's most recent Awards & Appointments honorees — including Dr. Omar Abdel-Wahab, elected to @theNAMedicine; Dr. Christian Figueroa-Espada, named a 2025 @statnews Wunderkind; @AndreaCercek and Dr. Luis Díaz Jr., named to the Fierce 50 of 2025; and MSK, recognized as one of the Best in the Nation for Pediatric Cancer by U.S. News & World Report — and more: www.mskcc.org/news-releases/msk-awards-and-appointments-o…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK breast medical oncologist Dr. Larry Norton for winning the @ABCGlobalAll ABC Award!
The ABC Award is aimed at recognizing a researcher, physician, nurse, or organization that has made an outstanding and impacting contribution in the field of advanced #breastcancer throughout their career. Learn more: www.abc-lisbon.org/en/general-information/abc-award/1-482-1- -
Memorial Sloan Kettering Cancer Center reposted
VJ Oncology
@VJOncology
🎥 Michael Gormally at #esmo25 (@GormallyMDPHD of @MSKCancerCenter) highlights advances in HLA‑restricted immunotherapies including insights on resistance via HLA LOH & neoantigen burden in KRAS/TP53‑mutant tumors.
Watch ➡️ www.vjoncology.com/video/tao-3k4ctxu-hla-restricted-immun…
#oncology #immunotherapy -
Memorial Sloan Kettering Cancer Center reposted
Ghassan Abou-Alfa
@GABOUALFA
Incredible finale of 80802 1st @ALLIANCE_org #hcc study led by @MSKCancerCenter @MSK_DeptOfMed @GABOUALFA with radiomic signatures to estimate survival. Congratulations @msk_radiolgoy Larry Schwartz @laurentdercle! Stay tuned with more @AI efforts coming!
www.sciencedirect.com/science/article/pii/S205970292501717X -
Memorial Sloan Kettering Cancer Center reposted
HemOnc Today
@HemOncToday
💻 Patients benefit from accessing their clinical notes, but certain groups look less than others, such as Black and Hispanic patients and single men.
Dr. Susan Chimonas @MSKCancerCenter discussed the importance of eliminating #disparities with @GoHealio.
www.healio.com/news/hematology-oncology/20251201/black-hi… -
Memorial Sloan Kettering Cancer Center reposted
Vumedi Oncology
@VuMediHemOnc
Dr. @GABOUALFA @MSKCancerCenter breaks down how new checkpoint inhibitor data is reshaping frontline and intermediate-stage HCC therapy—including STRIDE, IMbrave150, EMERALD-1, and emerging neoadjuvant insights. #esmo2025
🎥 Watch on #vumedi: www.vumedi.com/video/hcc-systemic-therapy-impact-of-new-e…
#hcc -
Memorial Sloan Kettering Cancer Center reposted
Cancer Nursing Today
@cancer_nurses
⏰ ICYMI: Check out our interview with Amy Pierre, RN, BSN, ANP-BC, of @MSKCancerCenter, in which she shares key advice for oncology nurses on blood cancer care, education, and more!
🌟 You don't want to miss this!
➡️ Watch Now: www.cancernursingtoday.com/videos/amy-pierre-rn-bsn-anp-b…
#bloodcancerawareness -
Memorial Sloan Kettering Cancer Center reposted
Lung Cancers Today
@Lung_Cancers
🫁 In honor of Lung Cancer Awareness Month, @alexdrilon of @MSKCancerCenter, joined us to discuss the importance of #lcam, as well as biomarker testing, lung cancer screening & prevention efforts.
➡️ Watch: www.lungcancerstoday.com/videos/lung-cancer-awareness-dr-… -
Memorial Sloan Kettering Cancer Center reposted
CURE Today
@cure_today
Exciting advances in #lungcancer! T cell engagers like #imdelltra & ADCs are showing real potential, shrinking tumors & improving survival. Early data is changing the standard of care. @charlesrudin @MSKCancerCenter #lungcancerawarenessmonth
Read more! www.curetoday.com/view/how-new-therapies-are-changing-the… -
Memorial Sloan Kettering Cancer Center reposted
Yelena Y. Janjigian MD
@YJanjigianMD
FDA approval of perioperative durvalumab is sinking in today as I’m in clinic. Grateful for the incredible team behind this — it truly takes a village. Proud of everyone pictured here who helped make this possible to help patients all over the world 🌎. The best is yet to come.
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨: A new @FDA approval gives hope to people with #stomachcancer and #esophaguscancer.
The clinical trial that resulted the approval, led by @YJanjigianMD and researchers at MSK, investigated using the immunotherapy treatment #durvalumab (INFINZI) in combination with a standard-of-care chemotherapy regimen before and after surgery.
The success of the trial led the FDA to approve the use of the treatment in people with early stage gastric and gastroesophageal cancers, making durvalumab the first and only immunotherapy approved for these patients before and after surgery.
Read more: www.mskcc.org/news/new-hope-for-people-with-stomach-and-e… www.mskcc.org/news/new-hope-for-people-with-stomach-and-e… -
Memorial Sloan Kettering Cancer Center reposted
Prostate Cancer Foundation
@PCFnews
Patients with advanced prostate cancer can face treatment side effects.
Dr. @KristineLacuna of @MSKCancerCenter describes why it’s essential to tackle these side effects early—working with your primary care doctor, urologist or oncologist and cardiologist. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨: A new @FDA approval gives hope to people with #stomachcancer and #esophaguscancer.
The clinical trial that resulted the approval, led by @YJanjigianMD and researchers at MSK, investigated using the immunotherapy treatment #durvalumab (INFINZI) in combination with a standard-of-care chemotherapy regimen before and after surgery.
The success of the trial led the FDA to approve the use of the treatment in people with early stage gastric and gastroesophageal cancers, making durvalumab the first and only immunotherapy approved for these patients before and after surgery.
Read more: www.mskcc.org/news/new-hope-for-people-with-stomach-and-e… www.mskcc.org/news/new-hope-for-people-with-stomach-and-e… -
Memorial Sloan Kettering Cancer Center reposted
Blood Cancers Today
@Blood_Cancers
🎉 Ross Levine, MD (@rosslevinemd), a leading physician-scientist in the field of blood and bone marrow cancers, has recently been named chief scientific officer of @MSKCancerCenter.
📰 Read more: www.bloodcancerstoday.com/post/dr-ross-levine-appointed-c… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Applications for MSK's Quantitative Sciences Undergraduate Research Experience (QSURE) 2026 summer internship program are now open!
This program provides undergraduate students hands-on skills in biostatistics, epidemiology, health outcomes, and computational oncology. The deadline to apply is 1/19. Learn more: admissions.mskcc.org/portal/apply-at-mskcc?ts=17637417247… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The @FDA has granted full approval to the targeted immunotherapy drug tarlatamab (Imdelltra®) for treating adults with advanced small cell #lungcancer (#sclc) that that has spread after platinum-based chemotherapy.
The approval was based on an international phase 3 clinical trial led by MSK scientist and thoracic medical oncologist Dr. Charles Rudin.
“This FDA approval confirms that tarlatamab is a better option than traditional chemotherapy for most patients with recurrent small cell lung cancer,” says Dr. Rudin.
Learn more: www.mskcc.org/news/fda-grants-full-approval-to-lung-cance… -
Memorial Sloan Kettering Cancer Center reposted
Oncology News Central
@OncNewsCentral
What’s next for ctDNA and MRD in bladder cancer? @MSKCancerCenter's @DrRosenbergMSK explores key questions — from perioperative strategies to adjuvant therapy decisions — and the trials shaping the future: www.oncologynewscentral.com/video/bladder-cancer/whats-ne…
#esmo25 #oncology #bladdercancer #mrd -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
This morning we met with @LaurenSchaffMD of @MSKCancerCenter to discuss the implications of data from a phase Ib study of copanlisib plus ibrutinib for future BTK- and PI3K-targeted development in PCNSL. Check back at onclive.com tomorrow to hear some of her insights!
-
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
We’re pleased to announce the full program for the 2026 Translating Evidence into Action Conference, taking place virtually on Thursday, February 26, 2026. This annual forum brings together healthcare professionals across disciplines to explore how high-quality evidence drives meaningful improvements in clinical practice. A dynamic group of presenters will showcase exemplary quality-improvement projects and practice-based initiatives that have led to measurable advances in practice and patient outcomes.
🔗 View the full program and register: mskcc.cloud-cme.com/course/courseoverview?P=5&EID=56150
@MSKCancerCenter #mskebpcme #mskebp2026 -
Memorial Sloan Kettering Cancer Center reposted
Benjamin D. Greenbaum
@bengrbm
Thank you @sciam for highlighting our work at @MSKCancerCenter with @TheVinodLab and an amazing group of colleagues!
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
In @sciam's December 2025 cover story, MSK researchers including @TheVinodLab and @bengrbm, showcase how #mrna-based vaccines can be personalized to target a patient’s unique tumor mutations.
This groundbreaking work is part of MSK's Olayan Center for Cancer Vaccines, which is pioneering science and transformative clinical trials to accelerate precision cancer vaccines as the next breakthrough cancer therapy. www.scientificamerican.com/article/personalized-mrna-vacc… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
In @sciam's December 2025 cover story, MSK researchers including @TheVinodLab and @bengrbm, showcase how #mrna-based vaccines can be personalized to target a patient’s unique tumor mutations.
This groundbreaking work is part of MSK's Olayan Center for Cancer Vaccines, which is pioneering science and transformative clinical trials to accelerate precision cancer vaccines as the next breakthrough cancer therapy. www.scientificamerican.com/article/personalized-mrna-vacc… -
Memorial Sloan Kettering Cancer Center reposted
𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿
@break_cancer
Thrilled to celebrate Dr. Adrienne Boire, who’s delivering the Quinn & Zeng Spinal Oncology Keynote at #sno25 this morning.
A core member of our Accelerating GBM Therapies Through Serial Biopsies TeamLab and physician-scientist at @MSKCancerCenter, Dr. Boire is sure to bring bold science to a scientifically brilliant and engaging talk, as always.
Congrats, Dr. Boire! -
Memorial Sloan Kettering Cancer Center reposted
Duke Department of Medicine
@dukemedicine
DOM Research Day is tomorrow and we are kicking off with an exciting MGR featuring Dr. Ivan Maillard, the Head of the Division of Hematologic Malignancies at @MSKCancerCenter. Join us in Trent Semans Great Hall at 8am, or scan the QR code to join virtually!
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A new era in the treatment of muscle-invasive bladder cancer (MIBC) is on the horizon, with the combination of enfortumab vedotin plus pembrolizumab poised to become the new standard of care in the perioperative treatment of cisplatin-ineligible or cisplatin-refusing patients.
We spoke with @Dr_Aggen, a genitourinary medical oncologist and cellular therapist at Memorial Sloan Kettering Cancer Center (MSK), to discuss the evidence supporting this potential new standard-of-care and the groundbreaking news from the IMVigor011 study, the first prospective circulating tumor DNA (ctDNA) trial in MIBC announced at ESMO Congress 2025.
Read the Q&A here: www.mskcc.org/clinical-updates/groundbreaking-advances-fo…
(cc: @urology_MSK; @MSK_DOM) -
Memorial Sloan Kettering Cancer Center reposted
DAVA Oncology
@DAVAOnc
Starting Now: Recent Phase III Data in Prostate Cancer
Moderated by: Dr. Susan Slovin @MSKCancerCenter
#davagu -
Memorial Sloan Kettering Cancer Center reposted
Isabel Preeshagul
@ipreeshagul
It’s 🫁 cancer awareness month. We are laser focused today & always on advocating:
🩻spreading awareness about lung ca screening @LungCheckorg
🤍 if you feel something, check it out!
🩺anyone with 🫁 can get lung cancer NO STIGMAS @MSKCancerCenter #lcam #hearher #lcsm #meded -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🚨 Last call: The deadline to apply for the Cancer Biology or Cancer Engineering #phd programs at MSK's @GSKGradSchool is 12/1. Don't miss the opportunity to make the next groundbreaking discovery in cancer and biomedical sciences. Apply: www.sloankettering.edu/gerstner/admissions
-
Memorial Sloan Kettering Cancer Center reposted
Zhen Sun
@zhensun24
A day of inspiring science at 1st MSK Center for Epigenetics Research Symposium @MSKCancerCenter! Thank you Iestyn, @Yael_David__ , @RichardKoche, and @TommyVierbuchen for organizing this amazing meeting and opportunity to share my latest work at @SawyersLabMSKCC and @HHMINEWS.
-
Memorial Sloan Kettering Cancer Center reposted
Jamaica Hospital
@JamaicaHospital
Our MediSys Health Network Cancer Center and @MSKCancerCenter, with support from the MSK Ralph Lauren Center and the City College of New York-Memorial Sloan Kettering Partnership Program for Cancer Research, proudly presented the third annual Achieving #healthequity in #cancercare conference.
-
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Congratulations to Dr. Lorenzo Falchi of @MSKCancerCenter on the FDA approval of epcoritamab-bysp with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma! Dr. Falchi will present phase 3 trial data at #ash25. #cancer
AACR
@AACR
The @US_FDA approved the immunotherapy epcoritamab-bysp with lenalidomide and rituximab for relapsed or refractory follicular lymphoma: www.fda.gov/drugs/resources-information-approved-drugs/fd…
-
Memorial Sloan Kettering Cancer Center reposted
Element Biosciences
@ElemBio
Congrats to 2025 Teton Atlas™ Global Grant recipient Dr. Thomas Norman at @MSKCancerCenter! Using #aviti24 for optical pooled #crisprscreens to map regulators of fibroblast states. 🧬👏 #genomics #multiomics
-
Memorial Sloan Kettering Cancer Center reposted
MSK CME
@MSKCME
Thank you to everyone who joined us for the 9th Annual Advances in #colorectaloncology Symposium @MSKCancerCenter. Each year, this program serves as a vital forum for exchanging insights and exploring the latest evidence-based and multidisciplinary approaches to treating #colorectalcancer—all with the goal of advancing clinical practice and improving patient outcomes.
As we look ahead to 2026, we’re thrilled to be celebrating the 10th anniversary of this symposium. Stay tuned for milestone highlights and details on next year’s program.
#mskcolorectalcme #mskcme #colorectalsurgery #crcsm @AndreaCercek @DrPaulRomesser @RonaYaeger @abbassmohd @TheVinodLab @craneMSKCC @KarunaMDPhD @geo_karag @malihanusr @EmmanouilPappou @segaln @FicheraAlessand @skopetz @AnwaarSaeed3 @KaiKeenShiu @patsyllamd @JurriaanTuynman @Doc_JinKim -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Since its founding 19 years ago, the @GSKGradSchool at MSK has attracted bright minds drawn to its connection at MSK. GSK students receive close mentorship from 130 world-class experts, and their exposure spans the spectrum from basic science to translational research to clinical trial studies.
Learn from two current GSK PhD students about why they chose to pursue their degrees at GSK: www.mskcc.org/news/training-tomorrows-leaders-graduate-ed… -
Memorial Sloan Kettering Cancer Center reposted
Blood Cancers Today
@Blood_Cancers
📰 Extra extra! Our November issue is out now 📰
This issue dives into a new liquid biopsy test developed at @MSKCancerCenter, consequences of NCI funding cuts, links between Ozempic and reduced blood cancer risk, and more.
📖 www.bloodcancerstoday.com/page/publication -
Memorial Sloan Kettering Cancer Center reposted
Wungki Park, MD MS
@CentralParkWMD
Practice-changing contributions and a beautiful narrative of a career dedicated to advancing oncology #gastriccancer #esophagealcancer
Congrats 🎉 to @YJanjigianMD 🪑#endowment
Full circle. Her journey began with @DrSDNimer 🌟#gionc #leadership #sparklab 💜 @MSK_DeptOfMed -
Memorial Sloan Kettering Cancer Center reposted
Isabel Preeshagul
@ipreeshagul
Anytime I hear @charlesrudin speak, I learn something new!
Love this sequencing map for ES small cell lung cancer .
⁉️are ADCS moving into the frontline setting? Do we combine with carbo etop? are they better than carbo etop? Time will tell. @gotoPER @MSKCancerCenter #lcsm -
Memorial Sloan Kettering Cancer Center reposted
Alexis Chidi, MD PhD
@AlexisChidi
@MSKCancerCenter @LUNGevity and @AmLungCSI are here at the Ralph Lauren Center doing same day cancer screenings - no insurance needed. Join us from now until 2pm for food, fellowship, and information about staying healthy!
-
Memorial Sloan Kettering Cancer Center reposted
Brendan Guercio
@BrendanGuercio
Tour de force review of refractory non-clear cell RCC by @MVossMD of @MSKCancerCenter at #ikcsna25 @KidneyCancer.
Many important ongoing studies as below.
Promising novel targets / mechanisms: ENPP3xCD3 bispecific, NF2, PRMT5 for CDKN2A/MTAP loss.
Still huge unmet need requiring more work on behalf of the entire #kidneycancer community -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Out in @BMJMedicine: Dr. Corita Grudzen & team examined whether follow-up palliative care via outpatient visits or nurse-led phone calls led to better outcomes for seriously ill adults who recently visited the emergency department. @MSKCancerCenter
➡️ bmjmedicine.bmj.com/content/4/1/e001392 -
Memorial Sloan Kettering Cancer Center reposted
Alexis Chidi, MD PhD
@AlexisChidi
*Tomorrow* @MSKCancerCenter and @LUNGevity are joining forces for an amazing event in Harlem with lung & other cancer screenings, open to anyone - no insurance needed!
Join us at the MSK Ralph Lauren Center tomorrow 11a-2p!
Let us know you're coming: www.eventleaf.com/stepintoscreening -
Memorial Sloan Kettering Cancer Center reposted
Yale Cancer Center
@YaleCancer
Thank you to Dr. Omar Abdel-Wahab @AbdelWahablab
for visiting @SmilowCancer and presenting #grandrounds on "New Therapeutic Approaches for the Treatment of Myeloid Blood Cancers."
@MSKCancerCenter -
Memorial Sloan Kettering Cancer Center reposted
David H Aggen, MD PhD
@Dr_Aggen
🚀 Exciting advances in NMIBC at @MSKCancerCenter led by @UrologyMSK
🚨 Pragmatic trial for BCG-refractory NMIBC
Led by Eugene Pietzak (@eugene_pietzak) — Trial #25-069 / NCT06929286
www.mskcc.org/cancer-care/clinical-trials/25-069
clinicaltrials.gov/study/NCT06929286
🚨 CD40 Agonist Trial for BCG-unresponsive NMIBC
Led by Bernie Bochner (@bbmdmsk) A shining example of bench to bedside medicine co-led by @juanosoriomd Trial #21-314 / NCT05126472.
www.mskcc.org/cancer-care/clinical-trials/21-314
clinicaltrials.gov/study/NCT05126472
Proud work from @urologymsk @MSKCancerCenter @BladderCancerUS -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Look for MSK's @OncoKB team at the @AMPath's 2025 Annual Meeting. The team will have a booth (#430) throughout the meeting and Nicole Fernandez, a nurse practitioner at MSK, will be presenting a related poster (#i011) on Saturday, November 15 from 9-10am. #ampath2025
-
Memorial Sloan Kettering Cancer Center reposted
Oncology News Central
@OncNewsCentral
What’s holding back MRD-guided strategies in bladder cancer?
In a new interview with @oncnewscentral, @MSKCancerCenter's @DrRosenbergMSK shares insights on testing access, workflow challenges, and evidence gaps: www.oncologynewscentral.com/video/bladder-cancer/whats-ne…
#oncology #bladdercancer #mrd #esmo25 -
Memorial Sloan Kettering Cancer Center reposted
Urvi Shah
@UrviShahMD
Josh Weinreb @AbdelWahablab and I have summarized how modifiable lifestyle factors may influence myeloid disorder disease risk progression and survival which may guide future research trials! @BCD_AACR @MSKCancerCenter @MSK_DeptOfMed
doi.org/10.1158/2643-3230.bcd-25-0056
Blood Cancer Discovery
@BCD_AACR
Now online: The Link between Modifiable Risk Factors and Myeloid Disorders—From Plate to Pathogenesis doi.org/10.1158/2643-3230.BCD-25-0056
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Are you interested in completing a PGY2 Pharmacy Residency at Memorial Sloan Kettering Cancer Center (MSK)?
We are excited to share that we will be hosting Virtual Residency Information Sessions for our PGY2 Pharmacy Residency Programs staring on Tuesday, November 18.
During these sessions we will provide an overview of our programs and answer any questions you may have. Learn more and register here: www.mskcc.org/hcp-education-training/pharmacy-pgy-2-resid… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The Center for Implementation Research in Cancer in Later Life (CIRCL), a collaboration between Memorial Sloan Kettering Cancer Center (MSK) and Weill Cornell Medicine, is hosting its first "Work in Progress" session on Friday, November 14 at 2pm (ET).
Dr. Melissa Loh, a geriatric hematologist and oncologist at University of Rochester Medical Center who specializes in caring for older adults with myeloid malignancies, will be presenting her work, moderated by MSK psychologist Dr. Kelly McConnell. Dr. Loh's project focuses on developing, adapting, and testing behavioral and supportive care interventions to improve outcomes for older adults with hematologic malignancies.
Learn more and register here: events.teams.microsoft.com/event/dc7e1d74-5361-4d82-821e-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
#icymi: 36 MSK researchers are among the @ClarivateAG list of Highly Cited Researchers 2025, which identifies scientists who have demonstrated significant and broad influence in their field(s) of research. Learn more: www.mskcc.org/news/mskcc-applauds-highly-cited-researcher…
-
Memorial Sloan Kettering Cancer Center reposted
Lauren Kriger Groner
@LaurenGroner
When Dr. Jamie Ostroff @MSKCancerCenter gives a lecture about “How to Talk to People about Smoking”, everybody listens!
🔑 recommendations:
🫁 Use person-first language
🫁 Provide a rationale for talking abt smoking
🫁 Ask open-ended questions
🫁 Use empathic language -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Experts at MSK are making strides in cancer care.
New research from MSK uncovers unique genetic signatures in cancer patients of non-European ancestry; identifies social adversity as a potential risk factor for higher rates of triple-negative #breastcancer among Black women; and more: www.mskcc.org/news/msk-research-highlights-october-31-2025 -
Memorial Sloan Kettering Cancer Center reposted
Anwaar Saeed
@AnwaarSaeed3
Enjoyed presenting STELLAR-303 results at the 9th Annual @MSKCancerCenter Symposium on Advances in Colorectal Oncology. Inspiring discussions with world-class colleagues pushing the boundaries of #crc research.
@OncoAlert @UPMCHillmanCC -
Memorial Sloan Kettering Cancer Center reposted
Blood Cancers Today
@Blood_Cancers
MSK-ACCESS, a new liquid biopsy test developed at @MSKCancerCenter, is reinventing how hematologic malignancies are diagnosed, monitored, and treated.
📰 Read more: www.bloodcancerstoday.com/post/memorial-sloan-kettering-c… -
Memorial Sloan Kettering Cancer Center reposted
VJHemOnc
@VJHemOnc
How may off-the-shelf cellular therapies, such as allo and in vivo CARs, change the treatment landscape in #myeloma?🩸
We asked Karlo Perica (@MSKCancerCenter) this question at #iwhrmm25, and here's what he had to say:
🎥 www.vjhemonc.com/video/79owgvzwdgu-how-off-the-shelf-cell…
#mmsm #immunoonc #multiplemyeloma #cartcell #hemonc -
Memorial Sloan Kettering Cancer Center reposted
VJHemOnc
@VJHemOnc
Yannis Valtis (@MSKCancerCenter) at #iwds25 looks ahead to the future of DS management:
🔬 Understanding DS biology - cytokines, cell drivers & steroid-refractory cases
💊 Exploring novel anti-inflammatory agents through biomarker-driven trials
#iwds #differentiationsyndrome #leusm -
Memorial Sloan Kettering Cancer Center reposted
Open Medicine Insights
@OpenMedInsights
@JCO_ASCO Oncology Advances EV-202 Phase II
🧬 Enfortumab Vedotin shows activity in heavily pretreated #breastcancer
➡️ ORR: 15.6% in HR+/HER2– | 19% in #tnbc
➡️ Median OS: 19.8 & 12.9 mo
➡️ Safety: consistent w/ urothelial data
➡️ No correlation w/ Nectin-4 expression
💬 “Results support further exploration of EV beyond urothelial carcinoma.” ascopubs.org/doi/pdf/10.1200/OA-25-00053
👥 @antgiorda @ArifAliAwan2 @uw_hemeoncpc @UWCarbone
@MSKCancerCenter @RitaNandaMD @UChicagoMed
@ASCO @OncoAlert @JCO_ASCO @myESMO #adc #oncotwitter #tnbc #breastcancer -
Memorial Sloan Kettering Cancer Center reposted
Young Kwang Chae, MD, MPH, MBA
@youngkwangchae
🌟 Unforgettable plenary by @AndreaCercek (@MSKCancerCenter) at @TargetCancer! 💉 Neoadjuvant dostarlimab: CR — rectal 100% (49/49) ✅ non-rectal 63% (35/54) ⚡ Practice-changing innovation on the horizon! @OncoAlert @NEJM @GSK
-
Memorial Sloan Kettering Cancer Center reposted
Alliance for Clinical Trials in Oncology
@ALLIANCE_org
Hats off to our newly appointed @ALLIANCE_org Imaging Committee leaders! Andy Plodkowski, MD, and Heiko Schöder, MD, MBA, of @MSKCancerCenter, and Jeffrey Yap, PhD, of @HuntsmanCancer! #alliancefall25 #nci #nctn #imaging
-
Memorial Sloan Kettering Cancer Center reposted
The ASCO Post
@ASCOPost
Zenocutuzumab-zbco led to responses in 37% of patients in a small cohort of patients with NRG1+ cholangiocarcinoma
🔹Clinical benefit rate 58%, median PFS 9.2 mo
🔹Presented at #targets25 by Alison Schram, MD @MSKCancerCenter
ascopost.com/news/october-2025/zenocutuzumab-potential-ex… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
The first time Joey came to Memorial Sloan Kettering Cancer Center (MSK), he was in terrible shape. He had a rare #bloodcancer called #erdheimchesterdisease, and his symptoms included crushing fatigue, severe joint pain, and memory loss.
Joey’s extraordinary turnaround is the result of a novel targeted drug called ulixertinib.
His doctor, neuro-oncologist and early drug development specialist Dr. Eli Diamond, is first author of a paper recently published in @Cancer_Cell, that reports outcomes for Joey and four other patients — the first patients to receive ulixertinib for a family of diseases called histiocytosis, which includes Erdheim-Chester disease.
Learn more about this research: www.mskcc.org/news/targeted-therapy-drug-ulixertinib-for-… -
Memorial Sloan Kettering Cancer Center reposted
VJHemOnc
@VJHemOnc
How can we better predict & prevent #differentiationsyndrome?
At #iwds25, @kuokaichin (@MSKCancerCenter) outlines the path forward - from cytokine profiling in menin inhibitor trials to translational research uncovering DS biology & refining prophylaxis strategies
#leusm #iwds -
Memorial Sloan Kettering Cancer Center reposted
SOPHiA GENETICS
@SOPHiAGENETICS
🚀 Next stop: New York City. @JurgiCamblong joins global leaders in oncology at the @MSKCancerCenter Innovation Summit.
He’ll share how AI and data-driven medicine are redefining access to precision oncology, turning today’s insights into tomorrow’s breakthroughs. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A team at MSK is shedding new light on VEXAS syndrome, a severe autoinflammatory condition arising from a mutation in the UBA1 gene.
“There currently aren’t any targeted treatments for VEXAS syndrome,” says Dr. Alexander Gitlin, an immunologist at MSK’s Sloan Kettering Institute and the paper's senior author. “We are hopeful that the therapeutic targets identified by our research can pave the way for new approaches.”
Read more about this research: www.mskcc.org/news/msk-researchers-make-strides-against-v… -
Memorial Sloan Kettering Cancer Center reposted
OncoDaily
@oncodaily
Paul Marks Prize 2025: Celebrating Next-Generation Leaders in Cancer Science
@MSKCancerCenter @cncurtis @AbdelWahablab
oncodaily.com/insight/paul-marks-prize-2025
#cancer #oncology #oncodaily #health #medicine @CancerWorldmag -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
UPDATE: Based on a clinical trial led by @Doctor_E_Stein, Chief of the Leukemia Service at MSK, the @FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have #leukemia that has come back after treatment and whose cancer carries molecular changes called NPM1 mutations.
In November 2024, the drug had previously been approved for treating the same class of patients whose cancer carries another molecular change, called a KMT2A translocation.
Learn more: www.mskcc.org/news/promising-new-type-drug-aggressive-leu… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Researchers at MSK are trying to figure out ways to identify which #prostatecancer patients will benefit from checkpoint inhibitor drugs in addition to developing more effective therapies.
Prostate cancer specialist Dr. Wassim Abida shares updates on this research and what it means for the treatment of people with prostate cancer.
www.mskcc.org/news/latest-on-prostate-cancer-checkpoint-i… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
More than a year after receiving a type of immunotherapy called tumor-infiltrating lymphocyte (#til) therapy, Pattie is doing well and has almost no signs of metastatic #melanoma
Learn more from @jsmithymd, a melanoma medical oncologist and cellular therapist at MSK and expert in #tiltherapy.
www.mskcc.org/news/new-treatment-for-metastatic-stage-4-m… -
Memorial Sloan Kettering Cancer Center reposted
Louisiana Cancer Research Center
@CancerLouisiana
Thursday at noon at the LCRC - Xueqian Zhuang, PhD, Senior Research Scientist in the Cancer Biology Program at @MSKCancerCenter, will present "Ironing out wrinkles – a story about aging and iron metabolism." Details below.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Welcome! 👏
Jason Lewis Radiochem MSK
@LewisLabMSKCC
Though a little late in sharing the news, we’re delighted to welcome new members to the Lewis Lab @MSKCancerCenter. Gerstner Sloan Kettering Graduate Students, Ana Rosu and Suchitra Dara, Clinical Fellow (Pediatrics) Dr. Anne Cochrane and research technician Mohamed Hussien.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to this year’s recipients of the Memorial Sloan Kettering Cancer Center (MSK) 2025 Paul Marks Prize for Cancer Research: Dr. @AbdelWahablab, of @MSKCancerCenter; Dr. Andrea Ablasser, of @EPFL_en; and Dr. @cncurtis, of @StanfordMed.
The prize, named in honor of MSK’s past President Emeritus, the late Paul Marks, recognizes a new generation of leaders who are making significant contributions to the understanding of cancer or are improving the treatment of the disease.
Learn more about the winners: www.mskcc.org/news-releases/three-investigators-named-win… -
Memorial Sloan Kettering Cancer Center reposted
Journal of Clinical Investigation
@jclinicalinvest
From earlier this week: Protection against the fungus among us after mold spore inhalation…
Tobias M. Hohl @tmhohl71 & team @MSKCancerCenter investigate Aspergillus fumigatus infection in mice, revealing communication between plasmacytoid DCs and neutrophils in the lung is necessary for antifungal activity.
www.jci.org/articles/view/190107 -
Memorial Sloan Kettering Cancer Center reposted
𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿
@break_cancer
Last night, we recognized members of our community who model the values of
#radicalcollaboration.
Congratulations to Drs. Anirban Maitra (@Aiims1742), Alexander Ling (@MassGenBrigham),
and Sohrab Shah (@SohrabShah @MSKCancerCenter), Cory Abate-Shen (@columbia), and Dinah Singer, recipients of the 2025 David M. Livingston Collaboration Award.
Your work strengthens not just our science, but our community.
#btcsummit2025 -
Memorial Sloan Kettering Cancer Center reposted
Focal One
@FocalOneHIFU
Urologic cancer surgeon, @BehfarEhdaieMD from @MSKCancerCenter, the #1 hospital for urology according to @usnews explained the benefits of @FocalOneHIFU, and his patient, John B., shared his personal journey in a recent article.
"It was pretty much back to normal right away. No cutting, no stiches, no lying in a hospital bed for days or weeks." - John B.
Nearly nine years after being treated with HIFU and avoiding both surgery and radiation, John continues to do well.
Read the full story here: www.mskcc.org/news/high-intensity-focused-ultrasound-hifu…
#cancer | #prostatecancer | #urology | #roboticsurgery | #medtech -
Memorial Sloan Kettering Cancer Center reposted
Fred's Team
@FredsTeam
CONGRATULATIONS, RUNNERS! You did it! You just completed one of the greatest races in the world. Thank you for your relentless dedication to training and fundraising with us this year. We are so proud of this incredible community. 🫶
-
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
Education, Proactive Management Are Key to Navigating Ocular Toxicities and Other ADC-Related AEs in Breast Cancer @jhaveri_komal @MSKCancerCenter #bcsm #oncology
www.onclive.com/view/education-proactive-management-are-k… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK's Department of Surgery is now accepting applications for a one-year International Surgical Oncology Global Cancer Disparities Fellowship to fully trained surgeons.
The aim of the fellowship is to train the fellow to effectively direct multimodality cancer therapy for cancer patients in both high- and low-income countries.
Learn more and apply here: www.mskcc.org/hcp-education-training/fellowships/internat… -
Memorial Sloan Kettering Cancer Center reposted
Fred's Team
@FredsTeam
Despite undergoing chemotherapy and radiation, Liz Healy is taking on the @nycmarathon this Sunday—her third consecutive year with Fred’s Team. She recently sat down with @ABC7NY to share her story and raise awareness about colorectal cancer. Tune in here. abc7ny.com/videoClip/18078057/?userab=kfsn_web_player-447…
-
Memorial Sloan Kettering Cancer Center reposted
Journal of Clinical Investigation
@jclinicalinvest
Little progress has been made in the treatment of anaplastic thyroid cancer
@VeraTiedje @Gnana_Krish et al. @MSKCancerCenter now find mice with aggressive ATC respond to the inhibitor combination dabrafenib/trametinib by affecting cancer cell MHCII expression & increasing T-cell infiltration.
www.jci.org/articles/view/191781
The image shows multiplex immunofluorescence for immune cell populations in the tumor microenvironment of thyroid cancers. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK's Global Cancer Research and Training Program is now accepting applications for the Stern Fellowship in Global Oncology Research.
This fellowship is open to current or recently graduated U.S. or Canadian residents and PhD students interested in gaining hands-on experience in global oncology research and developing the skills to collaborate effectively with cancer researchers in low- and middle-income countries.
Learn more and apply here: www.mskcc.org/hcp-education-training/fellowships/mskcc-st… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
"My experience tells me that the best way to tackle the challenges keeping us from curing all cancers in all patients using immunotherapy is through team science," says @andyjminn, the inaugural chair of MSK's Immuno-Oncology Program and co-director of the Marie-Josee Kravis Center for Cancer Immunobiology.
"I believe that through this process, we will deliver the hope for meaningful and durable responses to immunotherapy for many more patients — the type of responses the immune system is meant to provide. And I can think of no better place than MSK to do this work of further unlocking immunotherapy’s potential."
Learn more about Dr. Minn's vision for the program and what it means for patients: www.mskcc.org/news/future-of-immunotherapy-research-at-ms… -
Memorial Sloan Kettering Cancer Center reposted
VJHemOnc
@VJHemOnc
🚨The FDA has approved revumenib for patients with R/R AML and a susceptible NPM1 mutation.
Read our latest article to learn more and to gain valuable insight into the AUGMENT-101 trial from Eytan Stein (@MSKCancerCenter):
👉 www.vjhemonc.com/fda-approves-revumenib-for-patients-with… 👈
#amlsm #leusm #leukemia #ctsm #hemonc -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
.@PedramRazaviMD, a physician-scientist at MSK, explains MSK's efforts to prevent drug resistance from developing in #breastcancer patients.
“In the past, we’ve always been reactive — we give a treatment, the cancer adapts to survive, and then we give a drug that blocks that path of resistance,” says Dr. Razavi. “But the next line of therapy generally does not work as well as the first. Now we are trying to develop ways to predict the behavior of cancer and stay ahead of it.”
A new study seeks to anticipate the malignant cells' next move, like playing poker with cancer and being able to see most of its cards.
Learn more: www.mskcc.org/news/latest-research-into-overcoming-resist… -
Memorial Sloan Kettering Cancer Center reposted
WCM Englander Institute for Precision Medicine
@WCMEnglanderIPM
Join us for @WeillCornell and @MSKCancerCenter's Global Oncology Symposium, featuring a talk by Dr. Lisa Newman (@LANewmanMD) from @WCMSurgery and the @WCMEnglanderIPM, among other terrific speakers!
October 30th at 4:00pm, Weill Greenberg Center, WGC-A & B. -
Memorial Sloan Kettering Cancer Center reposted
Alliance for Clinical Trials in Oncology
@ALLIANCE_org
@eugene_pietzak of @MSKCancerCenter leads @ALLIANCE_org A032303/GAIN-BCG testing if adding the anti-cancer drug gemcitabine to the standard treatment of BCG immunotherapy helps patients whose non-invasive bladder cancer has come back. Learn more: clinicaltrials.gov/study/NCT07000084
-
Memorial Sloan Kettering Cancer Center reposted
Journal of Clinical Investigation
@jclinicalinvest
Protection against the fungus among us after mold spore inhalation…
Tobias M. Hohl @tmhohl71 & team @MSKCancerCenter investigate Aspergillus fumigatus infection in mice, revealing communication between plasmacytoid DCs and neutrophils in the lung is necessary for antifungal activity.
www.jci.org/articles/view/190107 -
Memorial Sloan Kettering Cancer Center reposted
OncoDaily GI
@OncoDailyGI
Privileged to Learn from Experts Who Set the Standard in Cancer Care and Research - Rixci Ramírez
@MSKCancerCenter
oncodaily.com/voices/rixci-ramirez-398529
#cancer #medicine #health #oncology #oncodaily #medx #mednews #meded #cancercare #cancerresearch -
Memorial Sloan Kettering Cancer Center reposted
PBMT Group
@PBMTGroup
📢 DON'T MISS: T-CELL LYMPHOMA EXPERT IN-PERSON! 📢
Listen to Dr. Jasmine M. Zain from @MSKCancerCenter Memorial Sloan Kettering, USA! A leading Lymphoma Specialist presenting IN-PERSON.
Topic: How I sequence treatment of T cell lymphoma.
🗓️ When: Friday, 7th November 2025 at 2035 PKT
FREE Registration Link: www.nibmtevents.com
This is a must-attend session for the latest sequencing strategies! 👆
#pbmt #psh #nibmt #ash2024 #asco2025 #eha2025 #drjasminezain #lymphoma #oncologyupdate -
Memorial Sloan Kettering Cancer Center reposted
VJHemOnc
@VJHemOnc
The final session of #iwhrmm25 is underway! Maximilian Merz of @MSKCancerCenter is discussing the importance of translational studies in clinical trials of HRMM.🔎
#mmsm #multiplemyeloma #myeloma #hemonc #ctsm -
Memorial Sloan Kettering Cancer Center reposted
Lurie Cancer Center
@LurieCancer
What’s new in #breastpathology? @HannahYWen of @MSKCancerCenter kicks off the #lsbc25 afternoon session with insights on “The Ever-Changing Field of Breast Tumor #biomarkers.” #breastpath
-
Memorial Sloan Kettering Cancer Center reposted
VJHemOnc
@VJHemOnc
🔎🧬 Kylee MacLachlan of @MSKCancerCenter provides insight into the prognostic impact of t(4;14), alone and in combination with other genomic risk factors.
#iwhrmm25 #mmsm #multiplemyeloma #myeloma #hemonc -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK experts are investigating whether #brachytherapy may be an effective treatment option for reducing local recurrence, lowering the risk of #necrosis associated with standard #radiation, and improving the quality of life for patients with brain #metastases.
“Brachytherapy is an important tool in our toolbox, but it is one of many options we provide within our multidisciplinary program.” Learn more: www.mskcc.org/clinical-updates/brachytherapy-for-brain-me… -
Memorial Sloan Kettering Cancer Center reposted
Oncology Central
@OncologyCentral
How do we address the unique challenges facing adolescent and young adult cancer patients? Find out in our latest article, which outlines ethical frameworks for different age subsets. www.oncology-central.com/ethical-dilemmas-in-aya-oncology… #ayaoncology @MSKCancerCenter)
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
We're proud to share that MSK has been recognized as #1 in oncology on @Newsweek's World's Best Specialized Hospitals List.
Learn more: www.mskcc.org/news-releases/msk-awards-and-appointments-s… -
Memorial Sloan Kettering Cancer Center reposted
AML Hub
@AML_Hub
🎥 The AML Hub was pleased to speak with Eytan Stein, @MSKCancerCenter, about the latest data presented for current and emerging treatments for IDH1m AML.
Watch the full video here: aml-hub.com/medical-information/clinical-research-round-u…
#amlsm #leusm #meded -
Memorial Sloan Kettering Cancer Center reposted
Santosh Vardhana
@SantoshVardhana
No one more deserving of this recognition than @AbdelWahablab, a truly exceptional physician, scientist, and mentor. Congrats Omar!
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
We're excited to share that Dr. Omar Abdel-Wahab, a leukemia specialist at Memorial Sloan Kettering Cancer Center (MSK) and Chair of the Molecular Pharmacology Program at Sloan Kettering Institute (SKI), has been elected to the @theNAMedicine (NAM).
NAM elects members each year who have demonstrated exceptional professional achievement and commitment within the National Academies. As a pioneering physician-scientist, Dr. Abdel-Wahab has made significant contributions to uncovering the genetic causes of blood cancers and translating these discoveries into therapeutic advances.
With Dr. Abdel-Wahab’s appointment, a total of 28 MSK faculty members have been conferred with this recognition. Congratulations, Dr. Abdel-Wahab!
www.mskcc.org/news-releases/mskcc-physician-scientist-ele… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
We're excited to share that Dr. Omar Abdel-Wahab, a leukemia specialist at Memorial Sloan Kettering Cancer Center (MSK) and Chair of the Molecular Pharmacology Program at Sloan Kettering Institute (SKI), has been elected to the @theNAMedicine (NAM).
NAM elects members each year who have demonstrated exceptional professional achievement and commitment within the National Academies. As a pioneering physician-scientist, Dr. Abdel-Wahab has made significant contributions to uncovering the genetic causes of blood cancers and translating these discoveries into therapeutic advances.
With Dr. Abdel-Wahab’s appointment, a total of 28 MSK faculty members have been conferred with this recognition. Congratulations, Dr. Abdel-Wahab!
www.mskcc.org/news-releases/mskcc-physician-scientist-ele… -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
#esmo25 may be over, but #cancerresearch continues! Dr. Vicky Makker presented 5-year follow-up data from the 309/KEYNOTE-775 study that confirmed the efficacy and safety of lenvatinib & pembrolizumab in advanced #endometrialcancer. @MSKCancerCenter
➡️cslide.ctimeetingtech.com/esmo2025/attendee/confcal_2/pre… -
Memorial Sloan Kettering Cancer Center reposted
Fred's Team
@FredsTeam
We just checked off our last training run of the season, and we couldn’t be prouder of this incredible team. 🧡 Over the past few months, you have shown up with positive energy, grit, and determination. We can't wait to cheer you on as you cross the @nycmarathon finish line!
-
Memorial Sloan Kettering Cancer Center reposted
I-Hsin Lin
@IHsinLin3
🔥📣🎊@MSKCancerCenter
#infectiousdiseases Dr. Anna Kaltsas & @IHsinLin3 published a new study in @AnnSurgOncol evaluating risk factors for recurrent cellulitis in #breastcancer patients with post-surgical lymphedema. Presenting @IDWeekmtg in ATL today!
🔗link.springer.com/article/10.1245/s10434-025-18598-7 -
Memorial Sloan Kettering Cancer Center reposted
Urology Times
@UrologyTimes
We had a great discussion with Karen Autio, MD, on a first-in-human trial of JNJ-78278343 for mCRPC. Stay tuned for the interview! #esmo25 @MSKCancerCenter
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
This past weekend, MSK researchers presented exciting advances in medical oncology for a range of cancer types at the @myESMO Congress 2025 held in Berlin, Germany.
Highlights included the latest updates on three phase 1 trials testing innovative treatment approaches for select patients with advanced solid tumors, non-small cell lung cancer (#nsclc), and #pancreatic cancer. Learn more: www.mskcc.org/clinical-updates/esmo-2025-research-roundup… -
Memorial Sloan Kettering Cancer Center reposted
James J. Harding, MD
@HardingJJMD
#hpb cancers focus of intense drug development. #adc. Honor to represent @MSK_DeptOfMed @MSKCancerCenter
Arndt Vogel
@ArndtVogel
Phase 1 Basket Study of Telisotuzumab Adizutecan, a c-Met Protein–Targeting Antibody-Drug Conjugate: Results From PDAC cohort
#esmo25 #esmoambassadors
👉 ORR: 23%
👉 mPFS: 5.4 mo
🧐interesting signal for Temab-A.... more options.... how to integrate with RAS inhibitors
@myesmo -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
We had the exciting opportunity to sit down with @HardingJJMD of @MSKCancerCenter to discuss early-phase data with telisotuzumab adizutecan in PDAC and other difficult-to-treat tumors.
Temab-A shows promising efficacy in MET-amplified tumors, highlighting the potential of next-gen ADCs to fill critical unmet needs. To hear more from Dr Harding about these results, keep an eye out for the full interview on onclive.com! @myESMO #esmo25 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Tomorrow at #esmo25: MSK’s Dr. James Harding (@HardingJJMD) will present “Phase 1 basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC)” @myESMO
Learn more: cslide.ctimeetingtech.com/esmo2025/attendee/confcal/show/… -
Memorial Sloan Kettering Cancer Center reposted
OncLive.com
@OncLive
Rounding out the day's interview with Vicky Makker, MD, of @MSKCancerCenter, who expanded on updated data from the KEYNOTE-775 study, which confirmed long-term survival benefit with lenvatinib plus pembrolizumab in advanced endometrial cancer?
Want to learn more? Keep an eye out on the website, or download the OncLive app to be notified when it goes live! @myESMO #gynsm #oncology -
Memorial Sloan Kettering Cancer Center reposted
CURE Today
@cure_today
Imfinzi Combo Improves Progression Free Survival in #ovariancancer @MSKCancerCenter #esmo25 www.curetoday.com/view/imfinzi-combo-improves-progression…
-
Memorial Sloan Kettering Cancer Center reposted
OncoDaily
@oncodaily
Live from #esmo2025!
Dr. Michael Gormally (@GormallyMDPHD) from Memorial Sloan Kettering Cancer Center (@MSKCancerCenter) discusses the exciting progress in HLA-restricted medicines — including TCR-engineered cell therapies, bispecific T-cell engagers, and cancer vaccines.
@myESMO
#esmo25 #esmo2025 #esmo #esmo2025congress #oncodaily #oncology #cancer #health #medicineThis media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center reposted
Jarushka Naidoo
@DrJNaidoo
#esmo25 Lung mini orals🔥
CNS activity of Zipalertinib in EGFR exon20+ NSCLC @HelenaYu923
- 16pts evaluable by RANO-BM
- icORR 31.3% icDCR 68.8%
- icDOR 8.1m
Some CNS activity, key outcome when there are several exon20 agents @EGFRResisters
#esmo25 #esmoambassadors @myESMO -
Memorial Sloan Kettering Cancer Center reposted
VJ Oncology
@VJOncology
🎥At #esmo25 @ILSONDavid from @MSKCancerCenter reviews updates in checkpoint inhibitor use for gastric cancer:
⚖️ CPS vs TAP scoring – both acceptable and often interchangeable
📊 NCCN guidance: ICIs for CPS ≥1%, with greatest benefit at higher scores
💥 Durvalumab + perioperative chemo = major new approval
Full interview ➡️ www.vjoncology.com/video/fyokffvrpja-checkpoint-inhibitor…
@myESMO #stcsm #immunoonc
This video is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Takeda (Gold) and Gilead Sciences (Silver). Supporters have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given. -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
Happening NOW at #esmo25: Stop by Kenneth Yu's poster to learn about a phase 1 trial of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells for stage 4 #pancreaticcancer or #breastcancer with an inherited BRCA/PALB2 mutation.
Learn more: cslide.ctimeetingtech.com/esmo2025/attendee/confcal_2/pre…
@MSKCancerCenter @myESMO -
Memorial Sloan Kettering Cancer Center reposted
MSK Department of Medicine
@MSK_DeptOfMed
At #esmo25, join @YoninaMG to learn about the results of a phase 1 study that evaluated telisotuzumab adizutecan in patients with MET-amplified advanced solid tumors. @MSKCancerCenter @myESMO
Learn more: cslide.ctimeetingtech.com/esmo2025/attendee/confcal/show/… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Coming up at #esmo25: MSK’s Dr. Carol Aghajanian will discuss present “Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: Final overall survival from DUO-O/ENGOT-ov46/GOG-3025” @myESMO
Learn more: cslide.ctimeetingtech.com/esmo2025/attendee/confcal/show/… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Next at #esmo25: MSK’s Dr. Jamie Chaft will share about optimised adaptive strategies with systemic #immunotherapy. @myESMO
Learn more: cslide.ctimeetingtech.com/esmo2025/attendee/confcal/show/… -
Memorial Sloan Kettering Cancer Center reposted
VJ Oncology
@VJOncology
🧬 At #esmo25, David Ilson (@ILSONDavid/@MSKCancerCenter), discusses CPS vs TAP scoring for checkpoint inhibitor eligibility in gastric cancer, noting both are acceptable & often interchangeable.
Watch here 👉www.vjoncology.com/video/fyokffvrpja-checkpoint-inhibitor…
This video is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Takeda (Gold) and Gilead Sciences (Silver). Supporters have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
@myESMO @OncoAlert #gism #gastriccancer #gej -
Memorial Sloan Kettering Cancer Center reposted
Joshua Zeidner MD
@LeukDocJZ
Outstanding talk by Eytan Stein at @MSKCancerCenter discussing the clinical activity of menin inhibitors, patterns & mechanisms of resistance, & future directions to decrease resistance @ESHaematology #eshaml2025
-
Memorial Sloan Kettering Cancer Center reposted
David H Aggen, MD PhD
@Dr_Aggen
I want to highlight some of the fantastic work done by Michal Sternschuss @MichalSternsch that is being presented to at #esmo25. She unfortunately could not be here in Berlin today but is first author on this work. @ESMO @myESMO @MSK_DeptofMED @MSKCancerCenter
-
Memorial Sloan Kettering Cancer Center reposted
Cell Press
@CellPressNews
Researchers from @MSKCancerCenter have developed a proximity-tagging method to map molecules that associate in 3D space to better understand chromatin organization. Read more in @molecularcell #ashg25 www.cell.com/molecular-cell/abstract/S1097-2765(25)00547-…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK immunologist @themis_brown for being named a 2025 @HHMINEWS Freeman Hrabowski Scholar. 🎉
Dr. Brown, whose research has been shedding light on the development of the early life immune system and its relationship to #autoimmunity, allergy, inflammation, and #cancer, was among 30 early-career scientists selected for the 2025 class. Learn more: www.mskcc.org/news/immunologist-chrysothemis-brown-named-… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
If you're attending the 2025 Magnet Pathway Conference hosted by @ANANursingWorld from Oct. 8-10, don't miss MSK Evidence-Based Practice Consulting team's booth (#3122) to learn more about MSK's proprietary EBP methodology. www.mskcc.org/commercialization/partnering/msk-evidence-b…
#magnetptecon -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Nearing the home stretch of #aacr25, but there’s still a lot to learn and see!
We’re excited for another packed day of cancer research and science. 🧬🔬🧪 @AACR -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
“Data suggests that, with efficacious therapy, AFR-patients should have equal or better clinical outcomes.”
Dr. Kylee Maclachlan shares results from her research on whole genome sequencing in #multiplemyeloma patients with African ancestry compare with those having European ancestry at @ASH_hematology. #ash24
ash.confex.com/ash/2024/webprogram/Paper203675.html -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🎉 Congratulations to MSK's most recent Awards & Appointments honorees, including @JunMaoMD for being awarded research money from @PCORI, Dr. Laurie Kirstein for being appointed to chair of the @AmCollSurgeons Commission on Cancer, and more: www.mskcc.org/news-releases/msk-awards-and-appointments-n…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Researchers in the Integrative Medicine Service at MSK are studying the science of #acupuncture, and how this approach might help relieve some of the symptoms and side effects commonly experienced by people with cancer.
Learn more: www.mskcc.org/news/acupuncture-for-neuropathy-cancer-pain… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Be a part of the symphony of lifesavers that helps patients get the blood stem cell transplants they need. #jointhesymphony with us, @MichelleObama, @BarackObama, @JonBatiste, @suleikajaouad, @MattHeineman, & @nmdp_org by learning how you can help 👉 giving.nmdp.org/campaign/601169/donate?currency=USD&c_src…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK chemical biologist Dr. @Yael_David__ for receiving the prestigious 2024 Alfred P. Sloan Research Fellowship in Chemistry. Learn more about Dr. David and her research on #epigenetics: www.mskcc.org/research/ski/meet-researchers/work-chemical…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Thank you to the @MSKCancerCenter staff members who joined the @nmdp_org blood stem cell registry at our swab drive. Learn more about the registry here: giving.nmdp.org/campaign/601169/donate?currency=USD&c_src… #jointhesymphony
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Dr. Christopher Klebanoff is developing a new type of immunotherapy called T cell receptor (#tcr) therapy that could one day treat more types of cancers. “Having worked on this for 20 years, I believe in the potential of this type of immunotherapy." More👇 www.mskcc.org/news/new-type-of-immunotherapy-msks-christo…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Dr. @Neil_Iyengar, director of MSK’s Healthy Living program, was presented with an Oncology Heroes art piece at the Chemotherapy Foundation Symposium for his dedication to cancer research and care. #cfs
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to our most recent Awards and Appointments honorees, including @michel_sadelain, @hedvighricak, @jesuserp350, and more. This month, MSK was also recognized by @castleconnolly & @newsweek. Read more: www.mskcc.org/news-releases/msk-awards-appointments-septe…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A new study by MSK and @nygenome reveals genetic “scars” that hold promise for identifying DNA repair-defective cancers. “These patterns could become an essential part of therapeutic decision-making,” notes @simonpowell213. Read more: www.mskcc.org/news/msk-research-highlights-august-24-2023
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
An MSK team led by @jaeparkmd found that giving a drug called anakinra patients undergoing #cartcelltherapy reduced severe neurotoxicity from a rate of 28%–38% usually seen with standard anti-CD19 CAR T therapy to only 9.7%. Read more here: www.mskcc.org/news/msk-research-highlights-july-17-2023
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Please join us in congratulating Dr. @AbdelWahablab on being named the William Dameshek Prize winner by @ASH_hematology. The award recognizes individuals age 50 or younger who have made significant contributions to the field of #hematology. www.hematology.org/news-and-media/press-releases/2023/ash…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
"This is an exciting advance in the field of cancer vaccines, an area notoriously tough to make progress in." - Dr. Margaret Callahan, research director of our Immunotherapeutics Program, on new #mrna vaccine research for melanoma #cancerresearch #aacr23 www.nbcnews.com/news/amp/rcna79543
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
.@RachelFeinstein, @hasanminhaj, @iamcolinquinn, and @SarahKSilverman are teaming up with MSK on April 20. Experience a one-night-only comedy show benefiting blood cancer research. Get your Comedy vs Cancer tickets today at cvc.live/tickets.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
During the pandemic, the lab of Dr. John Chodera (@jchodera) shifted gears to help find new drugs against #covid19. Learn how lessons from the effort are also aiding in cancer #drugdiscovery. www.mskcc.org/news/shooting-moon-how-drive-tackle-covid-1…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations to MSK's Danwei Huangfu & colleagues (Lorenz Studer, Thomas Vierbuchen & Ting Zhou) on being awarded a MorPhiC award from @genome_gov, part of an @NIH initiative to establish the function of every human gene.
Learn more: www.nih.gov/news-events/news-releases/nih-initiative-syst… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
👏 RT and congratulate Dr. Jedd Wolchok (@wolchokj) who is the #asco22 David A. Karnofsky Memorial Award and Lecture recipient for his outstanding contributions to the field of cancer #immunotherapy. www.mskcc.org/news-releases/fumiko-chino-craig-thompson-a…
@ASCO -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
💉 Could personalized #mrna vaccines fight cancer? It may sound like science fiction, but this research is happening right now in @TheVinodLab.
Watch for more. @drsanjaygupta @CNN @BioNTech_Group #cancerresearch #pancreaticcancer @PanCANThis media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
With the renewed interest in #cancermetabolism, researchers at SKI and beyond are discovering there is more to a cell's biochemistry than once thought. The latest surprise? An alternate version of the famous Krebs cycle. @lydfinley @Nature www.mskcc.org/news/ski-scientists-discover-new-twist-80-y…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today, we're proud to announce the winners of the 2021 Paul Marks Prize🏆, recognizing a new generation of leaders in cancer research: Ralph DeBerardinis of @UTSWNews, Sun Hur of @BostonChildrens, and @CharlesSwanton of @TheCrick. 👏 👏 Learn more below. www.mskcc.org/news/twenty-years-honoring-legacy-three-inv…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today is #glioblastoma Awareness Day. RT and help shine a light on the most common, complex, and treatment-resistant types of #braincancer and learn how MSK is working to change that. #gbmday @TabarViviane @NBTStweets www.mskcc.org/research-programs/brain-tumor
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
👏 Congratulations @juanosoriomd one of 2021 recipients of the @DamonRunyon Physician-Scientist Training Award! www.damonrunyon.org/news/entries/6226/Damon Runyon Cancer…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
MSK's Dept. of #radiology is part of a program, now in its 18th year, designed to foster a love of science in NYC high school students.
Learn more about "Radiology Day" and meet one of the department's future interns, Riya. @hedvighricak www.mskcc.org/news/more-field-trip-msk-radiologists-mento… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Please join us in congratulating our own @LarryNortonMD who was just elected to the @americanacad! 👏 He joins the Academy alongside 251 fellow new members including notable scholars, leaders, artists, and innovators. www.amacad.org/news/2021-member-announcement?sf245214437=1
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
It takes all kinds of #mskhealthcareheroes to keep us running. We couldn't do this without the MSK Housing & Parking Services, who have been doing everything 24/7 from greeting patients to accepting packages to delivering patient vehicles from parking garages. 💪
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
This #feelgoodfriday is extra special. We're happy to report #mskkids Dr. Richard O'Reilly was discharged after facing COVID-19 & received a loving send off from his fellow #mskhealthcareheroes.
We can't wait to welcome you back to MSK with an even louder celebration. 💛 -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Kevin Browne, one of our very own #mskhealthcareheroes, was discharged from the ICU yesterday after weeks of battling #covid19! Kevin is our Deputy Chief Nursing Officer and has been with us for 22 years, so we were beyond thrilled to wish him well on his road to recovery. 👏👏👏
This media couldn't be displayed. See it on the original post. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Our entire team at MSK remains fiercely dedicated to our mission during these challenging times, especially our Respiratory Therapists. These #mskhealthcareheroes have been working around the ⏰ doing what we do best — providing safe and exceptional care to our patients.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Thank our #mskhealthcareheroes with a virtual thank you card!
Send our team a virtual thank you note by leaving a message below and include a picture! You can also email us at socialmedia@mskcc.org. Your message could be highlighted on our MSK channels. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🐶 The #mskcaringcanines have an important message this #feelgoodfriday; they want to wish everyone a Happy "Howlidays!"
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Treatment plans are unique as each child. A new program at MSK seeks to further harness the power of collaboration to give children innovative treatments, which will in turn help other kids down the line. #mskkids #childhoodcancer #asco19 www.mskcc.org/news/one-one-how-msk-using-precision-medici…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Wonder Woman didn't need to wear a cape to be a superhero and neither did these "Sheroes" of science. In honor of Women's History Month, meet three MSK women who shook up cancer care. www.mskcc.org/news/scientist-turned-activist-mathilde-kri…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
New research from scientists at the Sloan Kettering Institute helps explain how growing tumors escape our immune defenses. #immunotherapy www.mskcc.org/news/immune-system-can-fight-cancer-so-why-…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
National #cancerprevention Month is coming to a close. Check out these 7 tips for lowering your cancer risk from our experts.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Hope for “Undruggable” Cancers. www.mskcc.org/blog/drugs-stall-don-t-kill-cancer-cells-ar…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
“She’s made this Momma feel very safe for a long time.” #moresciencelessfear #childhoodcancer #peopleofmsk #feelgoodfriday
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
We ❤️ our NPs! RT and help celebrate National Nurse Practitioners Week! At MSK, we're so grateful for all of our amazing NPs who help us deliver incredible patient care every single day. #npweek
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🇺🇸 RT and help us as #msksalutes our veterans, whose dedication and exceptional service has followed them from one life calling to another. #peopleofmsk #veteransday
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congratulations Dr. Hedvig Hricak!
National Academy of Medicine
@theNAMedicine
Congratulations to Hedvig Hricak @hedvighricak of @sloan_kettering, the recipient of this year’s David Rall Medal for notable service to the NAM! #nammtg nam.edu/news-and-insights/national-academy-of-medicine-ho…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Congrats Dr. Jim Allison, co-winner of the #nobelprize in Medicine for his discovery of cancer therapy by inhibition of negative immune regulation, who conducted some of his award-winning research right here at MSK. Learn how this type of #immunotherapy works in 60-seconds.
This media couldn't be displayed. See it on the original post. -
Post not available here, view on XPost not available here, view on X
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
“At MSK, we know what to look for in terms of late effects in #childhoodcancer survivors, and we understand what they've been through.” More from Pediatric Nurses Roseann & Gabriella Tucci #mskpediatrics #childhoodcancerawarenessmonth www.mskcc.org/news/mother-daughter-meet-msk-nurses-rosean…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Way to go @rosslevinemd, the 2018 winner of the @ASH_hematology William Dameshek Prize for his discoveries in the field of #leukemia and myeloproliferative neoplasms www.hematology.org/Newsroom/Press-Releases/2018/8858.aspx
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
🎉 RT and join the celebration! MSK has once again been ranked one of the top 2 hospitals for cancer care by @USNews! #besthospitals
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
When is the best time of month to do a breast self-exam? The answer to this and more in our all about #breastcancer screening quiz. #bcsm www.mskcc.org/news/how-much-about-breast-cancer-screening…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Have a minute? Learn something new! Watch to learn more about #nanotechnology in 60 seconds with Dan Heller. @HellerLab
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Traveling is fun but also stressful. When a child has cancer, it’s even harder. A little planning goes a long way in giving your family a trip they will always remember. #childhoodcancer www.mskcc.org/news/5-ways-make-travel-easier-when-your-ch…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Studying extremely rare cancer types presents many challenges. MSK's Make-An-IMPACT program provides genetic sequencing & testing at no cost to qualifying patients with rare cancers. Read more about becoming a volunteer: www.mskcc.org/research-programs/molecular-oncology/make-i…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
"The emergence of women as leaders across disciplines is a sign that times are finally starting to change." Dr. Morrow, Chief, Breast Surgery Service
Go behind the scenes of the cover shoot for MSK News, highlighting some of our many female leaders in science & medicine. -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
In a newly published review article, Michel Sadelain highlights CAR T, the emerging immunotherapy treatment for hematologic cancers. @NEJM goo.gl/ieywZS
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
How do cancer tumors grow and form in other parts of the body? Watch and find out more.
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A test that detects the expression of a protein called AR-V7 (shown in white) in the nuclei of circulating tumor cells can help doctors make treatment decisions. goo.gl/F6bAiG
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
"We have to earn our patients' trust, and we ask them to take a leap of faith with us. Ezzy was brave and ready to try this." #childhoodcancer #survivorshipmonth #immuontherapy #cim18 www.mskcc.org/pediatrics?sf192849151=1
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Researchers at the Sloan Kettering Institute have discovered that melanoma cells in zebrafish use fat from nearby fat cells to fuel their growth and spread. @whitefishlab #zebrafish www.mskcc.org/news/cancer-cells-eat-fat-grow-and-spread?s…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
It's the first day of #summer! It's important to always to wear sunscreen and know what to look for when it comes to skin cancer self-screening. Check out our tips! www.mskcc.org/archived/news/skin-cancer-screening-and-sel…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
“Exercise certainly appears to be beneficial” for people who have survived a #childhoodcancer, says Lee Jones, the chief of the exercise oncology service here at MSK. More from the @nytimes. @nytimeswell www.nytimes.com/2018/06/20/well/childhood-cancer-survival…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
"It's the best feeling in the world to be able to do what you want. To be a normal kid." #childhoodcancer #cancersurvivorsmonth #mskpediatrics www.mskcc.org/experience/hear-from-patients/payton?sf1915…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Just keep swimming. Just keep swimming. More on the small but mighty fish that is helping us change the way the world treats cancer. @whitefishlab www.mskcc.org/news/how-zebrafish-got-its-stripes?sf191512…
-
Post not available here, view on XPost not available here, view on X
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
"We find universal common signatures of metabolic changes that seem to happen in nearly every cancer type that we have in our data set." More in the study of #metabolism today's #msksciencebite #cancerresearchmonth www.mskcc.org/news/scientists-create-first-its-kind-metab…
Post not available here, view on X
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
A special delivery just in time for #cancerresearchmonth. Today's #msksciencebite - Nano-Size Particles Carry Personalized Medicines to Cancer’s Doorstep. Check it out research from @HellerLab! goo.gl/WRZh6V
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
"I think when people know that they are at a place where there is expertise and true collaboration, it increases their confidence and comfort." Check out Martina's story. #braintumorawarenessmonth #braincancer www.mskcc.org/experience/hear-from-patients/martina?sf187…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
#aacr18 is live! The latest developments in cancer research, incl. genomic mapping, #crispr, & CAR T therapy. @AACR cards.twitter.com/cards/18ce53v621r/5ll4q
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Eat this or eat that? MSK experts in our Medical Nutritional Therapy Service answer six frequently asked questions about nutrition and cancer. www.mskcc.org/news/nutrition-and-cancer-6-frequently-aske…
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Behind the scenes? More like behind the science! Thanks @kellanlutz for visiting the @ciacobu lab. #cancerscience @GEOFFREY_BEENE 🔬
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
22% of the most common cancers can be prevented by not smoking. RT & share with your friends and family #worldcancerday #cancerprevention
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Today is #worldcancerday, a day to stand united against cancer. Consider joining us in the search for cures.
give.mskcc.org/site/SPageServer?pagename=donate&donID=116… -
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Obesity might soon pass smoking as the #1 preventable cause of #cancer. Get tips on how to live healthier
-
Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Test Aids Prostate Cancer Treatment: goo.gl/KIywP3 via @WSJ


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































